%PDF-1.4%âãÏÓ
72 0 obj
<</Metadata 74 0 R/PageLabels 14 0 R/Pages 66 0 R/Type/Catalog>>
endobj
74 0 obj
<</Length 1664/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="ï»¿" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 4.2.1-c043 52.389687, 2009/06/02-13:20:35        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/">
         <xmp:CreateDate>2007-08-08T15:36:11Z</xmp:CreateDate>
         <xmp:CreatorTool>QuarkXPress(tm) 6.52</xmp:CreatorTool>
         <xmp:ModifyDate>2015-05-19T03:00:44-07:00</xmp:ModifyDate>
         <xmp:MetadataDate>2015-05-19T03:00:44-07:00</xmp:MetadataDate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/">
         <pdf:Producer>QuarkXPress(tm) 6.52</pdf:Producer>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/">
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">Layout 1</rdf:li>
            </rdf:Alt>
         </dc:title>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdfx="http://ns.adobe.com/pdfx/1.3/">
         <pdfx:XPressPrivate>%%DocumentProcessColors: Black&#xA;%%EndComments</pdfx:XPressPrivate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/">
         <xmpMM:DocumentID>uuid:1d54740c-1dd2-11b2-0a00-5c0927ad7b00</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:1d547410-1dd2-11b2-0a00-12f600000000</xmpMM:InstanceID>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>
endstream
endobj
14 0 obj
<</Nums[0<</S/D/St 1466>>]>>
endobj
66 0 obj
<</Count 10/Kids[59 0 R 67 0 R]/Type/Pages>>
endobj
59 0 obj
<</Count 6/Kids[60 0 R 61 0 R 62 0 R 63 0 R 64 0 R 65 0 R]/Parent 66 0 R/Type/Pages>>
endobj
67 0 obj
<</Count 4/Kids[68 0 R 69 0 R 70 0 R 71 0 R]/Parent 66 0 R/Type/Pages>>
endobj
68 0 obj
<</Annots 75 0 R/Contents 76 0 R/MediaBox[0 0 612 792]/Parent 67 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 77 0 R/GS2 78 0 R>>/Font<</T1_0 34 0 R/T1_1 18 0 R/T1_2 42 0 R/T1_3 22 0 R/T1_4 26 0 R/T1_5 58 0 R/T1_6 30 0 R/T1_7 79 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
69 0 obj
<</Annots 80 0 R/Contents 81 0 R/MediaBox[0 0 612 792]/Parent 67 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 82 0 R/GS2 83 0 R>>/Font<</T1_0 34 0 R/T1_1 42 0 R/T1_2 30 0 R/T1_3 58 0 R/T1_4 26 0 R/T1_5 22 0 R/T1_6 18 0 R/T1_7 79 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
70 0 obj
<</Annots 84 0 R/Contents 85 0 R/MediaBox[0 0 612 792]/Parent 67 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 86 0 R/GS2 87 0 R>>/Font<</T1_0 34 0 R/T1_1 26 0 R/T1_2 18 0 R/T1_3 22 0 R/T1_4 58 0 R/T1_5 79 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
71 0 obj
<</Annots 88 0 R/Contents 89 0 R/MediaBox[0 0 612 792]/Parent 67 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 90 0 R/GS2 91 0 R>>/Font<</T1_0 58 0 R/T1_1 26 0 R/T1_2 22 0 R/T1_3 18 0 R/T1_4 34 0 R/T1_5 79 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
88 0 obj
[92 0 R]
endobj
89 0 obj
<</Length 5424>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
318 745 234 10 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.02499 Tc 0.013 Tw 8 0 0 8 418.5493 749.5293 Tm
(Sodium Phosphate Dosing in Colonoscopy)Tj
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
10 0 0 10 259.0939 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 5 0 0 5 392.2189 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 405.4 23.9116 Tm
[(2007 September)110 (, V)110 (olume 41    )]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 5 0 0 5 519.569 25.4116 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 10 0 0 10 532.75 23.9116 Tm
(1475)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0 k
60 631.1249 492 106.875 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.0251 Tc 8.5 0 0 8.5 60 732.1874 Tm
(p)Tj
-0.02499 Tc 0.01199 Tw (opulations sp\216cifiques de patients, et les cliniciens doivent utilise\r des)Tj
0 -1.11765 TD
(m\216canismes de d\216pistage adapt\216s pour s\216lectionner les patien\ts adapt\216s)Tj
0 -1.11764 TD
(pour recevoir des pr\216parations de NaP pour coloscopie. R\216cemment, \des)Tj
0 -1.11765 TD
[(cas d\325insuf)20 (fisance r\216nale chez des patients qui auparavant avaient une)]TJ
0 -1.11764 TD
[(fonction r\216nale nor)-25 (male ont \216t\216 rapport\216s apr\217s une administration de)]TJ
T*
(pr\216parations NaP pour coloscopie. Ceci suscite des pr\216occupations \sur la)Tj
0 -1.11765 TD
(tol\216rance de ces agents. De nouveaux produits poss\217dent des doses)Tj
0 -1.11764 TD
(r\216duites de NaP et pourraient am\216liorer les pr\216cautions d\325em\ploi et la)Tj
0 -1.11765 TD
[(tol\216rance des pur)20 (gatifs de NaP sans alt\216rer l\325ef)20 (ficacit\216 de d\216tersion du)]TJ
0 -1.11764 TD
(colon, et ce avec une accumulation des donn\216es cliniques et/ou un)Tj
T*
(support rationnel d\325administration fractionn\216e de doses des produi\ts)Tj
-0.02521 Tc 30.35294 11.17647 Td
(N)Tj
-0.02499 Tc [(aP)109.9 (, de lar)20.1 (ges intervalles de doses et une agressive hydratation avant et)]TJ
0 -1.11765 TD
(apr\217s la pr\216paration intestinale, et \216galement apr\217s la proc\\216dure de)Tj
0 Tw 0 -1.11764 TD
(coloscopie.)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 6 0 0 6 318 700.6874 Tm
(CONCLUSIONS:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 364.2133 700.6874 Tm
[(L)90 (\325administration s\236re de produits NaP n\216cessite une)]TJ
-5.43686 -1.11764 Td
(rigoureuse attention aux \216l\216ments de dosage et autres recommandati\ons)Tj
T*
[(de traitement, y compris une administration de doses minimum ef)20 (ficaces)]TJ
0 -1.11765 TD
[(de NaP)110 (, un sch\216ma posologique par split doses fractionn\216es et une)]TJ
-0.0251 Tc 0 -1.11764 TD
(a)Tj
-0.02499 Tc (gressive hydratation.)Tj
ET
BT
/T1_4 1 Tf
0.013 Tw 8 0 0 8 467.8194 646.1874 Tm
[(T)35 (raduit par Thierry Y)100 (oumbi)]TJ
ET
0 0 0 0 k
66 54 480 211.2001 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
-0.024 Tc 14.7 0 0 14 202.2645 240.8298 Tm
[(A)-1 (r)1 (ticles published in )]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 14.7 0 0 14 328.2438 240.8298 Tm
(The Annals)Tj
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 14.7 0 0 14 395.4029 240.8298 Tm
(\311)Tj
ET
BT
/T1_4 1 Tf
-0.0251 Tc 12 0 0 12 80 219.3975 Tm
(\245)Tj
-0.02499 Tc 0.013 Tw 0.56234 0 Td
(Are posted in )Tj
ET
BT
/T1_1 1 Tf
12 0 0 12 150.6415 219.3975 Tm
(The Annals Online)Tj
ET
BT
/T1_4 1 Tf
12 0 0 12 238.6766 219.3975 Tm
(and indexed in PubMed weeks before appearing in print.)Tj
-0.0251 Tc -13.22305 -1.36666 Td
(\245)Tj
-0.02499 Tc 0.55208 0 Td
[(Appear on the prestigious HighW)40 (ire Press platfor)-25 (m at Stanford University)65 (, host to the most )]TJ
0 -1.2 TD
[(frequently cited jour)-25 (nals.)]TJ
-0.02521 Tc -0.55208 -1.36666 Td
(\245)Tj
-0.02499 Tc 0.56219 0 Td
[(Per)-25 (mit readers to access citations to other HighW)40 (ire jour)-25 (nals through free full-text access links.)]TJ
-0.0251 Tc -0.56219 -1.36667 Td
(\245)Tj
-0.02499 Tc 0.56232 0 Td
(Receive extensive peer review and contribute to )Tj
ET
BT
/T1_1 1 Tf
12 0 0 12 306.9492 155.7977 Tm
(The Annals)Tj
ET
BT
/T1_4 1 Tf
-0.0251 Tc 0 Tw 12 0 0 12 358.4271 155.7977 Tm
(\325)Tj
-0.02499 Tc 0.013 Tw 0.54534 0 Td
[(high jour)-25 (nal impact factor)55 (.)]TJ
ET
BT
/T1_3 1 Tf
-0.024 Tc 14.7 0 0 14 104.1823 125.6301 Tm
(Authors publishing in )Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 14.7 0 0 14 237.5474 125.6301 Tm
(The Annals)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 14.7 0 0 14 308.1978 125.6301 Tm
[(r)20 (ealize these additional benefits\311)]TJ
ET
BT
/T1_4 1 Tf
-0.0251 Tc 0 Tw 12 0 0 12 80 104.1978 Tm
(\245)Tj
-0.02499 Tc 0.013 Tw 0.56232 0 Td
(Quick and easy online manuscript submission for faster tur)Tj
0 Tw 22.27763 0 Td
(naround.)Tj
-0.0251 Tc -22.83995 -1.36667 Td
(\245)Tj
-0.02499 Tc 0.013 Tw 0.56233 0 Td
[(No submission fees or page char)20 (ges.)]TJ
-0.0251 Tc -0.56233 -1.36666 Td
(\245)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 12 0 0 12 86.7482 71.3978 Tm
[(And mor)21 (e)-1 (:)]TJ
ET
BT
/T1_4 1 Tf
-0.02499 Tc 12 0 0 12 142.4514 71.3978 Tm
[(visit www)65 (.theannals.com and select \322Author Infor)-25 (mation.\323)]TJ
ET
0 0 0 1 K
1.714 w 
60.857 48.857 490.286 221.486 re
h
S
0.85699 w 
63 51 486 217.2001 re
h
S
1.714 w 
65.144 53.1439 481.712 212.9121 re
h
S
BT
0 g
/GS2 gs
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 302.24986 11 Tm
( at DALHOUSIE UNIV on May 19, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
58 0 obj
<</BaseFont/SMFQXC+Times-BoldItalic/Encoding 55 0 R/FirstChar 32/FontDescriptor 57 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 667 722 0 0 0 0 0 0 667 0 0 0 0 611 0 667 556 611 0 0 0 0 0 0 0 0 0 0 0 0 500 0 444 500 444 0 500 556 278 0 0 278 778 556 500 500 0 0 389 278 556 0 0 500 444]>>
endobj
26 0 obj
<</BaseFont/PPLCJH+Times-Italic/Encoding 23 0 R/FirstChar 32/FontDescriptor 25 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 0 250 0 500 500 500 0 500 0 0 500 0 0 0 0 0 0 0 0 0 611 0 0 0 0 0 0 0 0 0 0 0 0 0 722 611 0 0 500 556 0 611 0 0 0 0 0 0 0 0 0 0 500 500 444 0 444 278 0 500 278 0 0 278 722 500 500 500 0 389 389 278 500 0 667 0 444]>>
endobj
22 0 obj
<</BaseFont/KYXJKS+ZapfDingbatsITC/Encoding 19 0 R/FirstChar 110/FontDescriptor 21 0 R/LastChar 110/Subtype/Type1/Type/Font/Widths[761]>>
endobj
18 0 obj
<</BaseFont/ILXTDE+Times-Bold/Encoding 15 0 R/FirstChar 32/FontDescriptor 17 0 R/LastChar 238/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 332 0 0 499 499 499 499 499 499 499 499 499 499 332 0 0 0 0 0 0 721 666 721 721 666 610 0 0 388 499 0 666 942 721 776 0 0 721 555 666 721 721 0 721 721 0 0 0 0 0 0 0 499 555 443 555 443 332 499 555 277 0 0 277 831 555 499 555 0 443 388 332 555 0 0 0 0 443 0 0 0 0 0 0 0 0 666 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 998 0 0 0 0 0 0 0 0 0 0 0 332 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 388 0 0 0 776]>>
endobj
34 0 obj
<</BaseFont/DMYLBO+Times-Roman/Encoding 31 0 R/FirstChar 32/FontDescriptor 33 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 833 0 0 333 333 500 0 250 333 250 278 500 500 500 500 500 500 500 500 500 500 278 278 564 564 0 444 0 722 667 667 722 611 556 722 722 333 389 722 611 889 722 722 556 722 667 556 611 722 722 944 722 722 611 333 0 333 0 0 0 444 500 444 500 444 333 500 500 278 278 500 278 778 500 500 500 500 333 389 278 500 500 722 500 500 444 0 0 0 0 0 0 0 0 611 0 0 0 444 444 0 444 0 0 0 444 444 0 0 278 0 0 0 0 500 0 0 500 0 0 0 500 0 0 0 0 0 0 350 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 1000 444 444 0 333]>>
endobj
79 0 obj
<</BaseFont/Helvetica/Encoding/WinAnsiEncoding/Subtype/Type1/Type/Font>>
endobj
31 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 37/percent 40/parenleft/parenright/asterisk 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon/less/equal 63/question 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y/Z/bracketleft 93/bracketright 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 131/Eacute 135/aacute/agrave 138/adieresis 142/eacute/egrave 146/iacute 151/oacute 154/odieresis 158/ucircumflex 165/bullet 191/oslash 208/endash/emdash/quotedblleft/quotedblright 213/quoteright]/Type/Encoding>>
endobj
33 0 obj
<</Ascent 684/CapHeight 662/Descent -215/Flags 34/FontBBox[-168 -218 1000 899]/FontFile3 32 0 R/FontName/DMYLBO+Times-Roman/ItalicAngle 0/StemH 0/StemV 84/Type/FontDescriptor/XHeight 677>>
endobj
32 0 obj
<</Length 10396/Length1 10396/Subtype/Type1C>>stream
  DMYLBO+Times-Roman   @ø øøøøû<ûnú|ú
 ‹‹
 ‹‹   û   ÷  º¬  ({ }ˆ002.000Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku RomanTurku  ^  I F   N B J O D M T P G C X Q S  U Z 6 4 E V 	 / 1 
 H W & ( -  # K   3 5     L Y         * 8 [ " R < $ > .  ' % ) o  0 i w  2 7 ‰ + ,   Ó “  Ê : ; 9 È Ï Ú Ø ² Ë Ò ß t `   p Î Ñ"Ôb½2·F‹èJâpİô@¸˜		z	¸


Ï™úwî4Tó^šŠÖt°6»DgÊ&”Òÿ#Zù8™/˜Â,Gµ„›Î%ô-®
!iíYÃD)ï ] œ!1!ê"s"ò#d$$Ç%N%à%ıû* vø+ÁÓß÷Nßøz›X‚—Ğ÷[öaÀ9R_rQ`‰÷Â…\{˜ kzŒ“‘‹°“‚aükF‚U†{÷k›T~œÎ÷…¹µ«±º¦eFûZG€}R‡{ûbĞ÷o«÷¯¤ĞFÒ÷cñôø<÷1{“W<dpJ‹.PŞ÷…÷Ë÷PÉ&û7(û&û Ñ6÷	ëÍ¿÷½ìû÷-ûcÙš®¯ÇÆ¥m7—ü$û*‹×ø¤Ô÷åáøn÷~md†pP‹û„÷=÷Dâæ³Ú‹Úí:Ù&ûHKûlŸ†¯ê²¯Ó‹İÄP6?\*95ûFûP~ø÷ vø-¿Œwáß÷Lß÷KŞÜù™›RŒ•»÷c÷dÆ=SXpSUÅxk¤Sbv‚XF†‡ƒ†ƒÖ¼ƒZyŒ‹1py›Œ–¤•x^û’V}}S‰{÷r›Yy™°÷¯••—•Ü£¨«—ª»¡iCûmU~Sˆ{÷s›SŒ|œÈ÷¸«ªœºÁn9ûgS„ƒP„{ûb–vŒÄø¤°ã÷6İxøO³¥{t…ˆ}r…—»÷W÷`¹û 1CYNrw¢¢¡ ¡˜‡˜‹˜¨ªŸ·¹¦lWNOuBqWg]kxj‹Z‹N·`É‹¸‹¸¢Â½¸T‘x·ª§›­§û0ßsˆ€ƒx{yb{sfo­¹Èºµ÷±ü vø^w÷$ğ×ğ8ßğ÷Eù§t¢opttop¡t§§¢¢¦Öı›èK–Ó÷÷†WwZyVy|©Œ‹“¦”{_û{CGˆ{û* vø)ÂŒwÚÜ:ß÷EßÔøx›]}›¼÷yè^ÄB[p|IDÛ¬„Yxˆ@ty™‘Œ“¦“{[û‹S}z\‰{÷gšY{˜­÷­Ì»Ã›”¬»£kJûeN}xZˆ{ûbÓø¨¤×ø0÷(}“`HapQ‹1Kİ÷ğÄÔØ²–‚c—‘w•kš|£‹¦¥ÁEº<û+!û!ûÚ/÷ßÆº÷Àü vìß÷”›MŒ~—Ãøç‡Hwv…Ey{Œ™’‹—°“€YüpV{}N‡{û™‚¡vøZw’¢¾È÷:Ñœ÷ğ÷»t«M° Ënœ|¤‹©¯­¨¶Å®d6œ›¬‡÷ƒ†‡‰…†„Œ…œ™cs:QXDOªeáZÅj­xq‹n_koYEi¯òs{\û/˜”’”“•Šˆ–œ´¤‡¥ÙÊÄÓû*‚¦ø4§¨ä÷šäøi÷~÷0éûû0+ûûç'÷÷êó÷2hû^FA8O÷÷*ç¼ÌĞßÇ*ûûÑ vø7«÷_¨òß7Şğøù«\§UûQAû2Š:kÜûÏB€B‡{÷˜›:–Ö÷Ï÷«èû÷Æ§² ”…oŸk¡”„œ¢¢û*«øËÏß÷wäøh÷‡÷?è$SWlXp‰÷Á†a{U{[~{Œ•’‹®”cüœmãiÚ÷ò÷÷!2bû	]L5[\££÷¶µ¬Ä×¿;ûÓ’v¡vødw ù4pùIøG›û{ªˆ˜y~‡u~l0ûr<÷ktÉ„‹˜£™“¶›û^{µŠ™v­%/û\kâH÷C‹†›Š“’Ÿ˜”¬›ûG{¢Š”€ŸX÷ûék˜‘’‘‘”©™÷÷ƒåû°^œ‹Œ’“ŒŒ»÷÷îœµ’û*ûVv÷a«øÇŒwÕß÷vàìøi÷ˆ÷Fä*R_sVa‰ÔÜ…TvŠŠ4m{Œ—‹—«‘[ügU„„M„{÷…›AŒ}—É÷0m«©²÷æ÷÷$6fûYAArm—s}—‚—•÷Šì¯“»ªºÕ¼>ûûÑ vø`w wÖßĞ÷âø+¬wŸhblsH]‰ä°†Jqw„Mu{š“Œ•¤•{_ûY‚ƒN{÷ƒ›KvÄ÷sœ˜¤™˜™“”’“‡ƒ”x “‡›¡›¥ûÑ v÷UË²÷Š÷±÷UËûŠKü¿ø«Ğß÷ªÍ~–vrzt‹g|¦Ê÷³ğ«&÷–‰…U<midp„†‰ˆ‹…‹‡Œ‰‹¿ûÂ5©bÉ¸²¤¾¬û*ûmğøËw™ø`ønøI™û}¯ˆ—„z„”qB<ûqû÷‚‹’‹–œ’’½‘™ûa}¨†—„”w÷ûŠ¦P®J|tpG{rt|z||wuloxzpkªr´Òµ¼÷*Ä÷/ø-–©™˜¡Ó}·øúòò÷ü¶ùSùŸû{wÖ‰r(û¢=`slakTtJO\®nn®‚°Û÷ÔÔ––ÚŸû®yÚƒ•BûËû@İ6÷:÷HÙİ÷P÷™ğ› Ù-~¯øø´Ñá÷~ïø~÷<Û\ÄûÕQ­"¼ÜÀµ²ÆåĞLû ¦¤u÷hvs…‚z„|}ŸOw‘q"?D)9­a÷C÷>¬hNGZ\C0MÀ÷Wu©ûh  –—¯«jç÷
ãØóû*¿ø§¦á÷wßøµ›ƒ‚Š‹‡f‚—¸øË†Ux|‡=v{Œ˜‘‹¯“‚aû0¬cr•bû.ûûû×2÷Àµ ¶ªNˆÙ§oë­û+Èm^l_9SŞ÷÷¾×ÔÂ»\Uû*Äø(wÑß÷Fß=Ùèør¯™YŠ–º÷ìû2{ğË‡•‚Yûrˆ€ƒuy^wlcj®µ÷Ûû%{»ˆ˜~[û;ºY×¯±›¦¦è·¶9ˆÙ§”¾™ûÑû1vùêw»à÷Äû6ûáZ÷÷l÷[¶ñ÷î‚›û@û@û‹ûLûµ#ë%²a§t²tÓ•v–ù÷ ¸ø1·xùTùŸû~wå„‘k4ûã‰üøuû?w¶Œ–„µ[üM%~y8ƒw÷Ÿ>z£ğø¸øJü¹œø¤ïšŸÚ‘-‹÷¡³÷½±xîò$ñ÷{÷Úø±øw÷$Ñû3ûšwÕƒ“‚DüFCŠp9‰w÷¬Ÿ<Œ|šÕ÷HŠ¤¢ŠÚÅ–¡²È­®ÇÏû‰!S\ûæz‹t÷™§’‘­÷ÍY-ûÑû1vùêw÷\à÷±÷Š÷aó+ñdµo¢d¢{÷5¼ûûlû[`%û(”{÷@÷Ö÷‹÷Lû*ûnÄ÷&Ö@Ôæ¤÷k²§§ĞnŞ÷EÙ¥¨İÀøiø²?u~“w]tm*AE-L¤hĞgCKyvtuš|²{¾ÀFZnfgTØ`ï÷÷ÙæÊ]´@ûTs•‹”˜™˜—˜™“”œ†¨çÏÍä¨‡|°PûSnf_İÀMaÌíÈ¦®»Ä¸B.óûŞR?bûŞÀ3M©µ£•œ²¹¬„›‰¤ˆ»‰À‰ğˆ¡€‹iû*’vøewø\øoøG›û{«Šš€v|‚oy]=û[%÷”†˜‡œ‹’œ˜”¬›ûW{ŸŠ•†—¤s÷û¿£N‚˜e”‹’‹’·÷÷Ô¦Î’”©d‹±e÷Èµb´÷“²xîğ÷œ¢¬¢«€øè÷>oû ^]sû7#²÷Œ÷.‰ßŠ–‚š6¢÷|t6|8û.÷q¨§÷÷~0¤‡÷#ü¥W€wÕ‡˜~CüQC~~A‡wø¯Ó}³÷É÷®³«÷øëùW÷ãû’xÙ‡•@û4iOq?û3'÷
÷O÷Kì÷÷%ôĞUûµ£ƒ÷fuu„{€s…€€¡Ej‘\û[û"û&ûbû|÷A!÷K÷÷Â÷\Å™šÃd‹²dùîğ°øè÷Bsû
SizûI0°ønÓ˜˜ÕŸû§wÕ‡˜~CüQpC~~A‡wø­ü$€÷Ñ÷÷I·ªr¤mlrrlm¤rª©¤¤©œ‹°f÷È³c²÷—±x÷ñ÷†ğ;÷¦€øå÷DÅo½\§ršy’Z™g è¡²¶Ú÷.Çû<û¬wŞˆ˜AüQA~8ˆw÷â¦€÷%ìÒô§ û÷Ì<Yb)Š› -Š÷y§Ã÷È]0¦€ ûÈ*O]ûO|“¬÷÷VŒĞdûüûXvù7w÷$ğçğ8ßğ÷Uù§t¢pottop¢t§¦¢¢¦èŒıø^†XwXyWy|©Œ‹“¦”{_ü!€jg}‚—€³i†wwwywk²tÂ÷ÆÖ÷"ü$›v£vÃ÷  ÷X–¿h²\jrskl¢w¯`™‹”•‡Š‰iogVg•xÎ­¸ÈÄû*}¯øçÆ÷ÑÚgÒĞøC÷lêk¹+·àÏ¹¤°ÅÚKÂ/,MXûdš‡³Ö¸«Ê‹Ì¸^L^r_cnpwvWyÁ¦†zªĞ»p¨XO8QICqv“ h£c‚ys}~ug·vÖ÷1÷ë÷œ‹÷Á¤÷®¯xññ÷}÷Üù'Ÿdv—p¬ûb÷‘÷¢ÄÀè÷/Êû7û§wÔ†—~DüD4…„=ƒw÷¨Ÿ=’—Ò÷XÃ÷‚ûÉNø"Kcû=Š÷Šì¨—’½÷Å]1d‹øí¶Ÿ¡÷gñ÷|vøãø„÷>üÄ„û>¤÷¡ ›÷Áü’@~8ˆw÷ºŸ8~—Öø’Á÷ {û¡û* v÷iáøš=Œy–ºøí‚ûG0~¥•œ’œ”‹¢•}jüm\y€=Š|û*}§øº÷‚š­ç÷‘äøh÷m÷Bßû[w„eLª÷1îê÷;«‡šûv‡ûMû;ûûDäû÷÷áê÷2jû cME4Sé÷'²­”™¡˜·´å¾Cûû* v÷;ËøQw÷·Ú>Øèøk÷;Ë&øQ_ûÎüQK÷­û;Ø÷;ğ<Ëû„÷‚÷éû*~§ù§ÃÖFÕ÷oĞT×ÔøQ÷0Øi»ûæØîÁ®µÎŞCÅ#!;H0J¢iñ4äû<ulG&ØI÷	÷
ØÍòØ1øPuiCVT¯E¿ÔÄ¸³ÊÏ¶_Gä™ü-G__IAUÇİÎ±É¾ªt”„‹èE£rNû* vİßø›`i¡d¼û.÷V¨¦ïè½®Ì‰™û_}“Š‹¢Š”‡Œ~Œƒƒ{|ûû‰ø3†Oxz†>w{Œ˜•‹’¯”ZüuU‰‰B€{÷~›M~”´÷I÷ûLr‡‹…ƒ‚…y{û* vøWwœøbøs›hy˜n·û÷Xß÷¦§›­Œšû3}¬‡’‡}~uU?~Ÿ…s³xª„š‹“‹›•‘«™ûb}µŠ‡°Sêû%ûû9pd}lŠ{÷%›n€—“—™¡Û÷Üû›s‹Š‹€{€„r‡{5 v÷Í÷Í©ø‹ø©÷ÕÍü‹Iø‹û]Íü‹Iû*~¥ù¥£ë÷˜ëøp÷ß÷c÷EÆ¤nd˜[[d~rnFPbûûû³ûÑOr¨²~»»²˜¤¨ÑÇ³÷÷+ûh`!44`õ÷h÷i¶õââ¶!ûiü›v£v÷ó÷Û÷ û÷h÷Tø)©r¤lmrrml¤r©ª¤¤ª°§ü¿h²\jrskl¢w¯p•”‹”•‡Š‰iogVg•xÎ­¸ÈÄû*~°øâàÙ÷ùÑøJù?‚‘yuƒ‡w‹ûeûû€Š‰Šˆ‹‰‡‰‘Š÷ƒ÷5Yû.&O?;u„«^¡l}pr}~tb·uİ÷5÷ ò÷.÷@ûÄû)¦µà÷XœŒ’û*‰w÷—¶ø§©ç÷€ï+ëôø^ø!÷5/÷
ûû4'û û
Ô:öÀ»±¹øŒˆmû%ûû>qw÷…›÷3÷<‹÷ô+bv‡‚uod}j>\Õ÷÷±ÊÏä¸4û;÷K“v˜ª÷—®š«÷g¤ÏwÈ×÷r¤ÌÖ÷q¥Àù—÷šÑf³Hûû ûû;»WÕóë÷÷ûø2eYYbyDd{’ oŸr{‘oû û	ûB¾QÍõï÷÷™‰–‡ƒ£—‰£·§’ °‰¿ÀûğıºÀø…÷£û:û<du¥·ÏË÷?â²ªf^ü÷¼û:û<cu£¸È°æ¹½£¡¡˜œ‘Š„’•š„¨ƒ‘w‹}û*™vøèÔŸø@øTùšü|_`%œƒ²Ì¢›Á‹÷mûZüèÌ5—vø w§øø«‚Ïü=÷Vø=÷VÏüû{MûÑ‹ù÷ñ÷ÌŸ8~—ÖøOÖ˜—ŞŸûºwŞˆ˜@üO@~8ˆw÷º–vù"ú1ú6ùŸûZwÂ†™‚l|„k‚sûûèû÷épĞ‹Š‹—¤¡•ÂŸûŸwÊ‡‡­:­9 û¯û%øƒ ˆ•‹˜¡—‘ÀŸûˆwÉ‚‡ÒûSÌûC†èû¡š÷.ø;‘y‘|‚‘|¡Uª;±*œ[ª4™Ù÷ƒ–ªÌ÷H¦Ôš³–©šµ›—»‘ûb‹©ø©¦øø6÷yv*|~/‹û÷¢ø*šûïˆûœÕ•™šÈ÷ûü*|øÓ‹÷[´ø4wšùGùVŸ^}˜lÓûøÌwûdüOû!}xY‡w÷ZŸ\Šu™ª••‘›¹÷
÷š´*•t”l‹pzƒWw†÷—û{÷÷§û*ûVv÷aÉø§£à÷|ßø|ûk›]zš´øê†NgUª|_‹û,ûû&ûÍ4ìÀÀ¤»¹ŠûNT|~A„{ä÷ëk„~t~sr…s>W×÷÷	ÁÙÜÍªkFûÑû/¤ù”¤ãØ÷Àû/¤1l}™©ù<©™™ªå¤ûhıÆœ}·øOv÷M²§÷ù÷yœ=AOp5‹û+,÷÷K÷Så÷	÷(öÒNû°¡‚÷tvƒu|wŒŒ{x’b™Y“a‹ûZ‹û!û#‹û]‹ûf÷û÷_‹÷‹÷ ¿¾×ûÑû/¤ù”¤÷=Ø÷Šû/ùÆûhråª™}mı<m}}l1r÷ƒ‹ùö·øœğùïŸFyĞøQÓ™™ÔŸû[ûoüû{øûZwİ†˜~Dü+&|x;„w÷}Ÿ@x¥íø$÷ü·™÷øÎüV9€~<†wü’vùFw‚÷º÷±ù8IûxıFÎ-‹÷Èµb´÷“²xîğ÷”¢´¢Ïøµøœˆ÷#ü¦wÕ‡˜~CüQC~~A‡w÷«Ÿ@{šÒ÷p÷&‰ßŠ–š7¢÷|t6|8û&÷q·¨§÷÷~0Ó‹x°øá°xòñø÷œù?÷â÷bû)÷ûû wÕ‡˜~CüQC~~A‡w÷¯÷‚÷&÷÷clû…ûU#)ûa\~”«ø­”‘Á÷Q÷	ûûLÓ‹÷¼·÷±õñ÷ÃñùPŸA~˜ÓøQÓ˜˜ÕŸû¨wÕ‡˜~CûWûÃ÷WÓ˜˜ÕŸû¨wÕ‡˜~CüQC~~A‡w÷¨ŸA~˜Ó÷b÷ÃûbC~~A‡wû* v÷]¼‹øˆøˆ÷]¼üˆZûÑÚ÷ ÷oøŞ¿h²\jrskk¢w¯”–‹“”Œ‘†Š‰hohVg•wÎ­¸ÈÅÓ}¯øş¯­÷ø?÷ùC÷Ş÷_û÷#ûSûTûû#û_û]÷û#÷T÷S÷÷#÷]ûŒûT:û	ûû:÷	÷T÷Rİ÷÷÷ŞûûRûb vøE÷ ¶÷ æ÷ ø2ø}«tŸg‡‹ƒ‚Š†•®§®À¯ŸHh^OQW®dº¬¤£«û{«tŸg‚€‡‹ƒ‚Š…Œ•®§®À¯ŸHi^NQW®dº¬¤£«ûb vøÍö©÷ æ÷ ø%øİ¿h²\jrskl¢w¯•”‹”•‡Š‰iogVh•wÎ­¸ÈÄû{¿h²\jrskl¢w¯•”‹”•Œ†Š‰iogVh•wÎ­¸ÈÄü€÷÷÷Ü÷÷Tø)©r¤mlrrml¤rª©¤¤ªûıªr¤mlrrlm¤rª©¤¤©ÓûF÷Gwù¯­÷ø?÷ùPûEûŒ=¶5÷ ÷2¥ò÷‹÷E‹÷_û÷#ûS‹ûT‹ûû#‹û_‹ûÁûâS®u©}¥…¹T=Í÷_÷,’Œ‹Œ²ûøûT:û	ûû:÷	÷T÷Rİ÷÷÷ŞûûRÓ•vù#›ù;àùKùŸû`àxÆ†™‚m}„qmû&üû,÷æmÍ©‹™¤–Êûàw½ˆœ{±6÷‹üºš÷pøÆ¨Õ››º÷ò v÷]¼‹ú|ú|÷]¼ş|Zû™’vù&÷CñøùŸû´wÚ‰™}Cüd\€wq|†‘£„²|›qqutp_²nÆ÷ ÈÓ÷øÓ™™ÚÓ‹ù÷ñàùeŸXz–ë2û|÷÷Q÷QÇÇ£—ÎŸû˜wÇ‡’ˆtrxs4:tuº¶û@û0÷WàŞ–—Ù‘û¬xÙ…–8ü;8€=…x÷¬=‘€—Ş÷D¥¡õ!Ø>ÀF‹tày‚ˆO‰wûb„óø¹¨÷Mó«èø2ø›æ?Ì .EM9dœt©¥››¤™…˜}š}›‡’•©»ª»ÆºUGb}PuVoIy`€XŠ\•Öš©ÏàÀÍ¢½‹¼ûün¨t¢nnttnn¢t¨¨¢¢¨ü vøbwÌ÷rûUßo ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œû³ıĞ÷›K–Ó÷÷†XyWxXx|©Œ‹“¦”{_û{CGˆ{û*‚¦ø4§¨ä÷šäøi÷~áeÑN±Ì÷fRû p—l‘i‹û0+û5¯CÆbBû °Ì÷§~«ƒ®‹÷êó÷û,÷7û3ûÄr¹|Ë‹Õç¼ÌĞª§~s¡ÊûZû^FAko›§t÷5÷Ç¥ašP‹Fû* vøßßw÷mÒøGø¤y˜X•f“x“p™~’˜’§š’¯“½•™£zœy{{€mpro|~o{„™ª —®”¦”™¢}švu}|t}‚”p–hvl}’o›{˜s§©p|–zx{zxs}½°ƒŸ…¦{—„~„o|yƒfƒXy~sxœzš›–©¦¤§›˜¦›—’}lˆvgƒqˆ}t™| ¡™š£˜‰•‚¥¯‡ ª™˜„§|š}£om¦›€››œûb–vŒÄø¤Éï°ãXïîï5İÃ÷ÑøÒ§u¡oouuoo¡u§§¡¡§û[§u¡oouuoo¡u§§¡¡§ûBüÒiøO³¥{t…ˆ}r…—»÷W÷`¹û 1CYNrw¢¢¡ ¡˜‡˜‹˜¨ªŸ·¹¦lWNOuBqWg]kxj‹Z‹N·`É‹¸‹¸¢Â½©T‘x·ª§›­§û0ßsˆ€ƒi{yb{sfo­¹Èºµ÷±Ó‹ù÷ÏñùRùŸûow¾Œ‚t‡€{û!ûxû)÷t€›…š‹˜¡™‘ÄŸû¬w¯‰™„§iŸt²W¥e÷ûTûM>~€2‰w÷ÆŸ2~–Ø÷U÷'÷wÁß¨¢Â‘d‹±øß±”øŞøç÷Dtûhjq%û–øCøöšü¡xû>¤òŸ°¨÷÷qüHüö|øÆÓ‹ù•ùHàùRŸWw˜eÂûS÷¦÷%÷KÅÕ¤šÌŸû€wÅˆ–†r|ƒ}kdûû`ÆCî~¦‹¢£š‘ÈŸûÁwĞ…¢wãû÷û5û0ûU;)~W†w÷}àVs–Œ¡Œœ˜¤°¸÷÷(êû!«\g‹}àuwƒSŠwûb–vŒÄø¤°ã¤÷r6İÄ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œüıtøO³¥{t…ˆ}r…—»÷W÷`¹û 1CYNrw¢¢¡ ¡˜‡˜‹˜¨ªŸ·¹¦lWNOuBqWg]kxj‹Z‹N·`É‹¸‹¸¢Â½´T‘x·ª§›­§û0ßsˆ€ƒt{yb{sfo­¹Èºµ÷±ûbĞ÷o«÷¯¤ĞFÒÀ÷rGñÃ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œüıòø<÷1{“W<dpJ‹.PŞ÷…÷Ë÷PÉ&û7(û&û Ñ6÷	ëÍ¿÷½êû÷-ûcÙš®¯ÇÆ¥m7—û*‚¦ø4§Éï¨äzïîïwäŞ,÷ÑøÒ§u¡oouuoo¡u§§¡¡§û[§u¡oouuoo¡u§§¡¡§û]üÒÒøi÷~÷0éûû0+ûûç'÷÷êó÷2hû^FA8O÷÷*ç¼ÌĞßÇ*ûû*‚¦ø4§¨äÆ÷rxäß÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œü#ıèøi÷~÷0éûû0+ûûç'÷÷êó÷2hû^FA8O÷÷*ç¼ÌĞßÇ*ûd‹±e÷Èµb´÷“²xîğ¬÷r”¢¬¢÷ ÷i ÷Ïùœ}™z|}„||û'û)³÷.ì—”™‹œü[ığªÀøè÷>oû ^]sû7#²÷Œ÷.‰ßŠ–‚š6¢÷|t6|8û.÷q¨§÷÷~0¤‡÷#ü¥VÀwÕ‡˜~CüQC~~A‡wø¯ûb–vŒÄø¤°ãY÷rİÃ÷…øû'÷)|š}’|‹z}}zz”}÷.*û•ütøO³¥{t…ˆ}r…—»÷W÷`¹û 1CYNrw¢¢¡ ¡˜‡˜‹˜¨ªŸ·¹¦lWNOuBqWg]kxj‹Z‹N·`É‹¸‹¸¢Â½´T‘x·ª§›­§û0ßsˆ€ƒt{yb{sfo­¹Èºµ÷±ûbĞ÷o«÷¯¤ĞFÒv÷r‘ñÃ÷…øû'÷)|š}’|‹z}}zz”}÷.*û•üòø<÷1{“W<dpJ‹.PŞ÷…÷Ë÷PÉ&û7(û&û Ñ6÷	ëÍ¿÷½êû÷-ûcÙš®¯ÇÆ¥m7—û*Äø(w÷‡wÑßP÷ÊBß=Ùß(÷Õøû÷:Kûû:¬÷ò÷$üüÒør¯™YŠ–º÷ìû2{ÔË‡•‚Yûrˆ€ƒuy^wlcj®µ÷Ûû%{»ˆ˜~[û;ºY×¯±›¦¦Ò·¶9ˆÙ§”¾™ûÀ³÷¢÷Ê÷ßÖOÇ@ANNAAÈNÕÖÇÈÕu¡øW–÷\š’‹÷š”ü}¦
ß
_÷ù
endstream
endobj
15 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma/hyphen 48/zero/one/two/three/four/five/six/seven/eight/nine/colon 65/A/B/C/D/E/F 73/I/J 76/L/M/N/O 82/R/S/T/U/V 88/X/Y 97/a/b/c/d/e/f/g/h/i 108/l/m/n/o/p 114/r/s/t/u 122/z 131/Eacute 201/ellipsis 213/quoteright 234/Iacute 238/Oacute]/Type/Encoding>>
endobj
17 0 obj
<</Ascent 912/CapHeight 676/Descent -203/Flags 262178/FontBBox[-168 -218 998 934]/FontFile3 16 0 R/FontName/ILXTDE+Times-Bold/ItalicAngle 0/StemH 0/StemV 25/Type/FontDescriptor/XHeight 921>>
endobj
16 0 obj
<</Length 5858/Length1 5858/Subtype/Type1C>>stream
  ILXTDE+Times-Bold   @ø øøøøû<ûnúzú:
 ‹‹
 ‹‹   ù   õ  l°  ½ }‡Œ002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku BoldTurku  8              0 # + & 5 * 7  ' 6 / 4  % 3 . " $ » - : ² 9 ¶  S U J D M F T Q V C I E O y P H B [ G N :   < “ şˆæRİCšç;À‚Ï[’ù_¾?B¦		Œ	í
R
Ævı†İ{¹Kzâ[Ô,—ø_ÄSœØ8Ùû+‹¤ù+w÷O÷&øN¤1x›×øÍzûûq Ä™™¤—u\ü:wz(Šrû+ v÷#÷øEw÷÷&û$÷$èøm÷#÷MøE;dYk_xrûû4‘#û2ûğ÷Šû#÷&÷#èû$÷ûcğ÷a÷»èû+~¦÷ş¹÷„¥§øRøn÷p÷AŞû kx‡}e³÷*ÑĞ÷/²¥û¨jû8û/ûwûBæû÷"÷æî÷û-KûnZuy–¡€|¦‚Úåµ¨‘º’Œ “Ì¢Qû6ûÒ v÷@÷·÷†÷²÷@÷û†ûû+}÷(û(½øÏÛ÷­÷&@÷¨øf÷‹ÜbÇ:¯°Ë±©ÇŞM¿(&@Y$U ®Ç°¤À‹Ç²bMIig,mxè÷ `ÇP+EdZT¨Dqí‹7iprlSÇgé÷9÷÷÷&û+ƒÇO÷(÷S÷Ü÷ø	Ø¸øiù8ûÕ+ûí÷
ºƒ»uÎm´VTU^\XøDZã‹BgqrhVÈhå÷4÷	ğ÷ÜfÍH³V«e“û”¡Ü÷©û+ vø¯÷œø^øoù8ü3`ûr¤Ëœ£ Ã÷bûZü¯êü$šv£v²÷Là÷sµÍ`ºO[jj[[©k·à’’‹“—“‚}fkd>S–tÉ°¢¦©¬± ¾»û+~ªù§§÷û÷÷9÷û÷
Øøj÷MãbÇûÒÔâ£¼½ÌãAÃû
û 6HûA³UïPè"l]X5&áH÷÷çÚ÷Ôû÷ôa‚gjeR¨CÄÒ¶±±·Â­]?è…ü+Gi_XOeÁàÅ•ª³Æ÷C£kDû+~¥÷„¹÷ı¦¥øRølø&÷>.÷ûû1*ûûÕ9ö°£™¨]û0DDû(kq÷¤÷C÷8÷vû1¦hŠoƒS†s…xMtÅ÷5÷—¨»¡x•›o–62û+‹÷øM÷÷½÷øq÷hrEo|‚(û*÷3÷.ŞÛ«Ç‹Ö÷@×û*DIûY¦Ä¥¶«¿Ğ¼V@YwSaN^K]Uûûsø3û+~§ù§£øVøn÷ß÷b,÷*ûû,û+ûaûZëû&÷÷ë÷&÷Zû2û û'wN\\wÈ÷'÷y÷&ŸÈººŸNû&÷x¬ù¬®ùVùy÷ã÷dû'÷(ûbûbû'û(ûdûb÷(û(÷a÷a÷(÷(÷bûEŒûhOûûû	P÷÷h÷_Ë÷÷÷Ìûû_›‹¤r«÷Ê¡÷®©r¤ò÷3÷L÷?®øı÷NåHÊû£÷°²°Øò/Äû;ûÇrÎˆŸzXüyX@‚r÷Õ÷?÷Ó÷şû[÷Ùû lpûˆ÷t®š™±Ñ¬`/§ûİ&cZ8`y¶÷©ô¼Xûû+,¬ù]¤÷"İ÷5øpù¤ûórÜ‰ }UüÀMyr_qv˜£¦”‹«²i®ddmj`DÕSê÷#ÔÔ÷&øHÔ››Ó›‹ªl¤÷Ä¬÷­¬r¤ò÷5÷6¥÷¤·ù÷dpûQBZûKw˜µ÷‡÷
„©n™û¥÷çqzûknûˆ÷}´—’Ï÷#Ä`û ¤÷\üÒÿrĞ…|YüwW~€A‚røÛ›‹¤øÿ«¬¦÷U÷6÷T¦ùøoˆ÷]üê‡û]¨¡÷±­÷”ü£B€6„r÷ø¤7}˜Õø£÷€¾oûûš‹¤ù¤÷÷4ø¤Btœ½øxÀ¢ÔŒ¤ûñrÒ‰¡zVüxZuzD‡rÒvù2¤›ù?ùOù¤ûhr«ˆÁŒa{ˆz]ûûÜû÷ĞpÌˆ”‹›§˜‘Ô¤ûãr½‚—¡X÷”üì¦÷vøß£É—–Á•ûÒ“vøywİ÷<÷ø¹f±]\ee]\±eº¹°±ºûÑºf±]\ee\]±eº¹°±¹c‹¤÷Ä¬÷­¬r¤ò÷5÷.¤÷£ŞøÙøo÷]üÉrĞ‡}WüzY}Cƒr÷û¤2u™À÷~õˆ¬i™û	¤÷ærxû	jk&‰÷~ş²—“Ç÷#Æ\ûÒx¼ù¤í÷2÷Õ·ùOù¤ûprÛƒyBûÄû*TGû(]É÷÷áÖœ›ÛŒ¤ûårÍ†›yFûá/\¿`a¼Ïvà×Û©¶²¯³ŸÏá÷ÓÆ™›Ë”Òv¤ù¤ò¶øB·øùNù¤ûkrÕ„vDûÃ‰ûîø?ûfr£‡™ºSüoT|}Cr÷v¤>•xŸÏø%øøQü²¦øáÄ˜™Ì”,x­vù:«®¨w÷÷…÷
ìø”÷SÙaÑG­û'Ö9µw ‹¼È¶²ÊçÑIû­§÷mmoƒ……xgg­1û7<û1¼O÷PÍlç_ r‹THY_?ô$BØ÷onûŒ¨ì¢”•›­±ií÷(ïà÷ü$Ò‹¤r®øó­r¤ë÷6÷•÷AÜùD÷ë÷eû÷û}ûÃrÌ…œ}\ü^vzN‡r÷Î÷p÷ ÷÷füûA{ûVH)ûa|š¶øŠ°˜•»÷Òûû]Ò‹¤øş¬r¤÷÷5÷K÷>øù]¤t‚‚˜û]÷²÷°¶¹ß÷
,ÈûOûÓrÔ‡™{DüNBƒ‚<€r÷å¤@•}šĞ÷V¥÷cûÍYøˆûdjû$Š÷”ø«š•ºŞ±^)÷¸‹¤ù¤s£óµø¦÷.øú+¤<•–ÒøOÓ™šÔ£ûû[ülû\ølûørÕƒ™WüpO€‚<€r÷~¤7“yÔøf÷üâ¦÷øñüS}@„rÒ‹¤÷@²øZw”ù9ùB£]—W÷ûsø¢nûpü¸e.‚Yr÷_¤Ot—¤š˜±«Ù÷s§QRt~ƒ|ˆ€ˆ‹Y†r÷€ûVè÷‡Òyºù	­‡w¼÷EûEù`¤ôùA÷m¤;4Ig;‹ûIñ÷a÷kÈö÷çÛEûÇ¤ô÷~pk~}yèoB½‹#ûVû)û0û`ûd÷%û"÷j÷Î®÷î÷xvù„v®ùVùy÷ãûbû(û(ûaûaû(÷(÷b÷d÷'÷(÷b÷b÷'û(ûdûEŒ÷_J÷ûûKûû_ûhÆû÷	÷Ç÷÷hzø±v~mxû#4T÷÷0›•Ÿ‹¤Ÿws›‹ªl¤ù¤ó÷6ğù÷xnû*KO\ûDx—¸ølØ™—â¤ûğrÎ‡|XüyğX‚ƒ?røÕÒ‹¤ù¤÷©÷6ùLù¤ûnsÏ‡šƒnw~jq`ûûMû÷}t¸‰‹—£šÍ£ûár²‡ {i÷Kûàû&B9€r÷î¤:”€—Ó÷L÷Q÷Ëš¤•­› vùMvøX÷ù÷ddûdüÛ¤Õ”˜–¿øw½yšF‘¤øÒû\r÷vR¶û#G„bû}÷«¨œ÷¥ûçq}÷m¨û
’û‡aŸ~Ë÷Ô¼÷Åûù1v~mxû#4T÷÷0›•Ÿ‹¤ŸwsÒ‹¤ù¤›ù<ùL¤[qºt°ûI÷¯÷9÷uœíš¤ûŒrÌ†’„rr‡ûû(*÷+€†–‹•Ÿ—‘Ï¤ûír°ˆ–‚ª^÷Zû¸ûBûqrkt~T€r÷¤P‘u–Œ¤Œ¢£·Íâ²½ñû6™u’x‹v‡E…rûš vùMvŸ÷ñøûñ¤Ò¡œ¼øxÀuœD¤÷ñrBŠtyVüxY¢zÔˆxùèv‚~lxû"4T÷÷0›•Ÿ‹¤ŸwsûÒ vùGwÚ÷K÷šøÖÍaºO[jj[[©k·’’‹“—“‚}fkd>S–tÉ°¢¦©¬±Ÿ¾»ûc‹¤÷Â÷%5á€wİ÷û÷ ¨øEøºj©Y[anNc‰¸ÚûQr³‰˜|bûºd€aƒr÷¤¤N€˜É÷P¿¦¶«ä©P‹Á±¥¦´ûÒ”vøA·Ó÷÷ßîr—sa€v‹q~±÷Áç·/÷=r?&okMUq¿ûØI¶dÒÌ®¥à¸ü	‹¤øHw÷wÏ÷÷jøúµh®a`hha`®h¶µ®®¶²üú¤j~›¯øûSs¸€’„aû¹bƒƒ_rûc~Íøª¤÷!øAæyfbp|c‹7Rä÷õªÊÀ«“€UŒSŒ›u²µ¥¤²ÉG»3û)"û&ûä)÷×Í®Ğ¼ü	‹¤ùwÍ÷÷‘¤kŒ{Ÿ±øäûQr¯‡™{eü‘ezwjŠrûc}Ó÷O°÷4©¤÷$û$÷÷÷ôø<÷t™aXo{_‹BcÊ÷†÷÷*„JØû	û6'û û&İ'÷ŞÁ­æÇìû÷?û÷ »½¥Ÿ{l’‘u‹ƒ8ûš}­vøY¬Šw¤¦qï'¥÷gì¥÷ü÷÷?û~r‹ñªª¥¬Ä´f>¤¥µ÷&t|†…†}¥tk ‹X.IO8û3÷’‹.emp_£F]·äuépû:¤ ””’‘¥Än‹ÀçÌÈã,ûLv÷TÂø
Ã€wÕ÷ ÷5÷'ìø÷‡÷?ë!MfsUpˆÜÎûRr·„”aü‰b„„[‚s÷¤ PyŸÍ÷!]º¥~¶÷Øò÷-û'wûpQQjrŸ³y÷‡ì•¬È¿¿£Nû,~Ìø¤Ë÷÷÷øªŸ¢b}šµ÷ûû]r¿‡•^û®ifz‚od{Ÿ¾÷æûOr´ƒ’‚aû2¼XâÅµ§°µJÉ¢ÌÌ‘,}«vøDÀ÷`wÒ÷û÷ ÷6÷&zø›÷†÷?éû[k}bb÷—ûUr·„•€düó—ÚÃö`¾¬}½÷æó÷,û&{û$nKIen­·÷›´š¡«È«Hû,‹¤øÎ÷`wÏ÷÷÷ø¨¤h}œ´÷‹ãXÁ8U`tU^÷­ûSrµ…•dü’c€~b…r÷ƒ¤i}›°÷’³¾¹­oUû†f€}g†r,}Ãø
Ã÷H£¤÷(÷6÷ø©£_|™´øÓûlsÎ†•„]ûL¼\r˜^û:!û$û×*÷ ¼¯»·JĞ¦î•ûZè{aUbUrÅ÷÷¦ÇÃ­ªsf™,‹¤øÎ€wÔ÷÷÷Øø­¤h}œ´÷‹ãXÁ8U`tU^øÍûSrµ…•dû»c€~b…r÷ƒ¤i}›°÷Ø’±¾»­oUû†f€}g†r÷ğ“vİùÕú'Òºe±]\fe\]°eº¹±±¹ûàºe±\]ee\]±e¹º±±¹ûáºf±]\ee\]±eº¹°±¹û+~©ø=©¤÷'÷1÷&øo÷y÷ ,òûû,$û û!é&÷÷éğ÷!û&Œû3wUPQwÁ÷3÷2ŸÁÅÆŸUû2û+ûb«÷÷ã¦÷kÁ‚©§ã<÷û÷÷+÷fÚé@øvSÙO¸#J=v“©¢©¦¥Êò€ïÎÅáµ€§n§ÛÁûê@œXveû8J-G¸SØpŠé@;mfeXc¤q¿}Šì@Q‚jqeQ×g÷÷>á½ïê€ûEø/xg\^w²äé±º¹d.ì@íü1^Tq)5[¢¶¢”˜¥÷@Â¤{iû+}ÒZvø[ª¤÷&û÷÷÷¬øz¶} ˆˆ‡Š†‹~„”›÷™à>¿ûû>XBa£rµ²§¢«µl“‹©œ­Ä¤pMB´1qûE^û	N¹^ÊÅ¹Ÿ½ÂìX•¡y¿µ¦™µ³´ûVÄjn{qou¨²Å²²İ£ûc‹«ø!« ø"ø7÷4p#gjsûo÷zø'¥ü„û"¥î¦–÷$û}ü(røûÒ‹¤ø¸÷zwÑ÷Ã÷øøäÅP´7RYwjomh‚a'S^Ãûà`€^‡r÷©¤IŠ{šË÷Íá¸5÷Á™¢¬˜„‚Šzvz‹qm¥s«³££±÷I‹¤øÎIÍwÑ÷û÷÷÷÷÷«ù¾¤dŒ€˜µ÷áWÃ:QctKYÍml FMdsNbŠ»ÔûRrµ†—~cûºb‚_ƒr÷¤§j~›±÷”´¾·°œpRû…a€d‡r÷~¤i~›±÷ç”´½¹®šrQû…a€~f‰rxøa—÷_›÷p”÷Ÿ“üu¤
¤Œ
_÷ù
endstream
endobj
19 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[110/a73]/Type/Encoding>>
endobj
21 0 obj
<</Ascent 1667/CapHeight 1667/Descent -293/Flags 4/FontBBox[0 -143 976 814]/FontFile3 20 0 R/FontName/KYXJKS+ZapfDingbatsITC/ItalicAngle 0/StemH 0/StemV 0/Type/FontDescriptor/XHeight 0>>
endobj
20 0 obj
<</Length 178/Length1 178/Subtype/Type1C>>stream
  KYXJKS+ZapfDingbatsITC   6‹û¹Ïƒ
 ˆ?‹‹
 ˆ?‹‹   h   e   k‘   ¬ a73    ‡ %<ø
ú0û¹ÉıÌù7ùÌıYVøçúüçäú!ÑúsúsøÍù
endstream
endobj
23 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 46/period 48/zero/one/two 52/four 55/seven 65/A 79/O/P 83/S/T 86/V 97/a/b/c 101/e/f 104/h/i 108/l/m/n/o/p 114/r/s/t/u 119/w 121/y]/Type/Encoding>>
endobj
25 0 obj
<</Ascent 684/CapHeight 654/Descent -205/Flags 98/FontBBox[-169 -217 1009 884]/FontFile3 24 0 R/FontName/PPLCJH+Times-Italic/ItalicAngle -11/StemH 0/StemV 23/Type/FontDescriptor/XHeight 677>>
endobj
24 0 obj
<</Length 3657/Length1 3657/Subtype/Type1C>>stream
  PPLCJH+Times-Italic   Cø øøøø€û=ûmú…ú
 ‹‹
 ‹‹      ü  A¬  ( }‰002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku ItalicTurku    5 I F  " O B M T P G 1 S N D U Q Z    4 C  7 V   X  0 J !   Y ìLO³E¿|Á>³Ş+Ÿ ­ZŠ		v	¤	ù
‰
Ï#Ìì8¡- vøÿ®ÆøÑùù"ü§aû.‡¡ºœ¤¥Ÿ¤¬¦‘÷û#ü¥}YszF„{÷¶›9‘‚«•‘¥’¥÷ ø‡ÁÖ¨rKŠ‚‰xœŠû*—v©vøOvø]ğøpô—_Qvwz‹ƒ„’•–‘™“Ä÷e•®‘©‹˜²p§fKFMû#-‰÷
øK…L}w†Bƒz¤ŒœŒ¤‰‹tuj|Pûü‹Ö±÷)›µ²ÆÁÜÍÆ®‹›‹—€‹}‹†Œ‹ƒnWûS}W‚ağpœ{§¾·®Ú»ûb¸ø¢ªá÷yÌø/ø
¸o¢Tûû2û9û&3¾VàÎÕ²ÏÉ—CQk{`‹Se°Á™Ÿ’¥¨÷, ò×‹âJ’7+Gûv·°æÏÔÀ Œš{tü$d v÷v¯ø+vXøûøÈ›Sƒ•Ó,øÌqûµü‰Aû}{bƒ{÷O›\~’¢˜“¥—¢Å÷÷pŸûŒŒ‚‹gx~PŠ{¾÷šûV÷(÷˜û*—v©vøNv™ø`ğønó|˜UFy‹‚…’”’ •±·÷4—·”´‹š°q¤e,4û&H^‰Ë÷e‡ût‘Œ[‚{¾‰˜†x~‚n…v‹ƒl@û§Ö´÷$¢Ã¼ÑÊã±¬¯‹˜‹•‹z‹€…lf`û7{PŠƒ|ğl›{«¹©¤ãËû*€¼[»ø¡œŞğøpï–~~YSy‹„†“•¦–µØ÷Æ…L„€[ŠŒ€®od‹ûû1ûJû-=®bÎÑ²©÷ãˆ{L†q‹wğo˜¨±¬¥ßÍû÷”3,ûz!dr§·åé÷q÷®¢qdü•v´÷‚÷«ù;†Q{ˆ9{¤·Šr„–v>"üv;ˆ}‹zi›yªÁ§¢ñÑ”UCwxu‹†‘•’š“©û™“v¢vøA£Œv÷ Ô¹Ø|øøO}}‚„‡~|nqœ‹cC[aJ-÷?‹@[nkaRl³ìz|üwû4š›’‘–|­ªx‹±ßÉÂÖêûÙ‹Ô¬¢Ÿ­½«g=•|›û*•vøYv¦ß÷¦Şøh÷¹èUÃ2û(û*û0û-/ÂWë÷ ÷*÷<÷8«)Bûmû[k°Âîİ÷p÷¶§fPüûMvøï«÷x¡¯êø:øú±g¦Xaexdjibu\j#0ƒkå3ü9tûlX_‹„‘•””‹™ zšsw}zsi¬q·åĞì÷MµÔ÷Õ÷ ‘« ÷0¦±ÓÂ™•†„Š†€‹|sš{¡¢¡d v÷Å°÷®©ø‰òøğøŠîBÀûûŒz«†±`}‡v`û
ü={R„…P€{÷‰›S’“§š—”­À÷U¶…¤‰±‹÷,óÛ÷	$‘ûOWûxt{Ñ÷‹‘ —“¨‹æ´g;û™ v÷èñŒv¸øğø0øªxŸnX@7(^‚wŠ¼÷[ğˆWW‚W‚{“Œ“ ˜y~…ih:û¹×¶÷ š´®Ğ°ÕµÀ ‹ğ f‹¶¨œ«Ó—v©vø¿\º—ùFxùRô}—ZOxyzŠƒ†•”Œ’£Ä÷g”­‘©‹˜¯s§k24ûHa‰¦ã•±‹œ¯t£iO?Dû8ˆÄ÷[ˆ$vŒŒP€{ÀŠ–‡zƒ‘{M8ûÊÖªğŸßÉãxÑ¼Â»¨˜“‚|ƒŒ|T‹‰;ûº×²÷, Â»ÏºÏÁ»¦‹—‹”‚‹}‹†Œ€^ZûZ}Q‡z~øoš{¦¹º°ØÀûb€¯ø5w©àø<÷ü½a«Hû%û û'û.)¿UëÔÉ®ÔÀ{”cZSk[‹Sh¸Ò÷$ì÷ñ£šƒ{|‚‹ru›|£¦¥ü–vø+¬¯÷˜÷¼øB;§òŒ‹‹ˆ……ŠŠ€‚\Sbib{m€‡ˆ‹‹‚‹”‹‚ÖBû§t5Œ‹‚uŠ y¦¤£–Ÿ¢›˜œ³Ä~‘rlpj{}‹…‘–Œ›ß÷Òßû*ûMv÷Wø¶øåøi÷Éßa¼BL[l=T‰§î‡’û0uz©­ˆ‹p„†s‚jûüN~Y……[†|÷bš\y”¡©¨ğ“®}¦˜ˆ¨÷!÷0÷=÷+1“û(û û5'ltš¡¹»÷(¹Ì¤Ä¼¿³¡mWûbûLvùv÷àéc³Ğø>ø²u£hàv{|wĞZÁ—‹dP,û/p]w÷…¬N÷qy‹vE}VzŸ“Œ”Á¤Yûl¼šG•V~{„|tmxqplww€…‚‹w‹}¨p‹t‹z{‹u‹pŸyª‹°‹¼²Ğà÷	÷#÷÷ƒ‹Úû*‹Öø¥ÔøàøWøíFÔ-*?Q%gŸ„²Íµ§É‹ÒÀWDP`C%ûûeûtz÷÷½÷z’rXv~U‹ûR÷U÷U÷
÷
©º‹Ïû*„§ù§«Ú÷ÈÙø…øH÷*Oæ(û.û,û|û~ûÎ0ê÷1÷&÷j÷y=âû*Tû]J5_jjvhUj½Ü÷½÷UÁîÆ¬·­·¿ª\<û*˜vøïÔÖøaø¬ù&…•ü
:û˜‚¼Å¥™Æ‹÷rˆüüìÒû*y®€vù¬Œv÷â÷ã¼øù0ty€~ƒy¼fz¤‹>ûDD*P—r÷ûÂQ›q]@SQB9KÓè’‹‘—wŒüjûsœ£’—•¼µÀf‹Æ÷äá÷Ít²/ç8Ş{¥¸È¶µÊã®^û	¼œ‰û*¡ø¼øàøn÷ÔÔ[¼D2V:J^Šğø†U‚‹#|{ ‰¸‘nyf‡{ûüŠˆrÕnÉ÷)÷:÷B÷06~#ûûSûh|—¦ìë÷‰÷µ§iWü$‡÷÷¬³s§invxpz’{š}ƒrurVg•xà¼¶Á‹Ædvù4v×øøùDù›ûN{¿„–…uy|hfKû^ûó‡IøJŠ‘‹‘‹«š”É’›û…{À„‘ƒ™9çüÃøøı›¦™•¥û*€ÀmvøNvªv÷à÷¸øo÷ }”[Nyy|‹„…‘•—Œ˜¼‹ Ù÷¼AaûrT`HP/XUn‹q‹¥“æø ¸ˆQ}zˆ@€} ‰²’lƒ‹Š‚gYûW\†p‹zgx¯Ğ¾¾÷O÷hûƒhwølœy©Ï¯Ğ»®û* v÷EÍKËŒøq°ørù:cü5üCwG÷™ZûGÚğº÷EîšÍ,™÷×,û×ûi÷Å÷Õû* v¼÷üø-ù0‘‰‡„2v{+{ ¯‹‹£Œ˜€xƒ‹……wûü‚€e‚‡0}÷«™tŒK‡°’‰ƒ Ö÷#øšš”‹œvø`v¡v÷Õ÷:Ê÷H»üùø¬v jt}|xj¶†‹f]_Iûû&k÷ı‹‡†‹‡‰Šƒ†ûSûÄ‰…çƒæzåü¯„‰ƒü‰ˆ‹Šˆ[z‡V‚}¡Œ‹‹§Œ“…“t•mšû‘#4€ŒŠf™“‘”·¤÷:÷º¨ûĞq…’Œ‘“’¢ÉÖ÷=÷]ïü$€÷¦÷÷·ªr¤mlrrlm¤rª©¤¤©Óy¬øÿ¬ÇôøAôùOø=÷&/ëû ûTûkû|ûdû(å*÷÷^÷g÷v÷m"Áû0û ûÈûS9[Éô÷0÷÷¼÷SÚ¼P+ü–vøÄõ÷;ì÷œøï©v¢povtmm t§¦ ¢©nüˆ~–j]jly‹ƒ…‘”’‹šÂä÷ÖˆH~sˆF‚{¿Š–‡y…ˆ{†ydû$lûŠ…‹re›x©¹³«ÜÁxøA™÷g¢’‹÷¡üs¡
¢
_÷ù
endstream
endobj
55 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 65/A 67/C/D 75/K 80/P 82/R/S/T 97/a 99/c/d/e 103/g/h/i 108/l/m/n/o/p 115/s/t/u 120/x/y]/Type/Encoding>>
endobj
57 0 obj
<</Ascent 700/CapHeight 669/Descent -204/Flags 262242/FontBBox[-200 -216 992 921]/FontFile3 56 0 R/FontName/SMFQXC+Times-BoldItalic/ItalicAngle -11/StemH 0/StemV 79/Type/FontDescriptor/XHeight 685>>
endobj
56 0 obj
<</Length 3329/Length1 3329/Subtype/Type1C>>stream
  SMFQXC+Times-BoldItalic   Cø øøøø€û\ûlútú-
 ‹‹
 ‹‹  	    >¯  İ }“002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku Bold ItalicTurku    % , 3 F Y 4 P E J V N  1 I T Q B U O H $ M D Z 5 "    p ü…èrì4¿,»loébØYÑ	E	¢	ë
8
¶eÓ‹­øñ©r¤ø¬÷'ğçù1rÏƒ‘„o€‰…{Pûü?}X{|Y„r÷²÷•÷N÷9÷x÷DûïûTğIG§’›•®÷ÀNûûfûWCBWBf5ay–£ŒŒ˜‹‹—·œ‹¤øÿ¤vùeøø$÷l÷Y´°—‘³¤ûgrŸ‰¯poMStwûIû6†ŒÇ÷q™¿ŸšÇ¤ûËrÎƒ’ˆk€ˆz„qûüU}X|}Xƒr÷µ¤W}”¨“‹‘‘Ê÷„“‰÷ ûz“zy‹|†T…r÷¬¤hz•€¢œ‹¤øø«r¤nùğøA÷ëÃ—¦•«¡º¬©Á‹¾‹ì>ºû3‹û¦rÎ‚‘ˆr}‡q…wûüU}W}W‚r÷¼¤Q|“¨™£”«Â÷V§÷ ûß÷^¤U}—wÅğûIø„¯””“ªÃ¬iO:bFPys„j‡bŠûb~Ë÷«÷l¬÷#û#÷÷>çô÷(÷j÷«¾àº”u(AM8v÷<CLegocì^u§ÁœŒ”¢å”÷:Î÷½`¯Oû'û"û<û13ÊLâÙÂ³íÄû*~÷÷üw w]ø•Ğ´øLo•˜‹•¬šyY•©û-_Dxm€|‹yv ‹qmsrmf¥s³¹  ßÁ¬¾¡û
£e¿‹¹²¬äÊv™cXƒƒy‹w™²ƒl÷1´Î¥¦¢‹Ÿx‹¡¨££©¬q¦k]gk Ağyà„£wª-y­ù®‡wğ÷÷÷ø÷Åø@G¿}Ÿ·Í±³ËÜµYû•¦‡ø³÷\ny„uø]l¨‹Aû26!û?÷‰_‹û!FVVC!^áñˆmŒhûs©§—’’¯·hæ÷äÛ÷ŞiÈûíû*}©ø5¨ˆ÷÷`÷÷¯øbû'ûû3û;5ÏKç÷%÷÷0÷9èLÉ.ƒn©ŠšvaBSû¬+iy¡·Ö¿÷­ö†û*ÓDÒ÷ıµv÷p÷¢ø9¢šwkbDû /rz£®ÍÛ÷€â÷Š÷«FyW†4…p §˜‚w„‡z…ueût£w”p‹û
û/ûSû1ğB¸UÇÌ¹¯æÀ‚cŠ‚{pd¡u±¼¼µß½u›mZwu{Š…Š†‘“¢º÷:”¬ü—vøÃ÷÷÷÷Vù@fmmff©m°°©©°°m©f¨ûr/z…Š#q¹Š—…r†‰„‡{Sûl€b‡v‹|e¦q´ÇÃ¸å¿u™jWqox‹ƒ„’“”Š‹”®‹È÷zª÷-—vø_w«wšøpĞø{øVû
aû&wUgGfFZXn‹}‹ƒ”‹›‹–¡•¬ğé÷ÉEI|B‰p»‡“‡u}†s€f_û+‚k…j‹xV£sÀÂ³¦ØÃ“–‘ª¶‰{\…opc¡w·ÄÅºÜ·v˜fUxx|‹‡‘˜Ğ™“¯š¾÷—v©vøÔŠwøÚ÷h÷}øaO~~‰ûq·Š•†w„Œ„kû‹ƒkMûq÷÷÷æ÷­––’‚|‚‰~†|‹Gûoiû÷°÷µ÷á÷¹‹™•~b3ûO‹8è_¢v¹Ç´­ìÃu—eQ|z|‹‚„’“°ã÷L‹çºm¨YXL`û?œ¸¡¨ø´q¤b-DûH]ˆü$d‹¤÷¹®÷±ªs£øe÷&è÷àøå±•“’¬¾ªiRWyMrhmud|S€„‹x‚k‡²œŠ¤÷7÷ Ù÷
òD¿û"û²øsÏ‚‘ˆo~‡u…tûüV}YUr÷º¤Q~“©—¢‘¡-—v©vøbw÷ô÷p÷¹ùO.zn‡6‚q£²h‰}…vû.üË÷¦ì§İ¡¸¸èÊÓ¯‹™‹”…‹{‹a3ûS‹8ğh¦r°á´ÔÉµv›eSrp}‹ƒ„’“å÷‹È¸n¨^GT^û4‰Œû™“vŒ¨ø1«Šw¹ë´ê\÷ßøao{ƒ…†}|nv¡‹^:VZ?T™nÎ=³[›mrlrsjYjºá~qüuû:¥™““‘™|¡¤x‹·äÈÂÙõûÜ‹Ò§Ÿ¢«¸©c<˜\¦ˆû*û`¥÷:®øÓ÷Ô÷÷køc*{£û|p¹Š“‡w„nƒjûü>~X}€_Šq÷Œ¥XŒ}’¥§¥Ù•º{«›†¡÷÷"÷J÷<ÙbºIZ\p;R‰ïª£™xlADûˆ*uz› ¬´÷™´Û§º¸²û*’vÑ÷ÿµv÷p÷ø9¢Š™xnIHûŒ1rx¢ªÌÜ÷Ş†÷P¯û…yS‰·…s£bûû)ûRû3=µ[ÎÇ·­çÃŒ€b‰ƒ‹}ğd§p³¸½¶ŞÁvšfWxx|‹ƒ†‘•§‘¨§çü—vø4¶€÷·÷‹øçhZ>^f2dh¾Lûp‚mxF‹n`¥r¸Å»³ëÆu™gStsy‹ƒ„’“š“¯œÈÈ÷oŞ¶C-—v©vøbw÷wp÷…øaS~Y„.…p «Œoqj Š†‹ƒlPûh÷÷èâğ½¥˜–‚~i4û[‹:ğb£u¸Ä¼´å¾u˜eP}{zŠƒ„’•¤ã÷i‹Ö½p¢X6N/*J‰û*û_­÷Kv÷4«÷‹ªWâ‹÷÷÷ @÷	ö÷„Øo‚¥~šwt`_qEC^©»·È³›õ÷!øK¨œtcWiûEn|Ÿ±¾¬÷ĞúûCü>+uipSN×`÷ ÷&ëÇæÇg¬ûªVši•y™‹››œ˜š™ƒ‹ õ÷êÚíœŠ’‡ÎÃû¥ik“aû$9*V¦dÀv9]}}emw´|œyÀøû®«ùù7ùAnt}‚…y„„Œ‘yšXb’aûtûKû\ûˆû-÷!÷4÷íÀëÊm¡N<Gd;‹-SÍ÷ ÷*è÷·÷QÚ»O)~‹…ˆ|«…ü—v÷³÷µùP3ym‡1‚q¢³jw}\„q'ûÿ}W„j‹zb¤sµÜ¼ÖÇ²ušiUqqy‹‚…’•—’¬šÀûb~Ìø¬†÷÷)÷÷Ñ÷!GYov`_n¯ÄÏÄ÷må™”„‚}vz‹pm¤tª²£¦¶Â^®Eûû%û:û//ÉLç×¼­ñÒûbûaÜ:÷ø»w wô÷·÷KËª˜ø0µ–‰ûT²¥û•JjWQIjêqm®‹gntsli¦p°ãäã÷Eõâ÷&¾÷Í½imìnqpkúVÂ‹b]Iûyg‰~Ôw÷wärÙK|vˆJ„d‹¤øõ®i­½øëğùù1üºeû?¤„¹ìÉ´÷‘û'ü¯|UrzI‹r÷ß¤C€‘ª˜¨‘ ğ÷øî†ªh“û¦‰œ‹¤÷L²øHwø÷ ø/ù@süüàm\x{hƒr÷Y¤Zz“¤–‘”›Çò÷j‹š7‹_d|€K…r÷Ã¤K„“~Õû\ø±û‰ûMxøV˜÷b›š‹÷œ–üv¤
ÚŒ
_÷ù
endstream
endobj
1 0 obj
<</OPM 1/Type/ExtGState>>
endobj
90 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
91 0 obj
<</OP false/OPM 0/op false>>
endobj
92 0 obj
<</A 93 0 R/Border[0 0 0]/Rect[261.505 9.0 303.25 16.0]/Subtype/Link/Type/Annot>>
endobj
93 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
84 0 obj
[94 0 R]
endobj
85 0 obj
<</Length 15519>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.02499 Tc 0.011 Tw 8 0 0 8 60 732.5292 Tm
[(31.)-475 (Schiller LR. Clinical phar)-25 (macology and use of laxatives and lavage solu-)]TJ
0.013 Tw 1.6875 -1.2625 Td
[(tions. J Clin Gastroenterol 1999;28:1)35 (1)50 (-)-24 (8.)]TJ
0 Tc 0.10699 Tw -1.6875 -1.3875 Td
[(32.)-500 (Markowitz GS, Nasr SH, Klein P)110 (, et al. Renal failure due to acute)]TJ
0.07201 Tw 1.6875 -1.2625 Td
(nephrocalcinosis following oral sodium phosphate bowel cleansing.)Tj
-0.02499 Tc 0.013 Tw 0 -1.2625 TD
[(Hum Pathol 2004;35:675)-25 (-)-25 (84.)]TJ
-0.015 Tc 0.015 Tw -1.6875 -1.3875 Td
[(33.)-485 (Balaban DH, Leavell BS Jr)39 (, Oblinger MJ, Thompson WO, Bolton ND,)]TJ
-0.00301 Tc 0.00301 Tw 1.6875 -1.2625 Td
(Pambianco DJ. Low volume bowel preparation for colonoscopy: ran-)Tj
-0.004 Tc 0.004 Tw T*
(domized, endoscopist-blinded trial of liquid sodium phosphate versus)Tj
-0.02499 Tc 0.013 Tw T*
[(tablet sodium phosphate. Am J Gastroenterol 2003;98:827-)-25 (32.)]TJ
-0.008 Tc 0.008 Tw -1.6875 -1.38751 Td
[(34.)-492 (Rex D, Malik P)110 (, Chasen R, Thompson WO, Galt DJB. A randomized,)]TJ
0 Tc 0.02299 Tw 1.6875 -1.2625 Td
(single blind evaluation of oral sodium phosphate solution \(OSPS\) as)Tj
-0.02499 Tc 0.01199 Tw T*
[(bowel preparation with dif)20 (ferent hydration and dosing regimens \(abstract)]TJ
0.013 Tw T*
(1309\). Am J Gastroenterol 2006;101\(9 suppl\):S504. )Tj
-0.02299 Tc 0.02299 Tw -1.6875 -1.3875 Td
[(35.)-477 (Rex DK, Schwartz H, Goldstein M, et al. Safety and colon-cleansing ef)-1 (-)]TJ
-0.005 Tc 0.005 Tw 1.6875 -1.2625 Td
[(ficacy of a new residue-free for)-25 (mulation of sodium phosphate tablets.)]TJ
-0.02499 Tc 0.013 Tw T*
[(Am J Gastroenterol 2006;101:2594)-75 (-)-75 (604.)]TJ
-0.01801 Tc 0.01801 Tw -1.6875 -1.3875 Td
[(36.)-482 (W)41 (ruble L, DeMicco M, Medof)19 (f J, et al. Residue-free sodium phosphate)]TJ
-0.02499 Tc 0.02499 Tw 1.6875 -1.2625 Td
[(tablets \(OsmoPrep\) versus V)60 (isicol for colon cleansing: a randomized, in-)]TJ
0.013 Tw T*
[(vestigator)20 (-blinded trial. Gastrointest Endosc 2007;65:660)-75 (-70.)]TJ
-0.01801 Tc 0.01801 Tw -1.6875 -1.3875 Td
[(37.)-482 (Balaban DH, Malik P)110 (, Thompson WO. Comparison of two dosing regi-)]TJ
-0.015 Tc 0.015 Tw 1.6875 -1.2625 Td
(mens of liquid sodium phosphate against a low dose PEG regimen \(ab-)Tj
-0.02499 Tc 0.013 Tw T*
(stract 970\). Am J Gastroenterol 2005;100\(9 suppl\):S354)Tj
0 Tw 21.3216 0.00001 Td
(-5.)Tj
-0.01199 Tc 0.01199 Tw -23.0091 -1.38751 Td
[(38.)-488 (Unal S, Dogan UB, Ozturk Z, Cindoruk M. A randomized prospective)]TJ
-0.021 Tc 0.021 Tw 1.6875 -1.2625 Td
[(trial comparing 45 and 90)-75 (-ml oral sodium phosphate with X-Prep in the)]TJ
-0.01401 Tc 0.01401 Tw T*
(preparation of patients for colonoscopy)Tj
-0.0137 Tc 15.17241 0 Td
(.)Tj
-0.01401 Tc 0.48617 0 Td
(Acta Gastroenterol Belg 1998;)Tj
-0.02499 Tc 0 Tw -15.65859 -1.26252 Td
[(61:281)50 (-)-125 (4.)]TJ
-0.015 Tc 0.015 Tw -1.6875 -1.3875 Td
[(39.)-485 (Khashab M, Rex DK. Ef)20 (ficacy and tolerability of a new for)-25 (mulation of)]TJ
-0.02 Tc 0.02 Tw 1.6875 -1.2625 Td
(sodium phosphate tablets \(INKP-101\), and a reduced sodium phosphate)Tj
-0.00999 Tc 0.00999 Tw T*
(dose, in colon cleansing: a single-center open-label pilot trial. Alimen\t)Tj
-0.02499 Tc 0.013 Tw T*
[(Phar)-25 (macol Ther 2005;21:465)-25 (-)-25 (8.)]TJ
-0.011 Tc 0.011 Tw -1.6875 -1.3875 Td
[(40.)-489 (Rex DK, Chasen R, Pochapin MB. Safety and ef)20 (ficacy of two reduced)]TJ
0 Tc 1.6875 -1.2625 Td
(dosing regimens of sodium phosphate tablets for preparation prior to)Tj
-0.02499 Tc 0.013 Tw T*
[(colonoscopy)65 (. Aliment Phar)-25 (macol Ther 2002;16:937-)-125 (44.)]TJ
-0.021 Tc 0 Tw -1.6875 -1.3875 Td
(41.)Tj
0.021 Tw 1.66743 0 Td
(Frommer D. Cleansing ability and tolerance of three bowel preparations)Tj
-0.02499 Tc 0.013 Tw 0.02007 -1.2625 Td
[(for colonoscopy)65 (. Dis Colon Rectum 1997;40:100)-75 (-)-125 (4.)]TJ
-0.002 Tc 0 Tw -1.6875 -1.3875 Td
(42.)Tj
0.002 Tw 1.74075 0 Td
(Berkelhammer C, Ekambaram A, Silva RG. Low-volume oral colon)Tj
0 Tc 27.17642 0 Td
(-)Tj
-0.002 Tc -27.22967 -1.26251 Td
(oscopy bowel preparation: sodium phosphate and magnesium citrate.)Tj
-0.02499 Tc 0.013 Tw T*
[(Gastrointest Endosc 2002;56:89)-25 (-94.)]TJ
0.01199 Tw -1.6875 -1.3875 Td
[(43.)-475 (Parra-Blanco A, Nicol\207s-P\216rez D, Gimeno-Garc\222a A, et al. The ti\ming of)]TJ
-0.01801 Tc 0.01801 Tw 1.6875 -1.2625 Td
[(bowel preparation before colonoscopy deter)-25 (mines the quality of cleans-)]TJ
-0.02499 Tc 0.009 Tw T*
(ing, and is a significant factor contributing to the detection of flat l\esions:)Tj
-0.0251 Tc T*
(a)Tj
-0.02499 Tc 0.013 Tw 0.65633 0 Td
[(randomized study)65 (. W)80 (orld J Gastroenterol 2006;12:6161)50 (-)-75 (6.)]TJ
-0.021 Tc 0.021 Tw -2.34383 -1.38751 Td
[(44.)-480 (K\232ssi J, Krekel\212 I, Patrikainen H,)1 ( )-1 (V)60 (uorinen T)76 (, Luostarinen M, Laato M.)]TJ
0 Tc 0.005 Tw 1.6875 -1.2625 Td
(The cleansing result of oral sodium phosphate is inversely correlated)Tj
-0.01401 Tc 0.01401 Tw T*
(with time between the last administration and colonoscopy)Tj
-0.0145 Tc 22.73598 0.00001 Td
[(.)-249.9 (T)]TJ
-0.01401 Tc 1.01198 0.00001 Td
(ech Colo)Tj
0 Tc 3.48175 0.00001 Td
(-)Tj
-0.02499 Tc 0.013 Tw -27.2297 -1.26253 Td
[(proctol 2007;1)35 (1:51)50 (-)-125 (4.)]TJ
-0.005 Tc 0.005 Tw -1.6875 -1.3875 Td
[(45.)-495 (Rostom A, Jolicoeur E, Dub\216 C, et al. A randomized prospective trial)]TJ
-0.008 Tc 0.008 Tw 1.6875 -1.2625 Td
[(comparing dif)20 (ferent regimens of oral sodium phosphate and polyethy-)]TJ
0 Tc 0.09801 Tw T*
(lene glycol\320based lavage solution in the preparation of patients for)Tj
-0.02499 Tc 0 Tw T*
(colonoscopy)Tj
-0.0251 Tc 4.71424 -0.00001 Td
(.)Tj
-0.02499 Tc 0.013 Tw 0.46236 0 Td
(Gastrointest Endosc 2006;64:544)Tj
0 Tw 12.65585 -0.00001 Td
(-52.)Tj
-0.022 Tc 0.022 Tw -19.51995 -1.38749 Td
[(46.)-478 (Huynh T)75 (, V)110 (anner S, Paterson W)90 (. Safety profile of 5)-25 (-h oral sodium phos-)]TJ
-0.00999 Tc 0.00999 Tw 1.6875 -1.2625 Td
(phate regimen for colonoscopy cleansing: lack of clinically significant)Tj
-0.02499 Tc 0.013 Tw T*
(hypocalcemia or hypovolemia. Am J Gastroenterol 1995;90:104)Tj
0 Tw 24.4173 0.00001 Td
(-7.)Tj
0.015 Tw -26.1048 -1.38751 Td
[(47.)-475 (Practice guidelines for preoperative fasting and the use of phar)-25 (macologic)]TJ
-0.02 Tc 0.019 Tw 1.6875 -1.2625 Td
(agents to reduce the risk of pulmonary aspiration: application to health\y)Tj
0.02 Tw T*
[(patients under)19 (going elective procedures: a report by the American Soci)]TJ
0 Tc 27.2299 0.00002 Td
(-)Tj
-0.02 Tc -27.2299 -1.26251 Td
[(ety of Anesthesiologists T)64.5 (ask Force on Preoperative Fasting. Anesthesi)]TJ
0 Tc 27.22975 0.00002 Td
(-)Tj
-0.02499 Tc 0.013 Tw -27.22975 -1.26252 Td
(ology 1999;90:896)Tj
0 Tw 7.19587 0.00001 Td
(-905.)Tj
-0.019 Tc 0.019 Tw -8.88338 -1.38752 Td
[(48.)-481 (DiPalma JA, Buckley SE, W)79 (ar)-25 (ner BA, Culpepper RM. Biochemical ef-)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.2625 Td
[(fects of oral sodium phosphate. Dig Dis Sci 1996;41:749)-25 (-53.)]TJ
-0.01401 Tc 0.01401 Tw -1.6875 -1.38751 Td
[(49.)-486 (Barclay RL, Depew WT)75 (, V)110 (anner SJ. Carbohydrate-electrolyte rehydra-)]TJ
0 Tc 0.006 Tw 1.6875 -1.26249 Td
(tion protects against intravascular volume contraction during colonic)Tj
-0.013 Tc 0.013 Tw T*
(cleansing with orally administered sodium phosphate. Gastrointest En-)Tj
-0.02499 Tc T*
(dosc 2002;56:633)Tj
0 Tc 6.7758 0.00001 Td
(-)Tj
-0.02499 Tc 0 Tw [0.3 (8.)]TJ
-0.01601 Tc -8.46329 -1.3875 Td
(50.)Tj
0.01601 Tw 1.68451 0.00001 Td
[(Tjandra JJ, T)70 (agkalidis P)110 (. Carbohydrate-electrolyte \(E-L)55 (yte\) solution en-)]TJ
-0.022 Tc 0.022 Tw 0.00299 -1.26251 Td
(hances bowel preparation with oral Fleet Phospho-soda. Dis Colon Rec-)Tj
-0.02499 Tc 0.013 Tw T*
[(tum 2004;47:1)35 (181)50 (-)-75 (6.)]TJ
ET
BT
/T1_0 1 Tf
0.01199 Tw 9 0 0 9 318 731.8455 Tm
(Consideraciones de Dosificaci\227n en el Uso de Preparaciones)Tj
0 -1.22222 TD
(Intestinales de Fosfato de Sodio para Colonoscopia)Tj
ET
BT
/T1_0 1 Tf
-0.0251 Tc 0 Tw 8 0 0 8 318 706.8455 Tm
(DK)Tj
-0.02499 Tc 1.63131 0 Td
(Rex)Tj
ET
BT
/T1_1 1 Tf
0.013 Tw 8 0 0 8 318 690.8455 Tm
[(Ann Phar)-25 (macother)]TJ
ET
BT
/T1_0 1 Tf
0 Tw 8 0 0 8 379.9947 690.8455 Tm
[(2007;41:1466)-25 (-75.)]TJ
ET
BT
/T1_0 1 Tf
7.5 0 0 7.5 318 665.3455 Tm
[(EXTRACT)20 (O)]TJ
ET
BT
/T1_2 1 Tf
-0.024 Tc 6 0 0 6 318 651.6905 Tm
[(OBJETIV)21 (O)-2 (:)]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 351.55 651.6905 Tm
(Repasar las consideraciones de dosificaci\227n y otras)Tj
-3.94705 -1.13588 Td
(recomendaciones  de tratamiento con el prop\227sito de maximizar la)Tj
0 -1.13588 TD
(eficacia, la tolerabilidad, y la seguridad de las preparaciones de fosfa\to)Tj
T*
(de sodio \(NaP\). )Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0.013 Tw 6 0 0 6 318 610.0705 Tm
(FUENTES DE INFORMACI\356N:)Tj
ET
BT
/T1_0 1 Tf
-0.0251 Tc 0 Tw 8.5 0 0 8.5 402.7048 610.0705 Tm
(Se)Tj
-0.02499 Tc 0.01199 Tw 1.18719 -0.00001 Td
(obtuvo acceso a la literatura a trav\216s de)Tj
-11.15247 -1.13588 Td
[(PubMed \(1990)-110 (\320mayo 2007\) y de abstractos de reuniones cient\222ficas.)]TJ
ET
BT
/T1_2 1 Tf
-0.024 Tc 0.013 Tw 6 0 0 6 318 587.7605 Tm
[(SELECCI\356N DE FUENTES Y M\203T)21 (ODO DE EXTRACCI\356N DE INFORMACI\356N:)]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0 Tw 8.5 0 0 8.5 531.2955 587.7605 Tm
(Se)Tj
0.01199 Tw -25.09358 -1.13588 Td
(evaluaron publicaciones en el idioma ingl\216s incluyendo ensayos cl\222\nicos)Tj
-0.0251 Tc T*
(y)Tj
-0.02499 Tc 0.7123 0 Td
[(reportes de casos. Infor)-25 (mes recientes evaluando preparaciones)]TJ
-0.7123 -1.13588 Td
(intestinales nuevas, conteniendo dosis reducidas de NaP fueron)Tj
-0.0251 Tc T*
(r)Tj
-0.02499 Tc [(epasados para evaluar la eficacia, la tolerabilidad y)65 (, la seguridad.)]TJ
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 536.4855 Tm
(S\352NTESIS:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 347.674 536.4855 Tm
(Entre las preparaciones intestinales usualmente administradas)Tj
-3.49106 -1.13588 Td
(para colonoscopia, los preparados de NaP son generalmente m\207s)Tj
T*
(efectivos y mejor tolerados en comparaci\227n con los regimenes de una)Tj
T*
[(soluci\227n electrolitica de lavado de glicol polietil\216nico. Sin emba\r)20 (go, los)]TJ
T*
(preparados de NaP est\207n contraindicados en poblaciones espec\222ficas\ de)Tj
T*
(pacientes, y los m\216dicos deben utilizar mecanismos de detecci\227n)Tj
T*
(efectivos para seleccionar los pacientes apropiados a recibir una)Tj
T*
(preparaci\227n de NaP para colonoscopia. En pacientes con una previa)Tj
T*
[(funci\227n renal nor)-24.3 (mal, recientemente se han reportado casos de)]TJ
T*
(insuficiencia renal despu\216s de utilizar un preparado de NaP para)Tj
T*
(colonoscopia, aumentando la preocupaci\227n sobre la seguridad de estos)Tj
T*
(agentes. Los nuevos productos contienen dosis reducidas de NaP y)Tj
T*
[(pueden mejorar la seguridad y la tolerabilidad de los pur)20.9 (gantes de NaP)]TJ
T*
(sin comprometer la eficacia de la limpieza del colon. En adici\227n, los\)Tj
T*
(datos cl\222nicos acumulados y/o  la exposici\227n razonada apoyan la)Tj
T*
(divisi\227n de la dosis de los productos de NaP)Tj
-0.0251 Tc 16.55293 0 Td
(,)Tj
-0.02499 Tc 0.46231 0 Td
(un amplio intervalo entre)Tj
-17.01524 -1.13588 Td
[(las dosis y)65 (, una hidrataci\227n agresiva antes y durante la preparaci\227n del)]TJ
T*
(intestino y despu\216s del procedimiento de colonoscopia.)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 359.6955 Tm
(CONCLUSIONES:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 368.0652 359.6955 Tm
(La administraci\227n segura de los productos de NaP)Tj
-5.89002 -1.13588 Td
(requiere una atenci\227n rigurosa a las consideraciones de dosificaci\227\n y)Tj
T*
(otras recomendaciones de tratamiento, incluyendo la administraci\227n de\)Tj
T*
(dosis m\222nimas efectivas, los horarios de dosis divididas, y la hidrat\aci\227n)Tj
0 Tw T*
(agresiva.)Tj
ET
BT
/T1_0 1 Tf
0.013 Tw 8 0 0 8 452.1866 304.5755 Tm
[(T)35 (raducido por Brenda R Morand)]TJ
ET
BT
/T1_0 1 Tf
0.01199 Tw 9 0 0 9 318 278.5755 Tm
(El\216ments de Dosage dans l\325Usage des Pr\216parations Intestinales p\ar)Tj
0 -1.22223 TD
(Phosphate de Sodium pour Coloscopie)Tj
ET
BT
/T1_0 1 Tf
-0.0251 Tc 0 Tw 8 0 0 8 318 253.5755 Tm
(DK)Tj
-0.02499 Tc 1.63131 0 Td
(Rex)Tj
ET
BT
/T1_1 1 Tf
0.013 Tw 8 0 0 8 318 237.5755 Tm
[(Ann Phar)-25 (macother)]TJ
ET
BT
/T1_0 1 Tf
0 Tw 8 0 0 8 379.9947 237.5755 Tm
[(2007;41:1466)-25 (-75.)]TJ
ET
BT
/T1_0 1 Tf
7.5 0 0 7.5 318 212.0755 Tm
(R\203SUM\203)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 6 0 0 6 318 198.5755 Tm
(OBJECTIF:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 350.6682 198.5755 Tm
(Analyser les \216l\216ments du dosage et autres recommandations)Tj
-3.84332 -1.11764 Td
[(de traitement pour maximiser l\325ef)20 (ficacit\216, la tol\216rance, et les pr\216cautions)]TJ
0 -1.11764 TD
(d\325emploi des pr\216parations de Phosphate de Sodium \(NaP\).)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0.013 Tw 6 0 0 6 318 167.0755 Tm
[(REVUE DE LITT\203RA)76 (TURE:)]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 394.5674 167.0755 Tm
[(De 1990)-110 (\320mai 2007, une recherche)]TJ
-9.00793 -1.11764 Td
(bibliographique fut men\216e \210 l\325aide de la base de donn\216e PubM\ed et des)Tj
T*
(extraits de conf\216rences scientifiques.)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0.013 Tw 6 0 0 6 318 135.5755 Tm
[(S\203LECTION DES \203TUDES ET S\203LECTION DE L)91 (\325INFORMA)77 (TION:)]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 495.5033 135.5755 Tm
(Des publications)Tj
-20.88274 -1.11764 Td
(en langue anglaise rapportant des \216tudes cliniques et des observation\s)Tj
T*
(ont \216t\216 analys\216es. De r\216cents rapports \216valuant de nouvel\les pr\216parations)Tj
0 -1.11765 TD
(intestinales contenant des doses r\216duites de NaP ont \216t\216 analys\\216s pour)Tj
0 -1.11764 TD
[(\216valuer l\325ef)21.3 (ficacit\216, la tol\216rance, et les pr\216cautions d\325emploi.)]TJ
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 85.0755 Tm
(R\203SUM\203:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 8.5 0 0 8.5 346.6308 85.0755 Tm
(Par)Tj
0.01199 Tw 1.28241 0.00001 Td
(mi les pr\216parations intestinales les plus couramment)Tj
-4.65074 -1.11766 Td
(administr\216es pour la coloscopie, les pr\216parations NaP sont g\216n\216\ralement)Tj
T*
[(plus ef)20.2 (ficaces et mieux tol\216r\216es en comparaison avec le sch\216ma)]TJ
T*
(posologique des solutions de lavage d\325\216lectrolytes poly\216thyl\217\ne glycol.)Tj
0 -1.11765 TD
(Cependant, les pr\216parations de NaP sont contre-indiqu\216es chez des)Tj
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.024 Tc 0 Tw 10 0 0 10 60.5 23.9116 Tm
(1474)Tj
ET
BT
/T1_3 1 Tf
0 Tc 5 0 0 5 89 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 102.181 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 5 0 0 5 235.3059 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 248.487 23.9116 Tm
[(2007 September)110 (, V)110 (olume 41)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0 Tc 8 0 0 8 60 749.5293 Tm
[(DK)-250 (Rex)]TJ
ET
BT
0 g
/GS2 gs
/T1_5 1 Tf
5 0 0 5 302.24986 11 Tm
( at DALHOUSIE UNIV on May 19, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
86 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
87 0 obj
<</OP false/OPM 0/op false>>
endobj
94 0 obj
<</A 95 0 R/Border[0 0 0]/Rect[261.505 9.0 303.25 16.0]/Subtype/Link/Type/Annot>>
endobj
95 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
80 0 obj
[96 0 R]
endobj
81 0 obj
<</Length 16156>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.02499 Tc 0.005 Tw 10.5 0 0 10.5 60 730.8196 Tm
(achieve comparable colon cleansing compared with 90 mL)Tj
0 Tc 0.05099 Tw 0 -1.22619 TD
(or 40 tablet NaP preparations. Doses of NaP should be)Tj
-0.02499 Tc 0.005 Tw T*
(split, with 1 dose taken the day before colonoscopy and the)Tj
-0.00571 Tc T*
(s)Tj
-0.006 Tc 0.006 Tw [(econd dose taken on the day of colonoscopy)65 (, 3)-50 (\3205 hours)]TJ
-0.00929 Tc T*
(b)Tj
-0.009 Tc 0.009 Tw (efore the scheduled time of the procedure. The doses of)Tj
-0.02499 Tc 0.004 Tw -0.00001 -1.22619 Td
[(NaP should be separated by at least 10)-110 (\32012 hours whenever)]TJ
0 Tc 0.23399 Tw T*
(possible. Specific volumes of clear liquid hydration,)Tj
0.095 Tw 0 -1.22618 TD
(preferably carbohydrate/electrolyte solution, should be)Tj
-0.01199 Tc 0.01199 Tw T*
(prescribed for the intervals before and during preparation)Tj
0 -1.22619 TD
(and after the procedure. Intravenous hydration during the)Tj
-0.02499 Tc 0.013 Tw T*
(procedure is also generally advisable.)Tj
ET
BT
/T1_1 1 Tf
0 Tc -0.013 Tw 8.5 0 0 8.5 60 578.0696 Tm
(Douglas K Rex)Tj
ET
BT
/T1_2 1 Tf
8 0 0 8 121.8632 578.0696 Tm
[(MD F)55 (ACP F)55 (ACG, Director of Endoscopy)73 (, Indiana)]TJ
-0.005 Tw -7.7329 -1.125 Td
[(University Hospital, Indiana University Medical Center)55 (, #4100, 550)]TJ
0.007 Tc 0.006 Tw 0 -1.125 TD
(North University Blvd., Indianapolis, IN 46202, fax 317/274-5449,)Tj
0 Tc 0 Tw T*
(drex@iupui.edu)Tj
ET
BT
/T1_1 1 Tf
8.5 0 0 8.5 60 540.0696 Tm
(Reprints:)Tj
ET
BT
/T1_2 1 Tf
-0.01401 Tw 8 0 0 8 99.4069 540.0696 Tm
[(Dr)55 (. Rex)]TJ
0.01801 Tc -0.004 Tw -4.92586 -1.87499 Td
(Support for preparation of the manuscript was provided by Salix)Tj
0 Tc -0.01401 Tw T*
(Pharmaceuticals, Inc.)Tj
-0.00101 Tc 0 Tw 0 -1.875 TD
(Dr)Tj
-0.0007 Tc 0.99856 0.00001 Td
(.)Tj
-0.00101 Tc -0.02699 Tw 0.52742 0 Td
(Rex has served on scientific advisory boards and speakers\325 bu-)Tj
0.002 Tc 0.011 Tw -1.52598 -1.12501 Td
(reaus for CB Fleet Company)Tj
0.0025 Tc 12.70612 0 Td
(,)Tj
0.002 Tc 0.57227 0 Td
(Inc. and Salix Pharmaceuticals, Inc.)Tj
0 Tc -0.01401 Tw -13.27839 -1.12501 Td
(and has received research support from these companies. )Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0 Tw 10.5 0 0 10.5 60 455.0697 Tm
(References)Tj
ET
BT
/T1_0 1 Tf
-0.037 Tc 0.021 Tw 8 0 0 8 63.8282 437.1447 Tm
[(1)-16 (.)-495 (Barkun A, Chiba N, Enns R, et al. Commonly used preparations for )1 (colon-)]TJ
-0.02699 Tc 0.01199 Tw 1.20897 -1.24063 Td
(oscopy: ef)Tj
0 Tw 3.86056 0 Td
(ficacy)Tj
-0.0269 Tc 2.21586 0 Td
(,)Tj
-0.02699 Tc 0.01199 Tw 0.45797 0 Td
(tolerability and safety\321a Canadian Association of Gas)Tj
0 Tc 20.69546 0 Td
(-)Tj
-0.03999 Tc 0.013 Tw -27.22985 -1.24063 Td
[(troenterology position paper)55 (. Can J Gastroenterol 2006;20:699)-25 (-710.)]TJ
-0.02299 Tc 0 Tw -1.21025 -1.36563 Td
(2.)Tj
0.02299 Tw 1.18178 0 Td
(Curran MP)Tj
-0.0228 Tc 4.17914 0 Td
(,)Tj
-0.02299 Tc 0.4771 0 Td
(Plosker GL. Oral sodium phosphate solution: a review of its)Tj
-0.02499 Tc 0.013 Tw -4.62776 -1.24063 Td
[(use as a colorectal cleanser)60.5 (.)-237.5 (Drugs 2004;64:1697-714.)]TJ
0 Tc 0.258 Tw -1.1875 -1.36563 Td
[(3.)-500 (T)70 (an JJ, Tjandra JJ. Which is the optimal bowel preparation for)]TJ
-0.02499 Tc 0.013 Tw 1.1875 -1.24062 Td
(colonoscopy\321a meta-analysis. Colorectal Dis 2006;8:247-58.)Tj
-0.02299 Tc 0.02299 Tw -1.21066 -1.36563 Td
[(4.)-477 (Belsey J, Epstein O, Heresbach D. Systematic review: oral bowel prepa-)]TJ
-0.02499 Tc 0.013 Tw 1.21066 -1.24063 Td
[(ration for colonoscopy)65 (. Aliment Phar)-25 (macol Ther 2007;25:373)-25 (-)-24 (84.)]TJ
-0.008 Tc 0 Tw -1.1954 -1.36562 Td
(5.)Tj
0.008 Tw 1.22631 0 Td
[(Aronchick CA, Lipshutz WH, W)39.6 (right SH, Dufrayne F)80.1 (,)-249.9 (Ber)20 (gman G. A)]TJ
-0.02299 Tc 0.022 Tw -0.03092 -1.24063 Td
[(novel tableted pur)20 (gative for colonoscopic preparation: ef)20 (ficacy and safe-)]TJ
-0.008 Tc 0.008 Tw 0 -1.24063 TD
(ty comparisons with Colyte and Fleet Phospho-Soda. Gastrointest En)Tj
0 Tc [0.4 (-)]TJ
-0.02499 Tc 0.013 Tw T*
(dosc 2000;52:346)Tj
0 Tw 6.7758 0 Td
(-52.)Tj
0 Tc 0.09399 Tw -7.9633 -1.36563 Td
[(6.)-500 (Kastenber)20 (g D, Barish C, Burack H, et al., for the INKP-100 Study)]TJ
-0.015 Tc 0.015 Tw 1.1875 -1.24062 Td
[(Group. T)70 (olerability and patient acceptance of sodium phosphate tablets)]TJ
-0.011 Tc 0.011 Tw T*
[(compared with 4)-69.9 (-L PEG solution in colon cleansing: combined results)]TJ
-0.017 Tc 0.017 Tw 0 -1.24062 TD
(of 2 identically designed, randomized, controlled, parallel group, multi\)Tj
0 Tc 27.22998 0.00001 Td
(-)Tj
-0.02499 Tc 0.013 Tw -27.22998 -1.24064 Td
[(center phase 3 trials. J Clin Gastroenterol 2007;41:54)-75 (-)-75 (61.)]TJ
0 Tc 0.02699 Tw -1.1875 -1.36563 Td
[(7.)-500 (Kastenber)20 (g D, Chasen R, Choudhary C, et al. Ef)20 (ficacy and safety of)]TJ
-0.017 Tc 0.017 Tw 1.1875 -1.24063 Td
(sodium phosphate tablets compared with PEG solution in colon cleans-)Tj
-0.002 Tc 0.002 Tw 0 -1.24063 TD
(ing: two identically designed, randomized, controlled, parallel group,)Tj
-0.02499 Tc 0.013 Tw 0 -1.24062 TD
(multicenter phase III trials. Gastrointest Endosc 2001;54:705)Tj
0 Tw 22.98301 0.00001 Td
(-13.)Tj
-24.19547 -1.36563 Td
(8.)Tj
0.02499 Tw 1.17514 0.00001 Td
[(Lichtenstein GR, Brown MD, Lottes SR, Forbes WP)112.1 (,)-249.8 (W)80 (alker K. Patients)]TJ
-0.011 Tc 0.011 Tw 0.03733 -1.24063 Td
(prefer new sodium phosphate \(NaP\) tablets vs 2 L polyethylene glycol)Tj
-0.02499 Tc 0.02499 Tw 0 -1.24063 TD
(electrolyte lavage solution \(PEG\) plus bisacodyl tablets for bowel pre\pa-)Tj
0.013 Tw T*
(ration \(abstract  1369\). Am J Gastroenterol 2006;101\(9 suppl\):S524)Tj
0 Tw 25.65548 0.00001 Td
(-5.)Tj
-0.011 Tc -26.8542 -1.36563 Td
(9.)Tj
0.011 Tw 1.21634 0.00001 Td
[(Cohen SM, W)80 (exner SD, Binderow SR, et al. Prospective, randomized,)]TJ
0 Tc 0.009 Tw -0.01761 -1.24063 Td
(endoscopic-blinded trial comparing precolonoscopy bowel cleansing)Tj
-0.02499 Tc 0.013 Tw T*
[(methods. Dis Colon Rectum 1994;37:689)-25 (-96.)]TJ
-0.02299 Tc 0.02299 Tw -1.6875 -1.36563 Td
[(10.)-477 (Golub R)55 (W)91 (, Ker)-25 (ner BA, W)40 (ise WE Jr)40 (, et al. Colonoscopic bowel prepara-)]TJ
-0.01601 Tc 0.01601 Tw 1.6875 -1.24063 Td
(tions\321which one? A blinded, prospective, randomized trial. Dis Colon)Tj
-0.02499 Tc 0.013 Tw 0 -1.24062 TD
(Rectum 1995;38:594)Tj
0 Tw 8.05344 0.00001 Td
(-9.)Tj
0 Tc -9.74094 -1.36563 Td
(1)Tj
-0.01401 Tc 0.01401 Tw 0.45106 0.00001 Td
[(1.)-486 (Law W)55 (-L, Choi H-K, Chu K-W)90 (, Ho JWC, W)80 (ong L. Bowel preparation)]TJ
-0.01601 Tc 0.01601 Tw 1.23644 -1.24063 Td
(for colonoscopy: a randomized controlled trial comparing polyethylene)Tj
-0.017 Tc 0.017 Tw 0 -1.24063 TD
(glycol solution, one dose and two doses of oral sodium phosphate solu-)Tj
-0.02499 Tc 0.013 Tw 0 -1.24062 TD
[(tion. Asian J Sur)22.9 (g)]TJ
0 Tw 6.97066 0.00001 Td
(2004;27:120)Tj
0 Tc 4.85566 0.00001 Td
(-)Tj
-0.02499 Tc 0.43276 0.00001 Td
(4.)Tj
-0.00999 Tc 0.05 Tw -13.94659 -1.3844 Td
[(1)-10 (2)-10 (.)-510 (M)-10 (a)-10 (r)-10 (t)-10 (\222nek J, Hess J, Delarive J, et al. Cisapride does not improve pre)-1 (-)]TJ
-0.034 Tc 0.024 Tw 1.6875 -1.25937 Td
(colonoscopy bowel preparation with either sodium phosphate or polyethy)Tj
0 Tc 27.2296 0.00001 Td
(-)Tj
-0.035 Tc 0.013 Tw -27.2296 -1.25938 Td
[(lene glycol electrolyte lavage. Gastrointest Endosc 2001;54:180)-75 (-5.)]TJ
-0.022 Tc 0.011 Tw 30.5625 85.49809 Td
[(1)-11 (3)-11 (.)-500 (Mathus-Vliegen EMH, Kemble UM. A prospective randomized blinde)1 (d)]TJ
-0.02699 Tc 0.017 Tw 1.6875 -1.26437 Td
(comparison of sodium phosphate and polyethylene glycol\320electrolyte so\-)Tj
-0.0351 Tc 0 -1.26437 TD
(l)Tj
-0.035 Tc 0.013 Tw [(ution for safe bowel cleansing. Aliment Phar)-25 (macol Ther 2006;23:543)-25 (-52.)]TJ
-0.01199 Tc 0.01199 Tw -1.6875 -1.38937 Td
[(14.)-488 (Oliveira L, W)80 (exner SD, Daniel N, et al. Mechanical bowel preparation)]TJ
0 Tc 0.058 Tw 1.6875 -1.26438 Td
[(for elective colorectal sur)20 (gery)65 (. A prospective, randomized, sur)20 (geon-)]TJ
0.07001 Tw T*
(blinded trial comparing sodium phosphate and polyethylene glycol-)Tj
-0.02499 Tc 0.013 Tw T*
[(based oral lavage solutions. Dis Colon Rectum 1997;40:585)-25 (-91.)]TJ
-0.01801 Tc 0.01801 Tw -1.6875 -1.38938 Td
[(15.)-482 (Nelson DB, Barkun AN, Block KP)110 (, et al. T)70 (echnology Status Evaluation)]TJ
-0.024 Tc 0.02299 Tw 1.6875 -1.26438 Td
(report. Colonoscopy preparations. May 2001. Gastrointest Endosc 2001;)Tj
-0.02499 Tc 0 Tw T*
[(54:829)-25 (-)-25 (32.)]TJ
0.008 Tw -1.6875 -1.38938 Td
[(16.)-475 (Aaseb\277 W)90 (, Scott H, Ganss R. Kidney biopsies taken before and after oral)]TJ
-0.008 Tc 1.6875 -1.26438 Td
[(sodium phosphate bowel cleansing. Nephrol Dial T)35 (ransplant 2006;22:)]TJ
-0.02499 Tc 0 Tw T*
[(920)-75 (-)-25 (2.)]TJ
-0.006 Tc 0.006 Tw -1.6875 -1.38938 Td
[(17.)-494 (Desmeules S, Ber)19 (geron MJ, Isenring P)110 (. Acute phosphate nephropathy)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.26437 Td
[(and renal failure. N Engl J Med 2003;349:1006)-25 (-7.)]TJ
0.008 Tw -1.6875 -1.38938 Td
[(18.)-475 (Gonlusen G, Akgun H, Ertan A, Olivero J, T)35 (ruong LD. Renal failure and)]TJ
-0.00999 Tc 0.00999 Tw 1.6875 -1.26438 Td
(nephrocalcinosis associated with oral sodium phosphate bowel cleans-)Tj
-0.004 Tc 0.004 Tw T*
[(ing: clinical patter)-25 (ns and renal biopsy findings. Arch Pathol Lab Med)]TJ
-0.02499 Tc 0 Tw T*
[(2006;130:101)50 (-)-75 (6.)]TJ
-0.02299 Tc 0.02299 Tw -1.6875 -1.38938 Td
[(19.)-477 (Markowitz GS, Stokes MB, Radhakrishnan J, D\325Agati VD. Acute phos-)]TJ
-0.024 Tc 0.024 Tw 1.6875 -1.26438 Td
[(phate nephropathy following oral sodium phosphate bowel pur)20 (g)1 (a)1 (t)1 (i)1 (v)1 (e)1 (:)1 ( )1 (a)1 (n)]TJ
-0.02499 Tc 0.02499 Tw T*
(underrecognized cause of chronic renal failure. J Am Soc Nephrol 2005;)Tj
0 Tw T*
[(16:3389)-25 (-96.)]TJ
-0.01801 Tc 0.01801 Tw -1.6875 -1.38938 Td
[(20.)-482 (Ell C, Fischbach W)90 (, Keller R, et al. A randomized, blinded, prospective)]TJ
-0.03 Tc 0.02 Tw 1.6875 -1.26438 Td
[(trial to compare the safety and ef)20 (ficacy of three bowel-cleansing solutions)]TJ
-0.02499 Tc 0.013 Tw T*
[(for colonoscopy \(HSG-)-96.9 (01*\). Endoscopy 2003;35:300)-75 (-)-125 (4.)]TJ
-0.008 Tc 0.008 Tw -1.6875 -1.38938 Td
[(21.)-492 (Kolts BE, L)55 (yles WE, Achem SR, Burton L, Geller AJ, MacMath T)75 (. A)]TJ
0 Tc 0.026 Tw 1.6875 -1.26438 Td
[(comparison of the ef)20 (fectiveness and patient tolerance of oral sodium)]TJ
-0.022 Tc 0.022 Tw 0 -1.26439 TD
(phosphate, castor oil, and standard electrolyte lavage for colonoscopy o\r)Tj
-0.02499 Tc 0.013 Tw 0 -1.26438 TD
[(sigmoidoscopy preparation. Am J Gastroenterol 1993;88:1218)-25 (-)-25 (23.)]TJ
-0.009 Tc 0.009 Tw -1.6875 -1.38938 Td
[(22.)-491 (Seinel\212 L, Pehkonen E, Laasanen T)75 (, Ahvenainen J. Bowel preparation)]TJ
0 Tc 0.054 Tw 1.6875 -1.26437 Td
(for colonoscopy in very old patients: a randomized prospective trial)Tj
-0.006 Tc 0.006 Tw T*
(comparing oral sodium phosphate and polyethylene glycol electrolyte)Tj
-0.02499 Tc 0.013 Tw T*
[(lavage solution. Scand J Gastroenterol 2003;38:216)-25 (-)-25 (20.)]TJ
-0.017 Tc 0.002 Tw -1.6875 -1.38937 Td
[(2)-15 (3)-15 (.)-513 (V)111 (anner SJ, MacDonald PH, Paterson WG, Prentice RSA, Da Costa LR,)]TJ
-0.036 Tc 0.021 Tw 1.6875 -1.26438 Td
[(Beck IT)75 (. A randomized prospective trial comparing oral sodium phosphate)]TJ
-0.02699 Tc 0.01199 Tw 0 -1.26437 TD
(with standard polyethylene glycol-based lavage solution \(Golytely\) in \the)Tj
-0.03999 Tc 0.013 Tw T*
(preparation of patients for colonoscopy)Tj
-0.0401 Tc 14.14036 0 Td
(.)Tj
-0.03999 Tc 0.43235 0 Td
(Am J Gastroenterol 1990;85:422-7.)Tj
-0.017 Tc 0 Tw -16.26021 -1.38938 Td
(24.)Tj
-0.01801 Tc 0.017 Tw 1.6803 0 Td
[(Ainley EJ, W)40 (i)-1 (n)-1 (w)-1 (o)-1 (o)-1 (d)-1 ( )-1 (P)-1 (J)-1 (,)-1 ( )-1 (B)-1 (e)-1 (g)-1 (l)-1 (e)-1 (y)-1 ( )-1 (J)-1 (P)109 (. Measurement of serum electrolytes)]TJ
-0.01401 Tc 0.01401 Tw 0.0072 -1.26438 Td
(and phosphate after sodium phosphate colonoscopy bowel preparation:)Tj
-0.02499 Tc 0.013 Tw 0 -1.26438 TD
(an evaluation. Dig Dis Sci 2005;50:1319)Tj
0 Tc 15.44291 0.00001 Td
(-)Tj
-0.02499 Tc 0 Tw [0.3 (23.)]TJ
-17.13041 -1.38939 Td
(25.)Tj
0.008 Tw 1.64999 0 Td
[(W)80 (exner SD, Beck DE, Baron TH, et al. A consensus document on bowel)]TJ
0 Tc 0.123 Tw 0.03751 -1.26438 Td
(preparation before colonoscopy: prepared by a task force from the)Tj
-0.015 Tc 0.015 Tw 0 -1.26437 TD
[(American Society of Colon and Rectal Sur)20 (geons \(ASCRS\), the Ameri-)]TJ
-0.01801 Tc 0.01801 Tw T*
(can Society for Gastrointestinal Endoscopy \(ASGE\), and the Society of)Tj
0 Tc 0.002 Tw T*
[(American Gastrointestinal and Endoscopic Sur)25.9 (geons \(SAGES\). Gas)2.3 (-)]TJ
-0.02499 Tc 0.02499 Tw 0.00001 -1.26438 Td
[(trointest Endosc 2006;63:894)-73.1 (-909. Cited by: Lowry A, Hawes R, Deziel)]TJ
0.013 Tw 0 -1.26438 TD
(D. Addendum. Gastrointest Endosc 2006;64:154.)Tj
-0.002 Tc 0.00101 Tw -1.6875 -1.38938 Td
[(2)-1 (6)-1 (.)-500 (Hookey LC, Depew WT)75 (, V)111 (anner S. The safety profile of oral sodium)]TJ
-0.019 Tc 0.019 Tw 1.6875 -1.26437 Td
(phosphate for colonic cleansing before colonoscopy in adults. Gastroin-)Tj
-0.02499 Tc 0.013 Tw 0 -1.26437 TD
[(test Endosc 2002;56:895)-25 (-902.)]TJ
0.008 Tw -1.6875 -1.38938 Td
[(27.)-475 (W)80 (exner SD, Beck DE, Baron TH, et al. A consensus document on bowel)]TJ
0 Tc 0.123 Tw 1.6875 -1.26437 Td
(preparation before colonoscopy: prepared by a task force from the)Tj
-0.015 Tc 0.015 Tw T*
[(American Society of Colon and Rectal Sur)20 (geons \(ASCRS\), the Ameri-)]TJ
-0.01801 Tc 0.01801 Tw 0 -1.26438 TD
(can Society for Gastrointestinal Endoscopy \(ASGE\), and the Society of)Tj
0 Tc 0.002 Tw 0 -1.26437 TD
[(American Gastrointestinal and Endoscopic Sur)25.9 (geons \(SAGES\). Gas)2.3 (-)]TJ
-0.02499 Tc 0.013 Tw 0.00001 -1.26437 Td
[(trointest Endosc 2006;63:894)-75 (-909.)]TJ
-0.02299 Tc 0 Tw -1.6875 -1.38937 Td
(28.)Tj
0.02299 Tw 1.659 0.00001 Td
(Khurana A, McLean LB, Concepcion LA, Nickel AE, Foulks CJ. Acute)Tj
-0.013 Tc 0.013 Tw 0.0285 -1.26438 Td
[(phosphate nephropathy \(poster\). Presented at: Renal W)103.6 (eek; San Diego,)]TJ
-0.02499 Tc 0 -1.26438 TD
[(CA, November 14)-110 (\32019, 2006.)]TJ
0 Tw -1.6875 -1.38937 Td
(29.)Tj
0.007 Tw 1.64999 0.00001 Td
(Patel V)Tj
-0.0251 Tc 2.67305 0.00001 Td
(,)Tj
-0.02499 Tc 0.45684 0 Td
(Emmett M, Santa Ana CA, Fordtran JS. Pathogenesis of nephro)Tj
0 Tc 24.13734 0.00001 Td
(-)Tj
-0.01601 Tc 0.01601 Tw -27.22972 -1.26441 Td
(calcinosis after sodium phosphate catharsis to prepare for colonoscopy:)Tj
0 -1.26437 TD
[(intestinal phosphate absorption and its ef)20 (f)1 (e)1 (c)1 (t)1 ( )1 (o)1 (n)1 ( )1 (u)1 (r)1 (i)1 (n)1 (e)1 ( )1 (m)1 (i)1 (n)1 (e)1 (r)1 (a)1 (l)1 ( )1 (a)1 (n)1 (d)1 ( )1 (e)1 (l)1 (e)1 (c)1 (-)]TJ
-0.02499 Tc 0.013 Tw T*
[(trolyte excretion. Hum Pathol 2007;38:193)-25 (-)-125 (4.)]TJ
-0.00999 Tc 0.00999 Tw -1.6875 -1.38939 Td
[(30.)-490 (Beloosesky Y)130 (, Grinblat J, W)80 (eiss A, Grosman B, Gafter U, Chagnac A.)]TJ
-0.02499 Tc 0.022 Tw 1.6875 -1.26437 Td
(Electrolyte disorders following oral sodium phosphate administration for\)Tj
0.013 Tw T*
[(bowel cleansing in elderly patients. Arch Inter)-25 (n Med 2003;163:803)-25 (-)-25 (8.)]TJ
ET
0 0 0 0 k
318 745 234 10 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
8 0 0 8 418.5493 749.5293 Tm
(Sodium Phosphate Dosing in Colonoscopy)Tj
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
10 0 0 10 259.0939 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 392.2189 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 405.4 23.9116 Tm
[(2007 September)110 (, V)110 (olume 41    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 519.569 25.4116 Tm
(n)Tj
ET
BT
/T1_6 1 Tf
-0.024 Tc 10 0 0 10 532.75 23.9116 Tm
(1473)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
BT
0 g
/GS2 gs
/T1_7 1 Tf
0 Tc 5 0 0 5 302.24986 11 Tm
( at DALHOUSIE UNIV on May 19, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
42 0 obj
<</BaseFont/STNCEH+Helvetica-Bold/Encoding 39 0 R/FirstChar 32/FontDescriptor 41 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 0 333 278 0 556 556 556 556 556 556 556 0 556 556 333 0 0 584 0 0 0 722 722 722 722 667 611 778 722 278 556 722 611 833 722 778 667 0 722 667 611 722 667 944 667 667 0 0 0 0 0 0 0 556 611 556 611 556 333 611 611 278 0 0 278 889 611 611 611 0 389 556 333 611 0 778 556 556]>>
endobj
30 0 obj
<</BaseFont/XRGZBK+Helvetica/Encoding 27 0 R/FirstChar 32/FontDescriptor 29 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[278 0 0 556 0 889 0 0 333 333 0 0 278 333 278 278 556 556 556 556 556 556 556 556 556 556 278 278 584 584 584 0 1015 667 667 722 722 667 611 778 722 278 500 667 556 833 722 778 667 778 722 667 611 722 0 944 0 0 0 0 0 0 0 0 0 556 556 500 556 556 278 556 556 222 0 500 222 833 556 556 556 556 333 500 278 556 500 722 500 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 584 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 556 0 0 0 0 222]>>
endobj
27 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 35/numbersign 37/percent 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon/less/equal/greater 64/at/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U 87/W 97/a/b/c/d/e/f/g/h/i 107/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 177/plusminus 208/endash 213/quoteright]/Type/Encoding>>
endobj
29 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 32/FontBBox[-166 -224 1000 931]/FontFile3 28 0 R/FontName/XRGZBK+Helvetica/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
28 0 obj
<</Length 5752/Length1 5752/Subtype/Type1C>>stream
  XRGZBK+Helvetica   @ø øøøøû:ûtú|ú7
 ‹‹
 ‹‹   ó   ï  Š¬  W €ˆ002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki  J  5 % P V H M B T  , 3 F Y " U I S J O G N Q W E  X D  [ Z  C 	 / 1 
 - .    o   & ) *  4 R      0 +  '  L  $ #  œ 8 2   6 (  !  L    d « ék€†‰ºy¶ğ![”¶ø1ô{‹É2Y¦Õ/h“Õ		(	ƒ	§

c
y
Ó1`up©ŞûsÊRÌïo¢Å"FŠö3nØI 1d vùà÷•ëøçùàüÙ6÷‡ıëùÓ‹İø½İÜíøîù5ø÷gû÷ûJû·ıa÷³÷R÷÷÷z(…ûA< ûûOø½÷I÷5Àûû-}×ø$×®æ÷Äæø÷š÷7'÷û#û#'ûû7û8îû÷$÷$î÷÷80ûP=..PÙ÷÷ÆÙèèÆ=û-|×cvøŸwÏâ÷‰ã8Şôø|øŸø3û´ TH2Hi²×÷ï4ü%ÉOöÛ´¢Ñ¸ô=-ûnÓ÷×ø!Û|w³æ@ã÷Ÿã7ß9İÔ€ø‡¶øt9@ù ‰Ì^^¤Hû4"û0ûDäû÷Òµ À«ö uûcZûHg¤Ä}3"œÍZ÷÷7Õİ÷Gù 7÷bûWH/5UØ÷÷»Îçé½Cûü@ vùawÎã÷/ùa3ıa-|Ô[v÷‰Í÷8Ô¯äLÛ÷…ã6àµø¤Ë‡~ƒŠ„vƒ”¡÷Áæ@ÂûûHTû
„ÛÑ•°©ÙÖ·kSi{wl‡û$y¹$~SQ.0ÍOí×Ã¤ÇÄöQ‘¤tÃ–”¡ºû%÷HK>Q5Qf«¿À¯©Ø”÷˜†Š³Ÿû*|Ö÷2ÙVÖ÷$×«ßGß÷yàDãÕøc÷2Ôc± ¦ö4¡<Ÿy˜‹±·µ¨ÊÜ±pNà÷ ‚FÃûû=J%I³aİwÙğrŞv }‹dW]k@2d©Ù7T’qp«\Óoæ‹÷‹ŞĞ‹óüœ vùawÖìù)ûÇø@÷¾÷µûûïûğ÷ğ*ıaì÷÷÷÷ûüÓ v÷ÇŞ÷ŠÜãëøîù>›oš…—‰¸…÷‡×y©K§Ö¹¤¶‹à‹÷6Ğû*‹ûßıaë÷Ç÷æ®i.ûŒ}˜R‚ø™6[a*ûv÷Š÷‡Ş¸a>-|×÷@Ñ÷/Û³è÷´â8æôø˜÷}÷V:÷û%û1.û ûKû6ç'÷*ø÷ØÈ÷
§4J{YeC.WÃ÷†ô÷¸Ñû¸ì”ÇÅİï°@;û* vøŸw˜ørøûL÷ ÷E÷“û ûûMû÷Mû÷Bû“ûKû ÷÷÷Y÷ûYœ v÷dâø:w™ùù û˜ùaûû ıaîÖ÷d÷³Òûd!÷»ûr÷÷Ğü„×øÕßã÷•Ğmez—¨÷çßÕ7÷&3û&EAÑûì?¬gĞœ™Œ‘³- vø_Û÷FwÌã÷âø÷÷÷
KÍûHbtLY‰÷œ3ıaã÷±÷ÂÊëĞªf:ûéûÑ vøPé|wØİ9ãğ÷ßøPæ~„Œ‡QamB]‰ğã9üŸèã÷ÄÜÃÆÙü@ vøŸw÷íÎã÷/øÿí3)ãüÿøŸ3üŸ- vø^Û|wÌŞ8ä÷âôø€÷÷÷IÎûEZpM_‰ôÕ8üŸìä÷°÷ÀÌåÕ­`.ûÖü vøUÕ÷awßã÷˜øUÕ3Ì¶›°“”Š‰ÚŒw€Œ‚/_f=1EAÑüUãøU÷K vø_Ú|wÌŞ8ã÷qã÷nãöù”÷ş÷KÎ%Lp|EJÅo^¦IGYoNc‰öÕ8üŸîã÷±ôÁĞß¾«fOûşã÷ÓÙÁÉÎÌ«c:ûæ-ûLv÷R×ø#Ú{wÅŞ8ã3ß÷±åéø™÷¨÷24ôûH^qL`‰ùÔ8ılåã÷˜Wµ®yÈ÷#ã÷÷H1…ûX?0ã2UĞ÷÷!¼Õçê¼Jûû* vøŸw“øwøøŸ+û(ü=‰Šûø>'÷RüŸè-|×cvø_Ù÷Hw®å÷±ã4â:Üyø†ùaú4û¡‰Î[d¡Eû7&û5ûEäû÷!Ï»§Å­yDü„÷‰ûTD24UØ÷÷ºËêæ¿>ûü‹õâó÷Sõ#!Ó vøŸw›ùIùYøŸ4 ü.‰&ø.)&ü.‰'ø.,÷+üŸåñø)ôü)æû*{Øø"Ú©é÷ à7ßèøq÷L7<y]_I1ZÒ÷÷ÂÕçğÏ±h>šà÷}GÌûû)*ûû?û8ç ÷"÷ÛÖ÷™ûÑ v÷{å·÷ˆ÷´÷{åûˆ1û*‹ÓøÕªøIøhÓûÕ÷ÍøÕü)A÷¶ûÎüFû*ûjÚù&w–øqø|øŸ+û!ü?‰ûø?(÷Vü¬bû‚d‹v|‘v<…›—ˆœò› ÷_Øï÷œ–Ş÷‚ü‹õ6vâóX¾Ğ÷S“íà#!ĞÀàŠHsc]Ó›«»æ-{Øcvø`Ù÷GwÅã3ß÷±åzø™÷¨÷24óûMZqTc‰÷˜3ıaŞÌöN¸¯wÎ÷å÷÷D1ƒûW?13TÒ÷÷½×æê¼IûûÑûMvú>wÏè÷¿ûb<÷2P÷÷J÷D³÷ë÷;OûûB]ûû=ûVÑûòû0Ó vùaw×èøêùùa,ü×‰ûúø×ûıaèøØøüØœ v÷ÂŞ÷İáí÷çîùø˜÷6Ûûû×ıaí÷Â÷u÷áá÷(‰6Y_+ûU÷÷Xé¼b;ûÑûNvú>w÷@è÷÷÷VE÷$÷0QÚû2ÆûûJûDcû+û;Ç÷÷B¹÷÷=-‹áùw×ìø¬áûÿù*ıa÷K vùawÔè.æøŠé/çäùŒùaûû_üñ‰ûaøñûıaèø<ÔÇ‰Æ‹Çè÷_üïë÷]øğäèŠû	Šº;‹‹‹üZ- vø†Ò÷w÷œêğø†÷7ü†êùREp$qxû€-xÔ÷IÚ÷ËÙµå9â÷¦ñ4âòø•ø÷k7÷û6û1+û%ûà2÷ÙÁ¦Ä®‰nûX`H)‹êEa´Õ„4û”ÔI÷ÖÆ¨Åµ½Î¨÷÷ô%í#XR.6YÁçñ¿ÊßâÃP0-wÛøÇÚ°è÷ºèø™÷é÷}6÷û/û/6ûû}ûzâû÷-÷-â÷÷z.ûKX)++Xí÷K÷O½êìì½+ûN- v÷ƒÕ‹øÀøÀ÷ƒÕüÀA-‹İø±Ú¥î:â÷¯çèøİü˜Ë»³Æ«Ô³ïÂã¼÷÷3ŞûØû3?$û)â÷‘¸ÁåàÄW=Dmk&Q/VèûFc5…û- vøíá÷êøøöØüy5ø@1W:UûOûl/}#ê­÷4¢ÒÁ÷ Ä÷ÀÚĞØœ‹á÷…à÷pàáìøüáüE÷…øàü÷pø<àüıaÓ v÷áâ÷½wØì*íø
ìôùùa*û½ü÷½*ıaìí÷áø
ûáü vùawæì÷Pùa*ıaüvù‡wz÷Ì÷»ùtIûŠı‡ÎœxŞ÷‹Ù`å÷nŞ¼æGè÷êæCèÕøÿ÷YïQÏ#£öûaºQ˜n¬‹½ÖÊºğ÷ÇZ*”æ÷/€3ÕûBû2,7û3¿SñsÙ÷&h÷
o¯p‹N4L_ûûDÆöˆ0ŒD•e©dG¿Ùi÷ ÷KöÛ÷-ûNv÷T×ø"Ú|w®æ÷­â7ß8ŞÙø‚ûcùn8A‰üÉa\¦Gû4"û1ûGãû÷!È³Ÿ¼³û™úøYûUF14VØ÷÷ºÍçé¾Aûü vø/õâóX¾Ğ÷Sø/õà#!óü'í#!ĞÀàŠHsc]Ó›«»æ- v÷>×ø]w÷ßãø÷>×%ø]BûÕüR4÷Æû>ã÷>3×ûu÷t÷ÔŒü‹õ÷Åõâó÷Sø/õ#!óü/õ#!-xÚ÷ÉÚ÷EÚ±ä2ò÷§àAåòø™÷q÷1èû@VpOdˆ•÷?Çæñ‹ìË³fC˜à†Ç~«i­e²Q¢R‹û5‹*û#‹û‹ûváû÷7‹ê÷ìñ÷1†0RJ94OËççÄÈàãÃP--x×÷ĞÚ÷*á«å÷½èø”÷x÷(ëûTfk^ª÷V÷½áûÿWüÖ†µ¼®À‹æÌK1*LJ/;\²Ù|1ûœ×K÷÷1ìé÷-÷xâøÜà²îø‰îùv÷û÷uû!÷-ûdûdû"û-ûuûv÷ û,÷f÷e÷ ÷,÷v(ûA%û
û(û)%÷
÷A÷Eï÷÷+÷*ïû	ûDû*xİù"wœå÷sìø?÷VøŸ*ü¥7fb>Bg²Ú½1DûØG÷÷ÖÙ÷-xÚ÷œÔ÷wÚ­ç÷ªåIéôø÷bŞi»8­øÃ ¬¿Î÷6Õûû(FDû3ƒá÷ “²¶ãİ½`DAYd,~…‹z?Œ›“‹ô÷Âc39MU+*`¹÷‡/û6™ÓC÷(÷/îã÷d v÷Ùá÷pááìøÚùáü„ıaì÷Ù÷ôáûô÷p-xÚ÷¢×÷oÙ±èEæ÷ŒæGèêø˜÷`ÙhÀ;²ìË¬¥´Î÷5Õûû7?ûI¨aÍmò5ck[/ûî4÷!÷$éã÷ìû÷ÑHV[BEW»ÌÌ¹´ÑÜ¾cKò¢ûÚ5XZ1.QÁâ×ÇÀàåÄV9û* vøŸw÷jwÎàø‰ûh÷Û÷\÷Xûûvûqø36ıaà÷ZÔÍ÷7ûœI v÷Ô÷Ô²øŒø³÷ÒÔüŒBøŒû`ÔüŒBÓwáøİà·îøHç5éèù;÷œ-ûqCHûû&8÷÷R÷Gçö÷+ğïÏV*¤ç÷*s!àû7ûaûû%ûxû‚÷û%÷\è÷?÷	õ÷F¤œ‹Ş÷Ù÷rİÔì÷ØëMëøù÷làg»-±Í­©»Ğö:ÓûûÎıa÷Êô÷%ëá÷øû÷Ë?Ye(ûC÷r÷Cï¼gCô­ûÍ7U\*ûc÷÷R÷Åb;÷ƒv˜Ñ÷\Ñ¡Ñ÷]Ñ²Ñ÷]Ñ÷Ñ÷]Ñ€ùå÷8é?×,-??--×?éê××éûJø°Uÿ€üıgÁöøµê?×-,??,-×?êé××é€ø#ûşT^^ST^¸ÂÂ¸¸ÂÃ¸^Tüi÷şT^^TS^¸ÂÃ¸¸ÃÂ¸^SI‹Ó÷\Ô÷“Ôø´÷¤Ôûl÷5Bû5ûlB÷lû5Ô÷5÷lû¤ÓüC÷º vùaw›ú"ú2ùa ûüÛ‰û4øÛ"û6üÛ‰ûøÛ#÷Oıağ÷:øçŒ÷7üèñ÷xâøÜà²îø‰îùv÷û÷uû!÷-ûdûeû!û-ûuûv÷ û,÷fÓÃš¬Ã÷6¼Å)ÖÑÖ­è‹÷(/o>WU1ÑZOÕRa{q†e‹û(%÷
÷A÷Dï÷	÷+÷*ïû	ûDI»ø{ø«–Ûü÷6ø÷6Ûü{ûdEI»ø{ø«÷mÑü{÷d;øû6üû6;ÓxáùwÚìøëù÷‘ød+üYûFCûûIÓ÷øV*ürû1÷ &÷<÷F÷ò÷=÷xŞ`v÷ÁŞ÷Ÿà»ïøeå|ùSøûÎ8÷tˆ@gqfüPcJm8û09ñ÷V÷Eé÷÷'÷ ĞY&«è÷(oûãû7ûbûû,ûûo÷û)÷TöØ®ØÉ|£.- v÷fÊ÷!Ê§ø‡ø£øq%¨÷gHnûgû¨÷gHnûg$‚Lówû!%‚LñnûfÎ¨÷f÷nûfÎ¨÷fò“Ê%÷!ñû=xû!û÷!øxÉèÌJÔ÷¸ÓñÈ÷'Ô×Şø:Ìßùöø>÷Cû*÷ûVûeû:û:ûdûk÷:û:÷l÷÷Î÷ÊI@H8d/ûBû÷÷C÷K÷÷÷A÷3÷ûû$ FûCyŠšš¤§éÈ÷cGwMlÄj W‹û$ûû,5ÍAØ¶¬˜½»a v±®À¢¬´ÒÆ±İèÿû“y*>%A[j³ÄìÕíÔ¹²`Yü@ vøøôÀóX¾Ğ÷1ù ìà#"ĞÀàŠHsc]Ó›«»æu¡øŸš÷)›™Ÿ÷¡–ü}š×
ã
_÷ªù
endstream
endobj
39 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 40/parenleft/parenright 45/hyphen/period 48/zero/one/two/three/four/five/six 56/eight/nine/colon 61/equal 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P 82/R/S/T/U/V/W/X/Y 97/a/b/c/d/e/f/g/h/i 108/l/m/n/o/p 114/r/s/t/u 119/w/x/y]/Type/Encoding>>
endobj
41 0 obj
<</Ascent 750/CapHeight 717/Descent -205/Flags 262176/FontBBox[-170 -227 1001 963]/FontFile3 40 0 R/FontName/STNCEH+Helvetica-Bold/ItalicAngle 0/StemH 0/StemV 140/Type/FontDescriptor/XHeight 737>>
endobj
40 0 obj
<</Length 4935/Length1 4935/Subtype/Type1C>>stream
  STNCEH+Helvetica-Bold   @ø øøøøû>ûwú}úW
 ‹‹
 ‹‹      ²    €•002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki BoldHelsinki  <  0 # + & $ 5 * 7  % " 4 6 3 : - / 9 ) , 8 B G F U Z  T V X J I 1 P M S Q O . ( C    H N ' E    D   	   
   Y >   T Î2„¦½çUS¸äÿ.j”Æ1±éK‡ÎÑ;‚Æî5zÁØ		ˆ	Ğ

v
Ö3¬F¨ıyØ&r¿,¢ê_ç÷x÷øŠ÷·ùFùr÷ú÷mû÷6ûvûuûû4ûoûn÷	û3÷x÷t÷÷4÷mû*Œû0A,ûûAê÷0÷/Öë÷÷Ö+û/Ó‹÷÷U÷÷0÷×÷$÷®÷#û÷)ôù0÷màmº:±øÊ®¤´Î÷5Óûûğıa÷ÅŞÈ•­ôÏ±´ÑÛøû:÷ÁXdmGûC÷0÷?×®tWôœûºKafCûM÷U÷SÏ³iQ-y÷øúw¡÷÷A÷*øw÷dø‘û*ü‘?snNKs±ò¦ûlûOÌD÷A÷'×Ø÷)œ‹÷÷O÷÷+÷×÷'ù ÷ü!÷O÷ğ÷ûğ÷+ø÷ü¢ıaÓx÷øƒ÷·ùù?÷‰û)*n_f6ûHç÷,÷4Íæ÷
Şµi1§÷(÷-~ûğûAû]ûû'û|û|÷û$÷^÷;öæ÷A°d vøã÷÷z÷+øèøã÷üÚû÷lüã÷+øãü vùawË÷*÷jùaû*ıaœ vùawùùùaû/û0ü³‰Šû.ø´û4÷†ıa÷#ûÑ‹÷%÷r÷%ç÷*÷†ø÷%û*û%÷*ü÷%û*û%Ó‹÷øi÷×÷'÷È÷,ù?ø÷n'÷ûSûĞıa÷Ë÷J÷÷%÷{û,û(M0'û&øi÷$÷À@û/Ó v÷'÷øQwŸù;ùOû‘ùaûAû‘ıa÷1½÷'÷¹û'3÷¤ûLç÷°œw÷÷I÷$÷'÷6÷²÷"û÷÷¥÷#û÷%Õù	÷lòSÃû¬öûC·S™v ‹´À¼¬×æºhB•÷#÷$„ âû;ûA&8û"û*õo÷nÙØyîtªv‹^NYl&,Z°Ùƒû"C™d±a¿Såk÷‹÷@‹÷ç‹÷$Óx÷øöwÓøÖù÷øgû,üm/[^*;[Âåøeû-üpû7õ*÷F÷Tñè÷DÓ v÷®÷÷T÷×÷(÷¸÷(ù9s”„À÷H€©:¯Õ©¯Äß÷3ÚûûÿŒıa÷'÷®÷/îšyû
ŒFo˜Zø†Ign:ûC÷T÷OÎ±hMœ vùawšùùùaû=û!ûËû*÷ËûD÷ŒüSû¢÷+÷¡d‹÷øßw×øøÚ÷ûøøßû*ıaÓ vùawĞ÷ ÷Ä÷ ù!ùaû üˆ‰û±øˆû1ıa÷ ø”÷¸ü”œ vùaw™ùùû|ø	÷m÷ìû@ûûzû÷zûF÷oûòû|ü÷B÷%÷‰÷û‰Ó v÷Õ÷÷¤wÒø×ùùaû*û¤û«÷¤û*ıa÷*÷Õ÷«ûÕÓ vùawâùùeûÈø=÷·÷¸ûUû¥ûµ÷µû+ıa÷+÷‡ÑÓ÷qûÏ÷º vùaw÷·Ï¬ÙÚ¬Ôú4ùaû+bûCbûBgûD‰h÷UƒB÷èû3Nû¾”¿Zû«‰h÷St7÷ùû3÷_ıa÷ ±÷N¶÷N©÷PªûO³ûP´ûM÷#-}ïJv÷zÜ÷÷¨÷÷Q÷|ø¡ u’‚£¿÷´ë;Åûû0FUû€÷½§£ÀÊ¨x`t|}i†ûx${XR‹*ü.ËMëÓ²ÆÉ|Œq”püz÷SRS[K`q¤²»¡Ò˜Ğ˜ˆŠ©œûÑ vøEíÜ÷á÷ ÷ÑøEí0 ¿‘“µ²÷h€‹q#XZ%_?)×üE÷ øE-}÷÷æ÷÷¢÷#û#÷ ÷p÷#ôø¢÷x¤÷P2ôû5û4.%ûDûIç&÷9÷ÚÂ÷¯û#cyny\ìAdµä„ô÷pæûmÚ˜«¬ÊÊ¯f@•ûÑ…õ÷ßïİ÷ ÷Èˆõ‰|„Š^„‘±÷³áï5÷%û û%C'ÓûÕ7³kò™Œ«-ûi÷ùw•ø£ø­ø§û'û ü‰ûøû/÷Xü¾{K{|U‹…ˆ‹sûŠ§Š›÷	÷_Ñü-}õ÷ğõ©÷#û÷û÷÷a÷ Ôøš÷9÷dûá?‹ê©«ÀÇ¨uZ‘÷÷„;Åû-û;D ûX÷İÊ‹3ggxVÌ=h¢Âˆäû#ûëE÷0÷#æĞ÷d}÷
8vø§wÍ÷ ÷[÷û÷ôø³ø§øûûÇB`\IOm¬Ì÷İû ûñûÍC÷Ö¾§È¯ô@÷ vø§w•ùˆù’ø§û#9üˆ<øû!@ü‰8øû(÷)ü§÷%İøŞü÷"ü vø§wŞ÷Ğ÷ ÷eøæ÷û û÷ üæø§û ü§d vø@÷÷>wÌ÷û÷ ÷]÷ôøµø÷CÑûCVnUoˆ÷‘ûıaì÷ ÷Åß³²ÕÆ§jCû×œ v÷—÷÷h÷øq÷)ùø€÷4áûûÜıa÷*÷—÷@÷çé÷û)‰Cfg@û÷h÷
í®o?d}÷	÷Ù÷
­÷#÷•÷#øÕ÷÷?!÷û9û:!ûû?ûAó ÷<÷;ó÷ ÷@û# _S76_Ãöô¸ÄßŞ¸R"ü vùawĞ÷ ÷eùaû ıaû™ vø(÷"|wË÷û÷ ğøø%÷"†‹Jgp<_‰ğæûü§è÷ ÷¨ß··ß–”Š‰ŸdûNv÷U÷÷Ù÷{wÉ÷û÷!÷{÷#êøÕ÷¤÷82÷ûAcsF^‰úØûıvæ÷!÷¦Œ­R¹rĞ‹÷á÷÷Dû#‚)^KEê?\Æé÷´ÆÙÖ·O$d vø?÷|wÌ÷û÷ ÷]÷ôø´ø÷DÏûC_rH`‰ôØûü§ì÷ ÷ÄØµ¹ÑÇ¨iEû×÷K vùawĞ÷ ø4÷ùùaûlûüÉˆûøÉûoıa÷ øì÷üì÷(÷øìüì÷x÷4v÷÷÷u÷ø×÷xù[øû½û÷9øû oQY*ûAç÷0÷4Ùì÷×Æ_B¡÷(÷)xûæûCûiûû(ûzûv÷û+÷YíÌ«ÙÈx™0d}÷;vø=÷÷>wÈ÷ û ÷÷ƒ÷#zøÕ÷¥÷72÷ûE]rQe‰÷‘û ıa÷ÎöS®»rĞ÷á÷÷Dû#*]JE@[Éìô·Ç×Ö·O%- vø}î÷w÷÷!û÷èøùZû8Td w(Ğ÷<ü}ü‹÷%Ë÷*÷j÷%û*û%ûÑ v÷k÷¦÷ª÷Å÷k÷ûªûdûmõ÷ ÷
÷É÷|w³÷#÷z÷û÷Úø¼¨øŠû<‰üËmX©Dû4!û<û?â#÷!Ğ´£Ä«‡L4hh>Kt˜´û,#—ŞS÷'÷’÷.çû÷„*eR:G`Çéê¶ÇÎ×·J1÷ƒ vø?÷
û	÷
|wË÷ û ÷÷E÷÷>÷ ëùÌø÷CĞûO`qPfçÎ_jCF^pJg‰÷Øûü§ë÷ ÷×Ğ¨¯ÄÉ¢n:ûÒ÷÷ÒëÓ«°É½¥m@ûÖd v÷Á÷÷7÷×ø‘øİøã÷ü‘ıa÷*÷Á÷Î÷ûÎ÷7d}÷;vø<÷÷?w­÷$÷|÷û÷zø¸ùaüûû“‰Ê^d Dû5û û;û@äû÷Ï¾¦Á®zHú÷˜&^Q=E^ÊìóµÆÖÚµR -‹÷øh÷
«÷÷]÷ ø’÷ûÈ¨Ä÷ÏÊÅÀ»¨Â‹Ú‹÷(ãû'‹û'‹<6†û9÷î¥¬ÒÇ³bL4Gkû4û*jS„û-x÷÷mï÷O÷¦÷û÷÷M÷ û÷$êø˜÷gÜdÆG£ìÈ¯¢±Î÷0Øûû1:û&Š÷Ü­­ÅÂ®hTIel:v'ò÷‰²q<K^]NHl°â†ûû)‰æ3÷,÷(ïè÷-x÷÷™÷÷÷	¦÷÷`÷$ø–÷€÷0ìûZg€na¥÷.÷´÷	ü[ü÷†®©›¶‹Ë´Y>:aVKQmªÎûû•â>÷ ÷*ïñ÷--}÷÷Û÷
­÷$÷`÷!øŸ÷Vû!KjnSHgÁ÷õ³ÅÕº©pP˜÷!÷ƒ+Ôûû71$ûOû?å(÷/÷åØ÷- v÷0÷øQw÷Æ÷ û÷èø¡÷0÷<øQû4û—üDûĞ÷«û0÷ ÷0ûø3Š'Š#%ûEÈ÷E÷Æ-x÷ø÷«÷$÷_÷$øŸ÷î÷Œ=÷û<û;=ûûŒûØû÷<÷=Ø÷÷û$ŒûRqK?@qË÷R÷P¥ËÖ×¥KûPûÑ vùqw®÷$÷ÍûbdÔ|¨|­_ñv÷ ‹÷‹÷¡÷´îš®”Ÿ¸Ş&ûû0Sû*û;û3Æû0÷
û+I vã÷÷÷³ø‹ø³÷È÷ü‹ûø‹ûp÷ü‹û-x÷÷‘÷èvÎ÷ª÷û÷÷f÷úø›÷}÷4ãûQi|`fŠ‘Õš÷ë‹¿ w\”÷÷	}=ÉûûA2û
û‘û…Şû	÷@÷ìô÷'û‡8eWNöI^ÁÙÖ´¹ÍÈµ[EûÑ vùqw÷-÷$÷½÷÷4R÷+û÷0%³@™nšjµ.¢û‹û‹ûxû`'|gzleEğ÷	÷)Å÷1÷:-x÷÷÷÷÷©÷÷d÷$û÷ôø÷í÷Š9÷û<û(.-û*û á-÷Ë¯›¸¯ˆ‡ûcHB‹[p¢º„ûûœÜH÷÷8é÷÷{øû$÷?c[LId¸Ùß´¶ÇÏ²];-x÷÷sõ÷D÷«÷$û÷÷E÷û
÷#êøŸ÷kÜs²:»ìÁ©¥·Ì÷3Õûû1<ûI¦_Æmò?dlX8ûê4÷*÷(íè÷!ìû2÷¼VhgWVf±À¾¯­Á¾¯gXòšûÆIa]OOa¹ÎÌ³¸ÆÊµ_H- vø§wšø ø¯ûH÷¢÷B÷™û94û.1÷.û>÷Bû™ûHû¢÷<ç÷4çû4wŸø§š÷,—’Ÿ˜‹÷£—ü|‹õ
÷ Œ
_÷ªù
endstream
endobj
82 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
83 0 obj
<</OP false/OPM 0/op false>>
endobj
96 0 obj
<</A 97 0 R/Border[0 0 0]/Rect[261.505 9.0 303.25 16.0]/Subtype/Link/Type/Annot>>
endobj
97 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
75 0 obj
[98 0 R]
endobj
76 0 obj
<</Length 12460>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
0.065 Tw 10.5 0 0 10.5 60 730.8196 Tm
[(conducted of 3 dif)20 (ferent dosing regimens: 200 patients)]TJ
-0.033 Tc 0.01801 Tw 0 -1.23809 TD
[(w)-15 (e)-15 (r)-15 (e)-15 ( )-15 (r)-15 (a)-15 (n)-15 (d)-15 (o)-15 (mized to receive two 45 mL NaP doses 6, 12, or)]TJ
-0.039 Tc 0.024 Tw 0 -1.2381 TD
(24 hours apart.)Tj
ET
BT
/T1_1 1 Tf
-0.037 Tc 0 Tw 6 0 0 6 117.0291 708.1197 Tm
(45)Tj
ET
BT
/T1_0 1 Tf
-0.039 Tc 0.024 Tw 10.5 0 0 10.5 125.0271 704.8197 Tm
(Colon cleansing, assessed on a 5 point scale)Tj
-0.03169 Tc -6.19306 -1.2381 Td
[(\(0)-235 (=)]TJ
-0.032 Tc 0.017 Tw 1.77189 0 Td
(best and 4 = worst\), was significantly poorer with the 6)Tj
-0.028 Tc 0.01199 Tw -1.77189 -1.23809 Td
(hour regimen versus the 12 hour schedule \(mean scores 3.3)Tj
-0.039 Tc 0.024 Tw T*
[(vs 2.3, respectively; p = 0.047\). Moreover)40 (, patients who took)]TJ
-0.015 Tc 0.013 Tw T*
(the 2 doses 24 hours apart versus 12 hours apart achieved)Tj
-0.03 Tc 0.015 Tw 0 -1.23809 TD
(comparable cleansing \(mean score of 2.2 vs 2.3, respective-)Tj
-0.033 Tc 0.01801 Tw 0 -1.2381 TD
(ly\). The incidence of AEs was generally comparable among)Tj
-0.015 Tc 0.028 Tw T*
(groups, although dizziness was more common in patients)Tj
-0.03999 Tc 0.00999 Tw 0 -1.23809 TD
(who took the 6 hour regimen, and the 24 hour group required)Tj
-0.01801 Tc 0.00301 Tw 0 -1.2381 TD
[(more time of)20 (f from work. Although that study reported no)]TJ
-0.02299 Tc 0.008 Tw 0 -1.23809 TD
[(dif)20 (ference in clinical laboratory parameters among patients)]TJ
-0.03999 Tc 0.004 Tw 0 -1.2381 TD
(who took the NaP doses 6, 12, or 24 hours apart,)Tj
ET
BT
/T1_1 1 Tf
-0.03799 Tc 0 Tw 6 0 0 6 244.6305 565.1197 Tm
(45)Tj
ET
BT
/T1_0 1 Tf
-0.03999 Tc 0.004 Tw 10.5 0 0 10.5 252.3937 561.8197 Tm
(another in-)Tj
-0.02901 Tc 0.01401 Tw -18.32321 -1.2381 Td
(vestigation reported that hyperphosphatemia was more pro-)Tj
-0.01601 Tc 0.00101 Tw 0 -1.23809 TD
(nounced when the two 45 mL doses of NaP solution were)Tj
-0.03999 Tc 0.013 Tw 0 -1.2381 TD
(separated by a shorter interval \(5 vs 12 h\).)Tj
ET
BT
/T1_1 1 Tf
-0.03799 Tc 0 Tw 6 0 0 6 219.5288 526.1196 Tm
(46)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0.011 Tw 9 0 0 9 119.7892 499.0197 Tm
[(Split Dosing for NaP T)74 (ablets)]TJ
ET
BT
/T1_0 1 Tf
-0.00301 Tc 0.00301 Tw 10.5 0 0 10.5 70.5 480.2197 Tm
[(T)70 (ablet NaP preparations are also more ef)20 (fective when)]TJ
-0.02 Tc 0.02 Tw -1 -1.21905 Td
[(administered in a split-)-75 (dosing schedule. W)40 (ruble et al.)]TJ
ET
BT
/T1_1 1 Tf
-0.017 Tc 0 Tw 6 0 0 6 274.3694 470.7197 Tm
(36)Tj
ET
BT
/T1_0 1 Tf
-0.02 Tc 10.5 0 0 10.5 282.7603 467.4197 Tm
(re-)Tj
0.02 Tw -21.21527 -1.21905 Td
(ported better bowel cleansing with a regimen of 32 MCC-)Tj
-0.004 Tc 0.00301 Tw 0 -1.21905 TD
[(free tablets in patients who followed a split-)-75 (dosing regi-)]TJ
0.004 Tw T*
(men \(n = 33\) versus those who took all 32 tablets on the)Tj
-0.02499 Tc 0.02299 Tw T*
(evening before colonoscopy \(n = 30\). All patients received)Tj
-0.01199 Tc 0.01199 Tw T*
(20 tablets, taken as 4 tablets every 15 minutes, beginning)Tj
-0.015 Tc 0.01401 Tw T*
(at 1800 on the evening before examination. However)Tj
-0.0145 Tc 20.60724 0.00001 Td
(,)Tj
-0.015 Tc 0 Tw 0.48537 0 Td
(the)Tj
-0.02499 Tc 0.024 Tw -21.09261 -1.21905 Td
(remaining 12 tablets were administered 3 hours later in the)Tj
-0.013 Tc 0 Tw T*
(evening-)Tj
0.013 Tw 3.47022 0 Td
[(only group and the next mor)-25 (ning \(3)-50 (\3205 hours be-)]TJ
-0.021 Tc 0.021 Tw -3.47022 -1.21905 Td
[(fore colonoscopy\) in the split-)-75 (dosing group. Although sta-)]TJ
-0.00301 Tc 0.00301 Tw 0 -1.21904 TD
(tistical comparisons between these groups were not per)Tj
0 Tc 21.95274 0 Td
(-)Tj
0.198 Tw -21.95274 -1.21905 Td
[(for)-25 (med, mean overall and ascending colon\320cleansing)]TJ
-0.02499 Tc 0.006 Tw 0 -1.21905 TD
(scores favored split dosing. Moreover)Tj
-0.0251 Tc 14.19063 0 Td
(,)Tj
-0.02499 Tc 0.45552 0 Td
[(the split-)-75 (dosing reg-)]TJ
-0.019 Tc 0.01801 Tw -14.64614 -1.21905 Td
[(imen, but not the evening-)-75 (only regimen, of 32 tablets was)]TJ
0 Tc 0.299 Tw T*
(statistically superior in mean overall and ascending)Tj
-0.008 Tc 0.008 Tw T*
[(colon\320cleansing quality versus a split-)-75 (dosing regimen of)]TJ
-0.02499 Tc 0.013 Tw T*
(40 MCC-containing tablets. )Tj
-0.015 Tc 0 Tw 1 -1.21905 Td
(Collectively)Tj
-0.01489 Tc 4.64498 0.00001 Td
(,)Tj
-0.015 Tc 0.015 Tw 0.48504 0 Td
(these studies)Tj
ET
BT
/T1_1 1 Tf
-0.01401 Tc 0 Tw 6 0 0 6 175.8618 253.1197 Tm
(36,41-)Tj
-0.013 Tc 2.56895 0.00001 Td
(46)Tj
ET
BT
/T1_0 1 Tf
-0.015 Tc 0.015 Tw 10.5 0 0 10.5 199.723 249.8196 Tm
(support the administra)Tj
0 Tc 8.64602 0.00001 Td
(-)Tj
-0.02499 Tc 0.022 Tw -21.95297 -1.21905 Td
[(tion of NaP preparations in a split-)-68.5 (dosing schedule, for op)]TJ
0 Tc 21.95293 0.00002 Td
(-)Tj
-0.02499 Tc 0.013 Tw -21.95293 -1.21906 Td
[(timal safety and ef)20 (ficacy of the bowel pur)20 (gative.)]TJ
ET
BT
/T1_2 1 Tf
0.011 Tw 8 0 0 8 70.5 196.4196 Tm
(DOSE SEP)Tj
0 Tw 4.84967 0.00001 Td
[(ARA)74.2 (TION)]TJ
ET
BT
/T1_0 1 Tf
0.01199 Tw 10.5 0 0 10.5 70.5 175.6196 Tm
(Longer intervals between doses of NaP allow more time)Tj
0.02499 Tw -1 -1.21905 Td
(for ingestion of additional clear fluids, and greater fluid in-)Tj
0 Tc 0.032 Tw 0 -1.21904 TD
(take may be associated with better bowel preparation.)Tj
ET
BT
/T1_1 1 Tf
0.002 Tc 0 Tw 6 0 0 6 287.9998 153.3196 Tm
(45)Tj
ET
BT
/T1_0 1 Tf
-0.006 Tc 0.005 Tw 10.5 0 0 10.5 60 137.2196 Tm
(Longer intervals between doses are associated with a re)Tj
0 Tc 21.95286 0.00001 Td
(-)Tj
-0.024 Tc 0.024 Tw -21.95286 -1.21905 Td
[(duced risk of dehydration. In theory)65.3 (,)-249.9 (dose separation could)]TJ
0 Tc 0.147 Tw 0 -1.21905 TD
[(reduce the risk of acute phosphate nephropathy)65 (. Peak)]TJ
-0.017 Tc 0.017 Tw T*
[(serum phosphate levels occur 4)-110 (\320)-110 (6 hours after an ingested)]TJ
-0.02 Tc 0 Tw T*
(dose.)Tj
ET
BT
/T1_1 1 Tf
-0.01801 Tc 6 0 0 6 80.8348 89.3196 Tm
(48)Tj
ET
BT
/T1_0 1 Tf
-0.02 Tc 0.02 Tw 10.5 0 0 10.5 89.2234 86.0196 Tm
[(Thus, allowing 10)-110 (\32012 hours or more between dos-)]TJ
-0.01489 Tc -2.78318 -1.21905 Td
(es)Tj
-0.015 Tc 0.015 Tw 1.05299 0 Td
[(per)-25 (mits increased phosphate levels to fall after the first)]TJ
-0.011 Tc 0.011 Tw -1.05299 -1.21905 Td
(dose but before the second dose is ingested. Split dosing,)Tj
-0.01199 Tc 0.01199 Tw T*
(with 1 dose taken the day before colonoscopy and 1 dose)Tj
0 Tc 0 Tw 24.57143 65.06667 Td
[(taken the mor)-25 (ning of the procedure, facilitates adequate)]TJ
0.07401 Tw T*
(dose separation, whereas administration of 2 doses the)Tj
-0.02499 Tc 0.007 Tw T*
(evening before colonoscopy usually necessitates a short in-)Tj
0.013 Tw T*
(terval between doses.)Tj
ET
BT
/T1_2 1 Tf
0 Tw 8 0 0 8 328.5 664.6697 Tm
[(HYDRA)74 (TION)]TJ
ET
BT
/T1_0 1 Tf
-0.00301 Tc 0.00301 Tw 10.5 0 0 10.5 328.5 643.9197 Tm
(Adequate hydration is an important component of the)Tj
-0.01801 Tc 0.01801 Tw -1 -1.21429 Td
(bowel preparation process, and maintaining proper hydra-)Tj
-0.009 Tc 0.009 Tw 0 -1.21428 TD
(tion before, during, and after the preparation is critical to)Tj
-0.013 Tc 0.013 Tw 0 -1.21429 TD
(avoid dehydration-related complications and to minimize)Tj
-0.01801 Tc 0.01801 Tw T*
[(AEs associated with NaP pur)20 (gatives.)]TJ
ET
BT
/T1_1 1 Tf
-0.017 Tc 0 Tw 6 0 0 6 466.7578 596.2197 Tm
(1,19)Tj
ET
BT
/T1_0 1 Tf
-0.01801 Tc 0.01801 Tw 10.5 0 0 10.5 479.4512 592.9197 Tm
(Adherence to rec-)Tj
0 Tc 0.07001 Tw -15.3763 -1.21429 Td
[(ommended fluid requirements \(T)70 (able 1\) promotes ade-)]TJ
-0.02499 Tc 0.02499 Tw T*
(quate filtration of excess phosphate,)Tj
ET
BT
/T1_1 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 460.6368 570.7197 Tm
(29,30)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.02499 Tw 10.5 0 0 10.5 476.0088 567.4197 Tm
(increasing the like-)Tj
-0.007 Tc 0.007 Tw -15.04845 -1.21429 Td
(lihood of safe administration of NaP preparations. In my)Tj
-0.02499 Tc T*
(practice, we use prescribed volumes of hydration with NaP)Tj
0.013 Tw 0 -1.21428 TD
[(preparations \(T)70 (able 4\).)]TJ
0 Tc 0.283 Tw 1 -1.21429 Td
(Carbohydrate/electrolyte rehydration solutions \(eg,)Tj
-0.005 Tc 0.005 Tw -1 -1.21429 Td
[(Gatorade, Quaker T)35 (ropicana Gatorade, Chicago, IL, and)]TJ
-0.017 Tc 0.017 Tw 0 -1.21429 TD
[(E-L)55 (yte, CB Fleet Company)65 (, Inc., L)55 (ynchbur)20 (g, V)130 (A\) may be)]TJ
-0.008 Tc 0.008 Tw T*
(administered as a preferred clear liquid for hydration be-)Tj
0 Tc 0.04401 Tw T*
(cause they result in better bowel preparation and better)Tj
-0.00999 Tc 0.00999 Tw T*
[(hemodynamic status on presentation for colonoscopy)65 (.)]TJ
ET
BT
/T1_1 1 Tf
-0.009 Tc 0 Tw 6 0 0 6 538.7384 455.9697 Tm
(49,50)Tj
ET
BT
/T1_0 1 Tf
-0.01601 Tc 0.01601 Tw 10.5 0 0 10.5 318 439.9197 Tm
(Also, an intravenous line during colonoscopy provides an)Tj
-0.02499 Tc 0.013 Tw 0 -1.21428 TD
(additional opportunity to hydrate.)Tj
ET
BT
/T1_2 1 Tf
0 Tw 10.5 0 0 10.5 318 399.4197 Tm
(Summary)Tj
ET
BT
/T1_0 1 Tf
0.007 Tw 10.5 0 0 10.5 328.5 378.5447 Tm
(Sodium phosphate preparations cause expected transient)Tj
-0.02299 Tc 0.02299 Tw -1 -1.22619 Td
(shifts in serum electrolyte levels due to their hyperosmotic)Tj
-0.013 Tc 0.013 Tw 0 -1.22619 TD
(nature and, for this reason, are contraindicated in patients)Tj
-0.024 Tc 0.024 Tw T*
[(with renal insuf)20 (ficiency and in patients at risk for dehydra-)]TJ
0 Tc 0 Tw T*
(tion. Given that NaP preparations are well tolerated and)Tj
-0.009 Tc 0.009 Tw T*
(preferred by patients compared with PEG-ELS products,)Tj
-0.00101 Tc 0.00101 Tw T*
[(the ideal NaP pur)20 (gative should minimize expected elec-)]TJ
-0.01801 Tc 0.01801 Tw T*
[(trolyte shifts while maintaining ef)20 (fective bowel cleansing.)]TJ
-0.01601 Tc 0.01601 Tw T*
[(The minimally ef)20 (fective doses are 75 mL of NaP solution)]TJ
-0.01401 Tc 0.01401 Tw T*
(or 32 NaP tablets. These doses reduce the phosphate load)Tj
-0.00101 Tc 0.00101 Tw T*
[(associated with administration of NaP pur)20 (gatives, cause)]TJ
-0.02299 Tc 0.022 Tw T*
(less-pronounced elevations in serum phosphate levels, and)Tj
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.024 Tc 0 Tw 10 0 0 10 60.5 23.9116 Tm
(1472)Tj
ET
BT
/T1_3 1 Tf
0 Tc 5 0 0 5 89 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 102.181 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 5 0 0 5 235.3059 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 248.487 23.9116 Tm
[(2007 September)110 (, V)110 (olume 41)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tc 8 0 0 8 60 749.5293 Tm
[(DK)-250 (Rex)]TJ
ET
0 0 0 0 k
318.5 48.5 233 143 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.02499 Tc 0.011 Tw 9 0 0 9 324.237 179.0416 Tm
[(T)74 (able 4.)]TJ
ET
BT
/T1_6 1 Tf
9 0 0 9 357.7526 179.0416 Tm
(An Example of an Aggressive Hydration Regimen)Tj
ET
0 0 0 1 K
0.5 w 
318.5 162.292 m
551.5 162.292 l
S
BT
/T1_6 1 Tf
9 0 0 9 366.8171 168.0417 Tm
(for Use with NaP Bowel Preparation)Tj
ET
318.5 147.792 m
551.5 147.792 l
S
BT
/T1_2 1 Tf
0 Tc 0 Tw 7.5 0 0 7.5 360.2777 152.0416 Tm
[(T)18 (iming)]TJ
15.604 0 Td
(Regimen)Tj
ET
BT
/T1_2 1 Tf
5 0 0 5 508.9674 154.7917 Tm
(a)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tw 7.5 0 0 7.5 321.5 136.0417 Tm
(Before preparation)Tj
-0.00011 Tc 15.72859 0.00001 Td
(8)Tj
0 Tc 0.81987 0 Td
(oz clear liquid every hour for )Tj
-0.31987 -1.20001 Td
(the 6 h preceding the first dose)Tj
-16.22859 -1.6 Td
[(W)0.1 (ith and after the first dose)-3570.7 (at least 48 oz of clear liquid)]TJ
-0.00001 -1.6 Td
[(W)0.1 (ith and after the second dose)-1957.7 (at least 24 oz of clear liquid)]TJ
-0.00001 -1.6 Td
[(After the procedure and the )-3350 (8 oz of clear liquid every hour for )]TJ
0.5 -1.2 Td
(patient is awake)Tj
15.72998 0 Td
(6 h or at least 6 times before )Tj
ET
318.5 66.792 m
551.5 66.792 l
S
BT
/T1_6 1 Tf
0 Tw 7.5 0 0 7.5 443.2144 73.0417 Tm
(retiring)Tj
ET
BT
/T1_2 1 Tf
5 0 0 5 321.5 58.7917 Tm
(a)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tw 7.5 0 0 7.5 324.2795 56.0416 Tm
(Carbohydrate/electrolyte solutions are preferred as clear liquids.)Tj
ET
318.25 48.25 233.5 143.5 re
h
S
BT
0 g
/GS2 gs
/T1_7 1 Tf
0 Tw 5 0 0 5 302.24986 11 Tm
( at DALHOUSIE UNIV on May 19, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
77 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
78 0 obj
<</OP false/OPM 0/op false>>
endobj
98 0 obj
<</A 99 0 R/Border[0 0 0]/Rect[261.505 9.0 303.25 16.0]/Subtype/Link/Type/Annot>>
endobj
99 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
60 0 obj
<</Annots 100 0 R/Contents 101 0 R/MediaBox[0 0 612 792]/Parent 59 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 102 0 R/GS2 103 0 R>>/Font<</T1_0 18 0 R/T1_1 22 0 R/T1_2 26 0 R/T1_3 30 0 R/T1_4 34 0 R/T1_5 38 0 R/T1_6 42 0 R/T1_7 46 0 R/T1_8 50 0 R/T1_9 79 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
61 0 obj
<</Annots 104 0 R/Contents 105 0 R/MediaBox[0 0 612 792]/Parent 59 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 106 0 R/GS2 107 0 R>>/Font<</T1_0 34 0 R/T1_1 18 0 R/T1_2 42 0 R/T1_3 26 0 R/T1_4 22 0 R/T1_5 30 0 R/T1_6 54 0 R/T1_7 79 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
62 0 obj
<</Annots 108 0 R/Contents 109 0 R/MediaBox[0 0 612 792]/Parent 59 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 110 0 R/GS2 111 0 R>>/Font<</T1_0 42 0 R/T1_1 34 0 R/T1_2 18 0 R/T1_3 22 0 R/T1_4 26 0 R/T1_5 58 0 R/T1_6 79 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
63 0 obj
<</Annots 112 0 R/Contents 113 0 R/MediaBox[0 0 612 792]/Parent 59 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 114 0 R/GS2 115 0 R>>/Font<</T1_0 34 0 R/T1_1 18 0 R/T1_2 42 0 R/T1_3 54 0 R/T1_4 58 0 R/T1_5 26 0 R/T1_6 22 0 R/T1_7 30 0 R/T1_8 79 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
64 0 obj
<</Annots 116 0 R/Contents 117 0 R/MediaBox[0 0 612 792]/Parent 59 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 118 0 R/GS2 119 0 R>>/Font<</T1_0 34 0 R/T1_1 18 0 R/T1_2 22 0 R/T1_3 26 0 R/T1_4 58 0 R/T1_5 42 0 R/T1_6 30 0 R/T1_7 79 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
65 0 obj
<</Annots 120 0 R/Contents 121 0 R/MediaBox[0 0 612 792]/Parent 59 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 122 0 R/GS2 123 0 R>>/Font<</T1_0 34 0 R/T1_1 18 0 R/T1_2 42 0 R/T1_3 58 0 R/T1_4 26 0 R/T1_5 22 0 R/T1_6 79 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
120 0 obj
[124 0 R]
endobj
121 0 obj
<</Length 12427>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.02499 Tc 0.02299 Tw 10.5 0 0 10.5 60 730.8196 Tm
[(for)-25 (mulations may improve patient tolerability without sub-)]TJ
-0.02 Tc 0.02 Tw 0 -1.23809 TD
[(stantially impacting cleansing ef)20 (ficacy)65 (. Additional studies,)]TJ
-0.00301 Tc 0.002 Tw 0 -1.2381 TD
[(including lar)20 (ge, prospective, double-blind clinical trials,)]TJ
0 Tc 0.112 Tw T*
[(are needed to confir)-25 (m these findings. Moreover)40 (, trials)]TJ
-0.011 Tc 0.011 Tw 0 -1.23809 TD
[(comparing NaP solution and tablet for)-25 (m)1 (u)1 (l)1 (a)1 (t)1 (i)1 (o)1 (n)1 (s)1 ( )1 (a)1 (r)1 (e)1 ( )1 (w)1 (a)1 (r)1 (-)]TJ
-0.02499 Tc 0.00301 Tw 0 -1.2381 TD
[(ranted to deter)-25 (mine which regimen is preferred by patients.)]TJ
0.00999 Tw T*
(These studies should include considerations such as cost of)Tj
0.02499 Tw 0 -1.23809 TD
(the preparations \(currently an advantage of NaP solution)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 284.8032 643.1197 Tm
(27)Tj
ET
BT
/T1_0 1 Tf
0 Tc 10.5 0 0 10.5 290.5047 639.8197 Tm
(\))Tj
-0.0179 Tc -21.95283 -1.2381 Td
(as)Tj
-0.01801 Tc 0.01801 Tw 1.04715 0 Td
(well as taste, ease of completion, and willingness to re-)Tj
-0.02499 Tc 0.013 Tw -1.04715 -1.2381 Td
(peat the preparation. )Tj
ET
BT
/T1_2 1 Tf
0.011 Tw 10.5 0 0 10.5 60 585.6696 Tm
(Dosing Considerations for Sodium Phosphate)Tj
0 Tw 0 -1.25238 TD
(Preparations)Tj
ET
BT
/T1_2 1 Tf
0.011 Tw 8 0 0 8 70.5 551.3697 Tm
[(MINIMALL)92 (Y EFFECTIVE SODIUM PHOSPHA)74 (TE DOSE)]TJ
ET
BT
/T1_0 1 Tf
-0.01601 Tc 0.01601 Tw 10.5 0 0 10.5 70.5 530.2197 Tm
[(Recommended dosing regimens \(T)70 (able 1\) are based on)]TJ
-0.00101 Tc 0.00101 Tw -1 -1.25238 Td
[(clinical trials evaluating the minimally ef)20 (fective dose of)]TJ
0 Tc 0.048 Tw T*
[(NaP)110 (. Recent studies reported similar cleansing ef)20 (ficacy)]TJ
-0.008 Tc 0.008 Tw T*
(with a reduced-volume 75 mL \(45 mL plus 30 mL\) regi)Tj
0 Tc 21.95294 0.00001 Td
(-)Tj
-0.004 Tc 0.004 Tw -21.95294 -1.25237 Td
(men of NaP solution compared with the standard 90 mL)Tj
0 Tc 0 Tw T*
(\(45 mL plus 45 mL\) regimen.)Tj
ET
BT
/T1_1 1 Tf
0.00101 Tc 6 0 0 6 184.7509 467.7698 Tm
(34,37)Tj
ET
BT
/T1_0 1 Tf
0 Tc 10.5 0 0 10.5 200.8695 464.4698 Tm
(However)Tj
-0.00031 Tc 3.62277 0 Td
(,)Tj
0 Tc 0.49964 0 Td
(ingestion of)Tj
-0.019 Tc 0.019 Tw -17.53855 -1.25239 Td
(less than 75 mL of NaP solution may compromise cleans-)Tj
-0.02499 Tc 0.02499 Tw T*
[(ing quality)65 (. For example, studies suggest that bowel prepa-)]TJ
0 Tc 0.01199 Tw T*
(ration with 45 mL of NaP solution does not provide ac-)Tj
0.32201 Tw T*
(ceptable cleansing for colonoscopic examination.)Tj
ET
BT
/T1_1 1 Tf
0.00101 Tc 0 Tw 6 0 0 6 280.8309 415.1698 Tm
[(1)55 (1,38)]TJ
ET
BT
/T1_0 1 Tf
0 Tc 10.5 0 0 10.5 60 398.7198 Tm
(A)Tj
-0.007 Tc 0.007 Tw 0.63952 0 Td
(vailable dosing )Tj
-0.022 Tc 6.23096 0 Td
[(regimens for tablet for)-18.2 (mulations are also)]TJ
-0.03 Tc 0.015 Tw -6.87049 -1.25239 Td
(based on clinical studies that evaluated the minimally ef)Tj
0 Tw 20.82279 0 Td
(fec)Tj
0 Tc 1.13023 0 Td
(-)Tj
-0.03999 Tc 0.002 Tw -21.95302 -1.25239 Td
[(tive dose of NaP)110 (. For the MCC-containing tablet for)-25 (mulation,)]TJ
-0.03391 Tc T*
(a)Tj
-0.034 Tc 0.019 Tw 0.64499 0 Td
(40 tablet regimen \(60 g NaP\) is the approved dose; studies)Tj
-0.02901 Tc 0.01401 Tw -0.64499 -1.25238 Td
[(have demonstrated ef)20 (fective colon cleansing with 28 tablets)]TJ
-0.036 Tc 0.02 Tw T*
(\(42 g NaP\) and 32 tablets \(48 g NaP\),)Tj
ET
BT
/T1_1 1 Tf
-0.034 Tc 0 Tw 6 0 0 6 206.2715 336.2698 Tm
(39,40)Tj
ET
BT
/T1_0 1 Tf
-0.036 Tc 0.02 Tw 10.5 0 0 10.5 221.1758 332.9698 Tm
(but these regimens)Tj
-0.037 Tc 0.021 Tw -15.35007 -1.25238 Td
(were not directly compared with the 40 tablet regimen. A 32)Tj
-0.02499 Tc 0.00999 Tw T*
[(tablet regimen has been approved for the newer)40 (, MCC-free)]TJ
-0.039 Tc 0.024 Tw T*
[(tablet for)-24 (mulation and is supported by the finding that a regi)]TJ
0 Tc 21.95292 0.00002 Td
(-)Tj
-0.015 Tc 0.179 Tw -21.95292 -1.25239 Td
(men of 32 or 40 MCC-free tablets, but not 28 tablets,)Tj
0.02699 Tw 0 -1.25237 TD
(achieved better cleansing compared with a regimen of 40)Tj
0.013 Tw 0 -1.25238 TD
[(MCC-containing tablets \(T)70 (able 3\).)]TJ
ET
BT
/T1_1 1 Tf
-0.013 Tc 0 Tw 6 0 0 6 199.6804 257.3698 Tm
(36)Tj
ET
BT
/T1_0 1 Tf
-0.015 Tc 0.013 Tw 10.5 0 0 10.5 208.1047 254.0698 Tm
(Thus, at this time, 75)Tj
-0.03999 Tc 0.01401 Tw -14.10521 -1.25238 Td
(mL of NaP solution and 32 NaP tablets appear to be the min-)Tj
0.011 Tw T*
[(imally ef)20 (fective doses. As noted above, there is increased risk)]TJ
0.013 Tw T*
(when more than 90 mL or 40 tablets are taken. )Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0.011 Tw 8 0 0 8 70.5 186.4699 Tm
[(SPLIT)55 (-DOSING SCHEDULES ARE MOST EFFECTIVE AND)]TJ
0 -1.64375 TD
[(POTENTIALL)92 (Y SAFER)]TJ
ET
BT
/T1_0 1 Tf
-0.005 Tc 0.005 Tw 10.5 0 0 10.5 70.5 152.1699 Tm
(The recommended dosing schedules for NaP prepara-)Tj
-0.02499 Tc 0.015 Tw -1 -1.25238 Td
[(tions \(T)70.8 (able 1\) are supported by several clinical studies.)]TJ
ET
BT
/T1_1 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 280.0043 142.3198 Tm
[(34)-23 (-)-74 (46)]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.00999 Tw 10.5 0 0 10.5 60 125.8699 Tm
(An important component of these schedules is split dosing,)Tj
-0.009 Tc 0.009 Tw 0 -1.25238 TD
(in which a portion of the dose is administered on the day)Tj
0 Tc 0.03 Tw 0 -1.25239 TD
(before colonoscopy and the remaining dose is adminis-)Tj
-0.02499 Tc 0.013 Tw 0 -1.25238 TD
(tered on the day of the procedure. )Tj
-0.011 Tc 0.011 Tw 1 -1.23809 Td
(In clinical practice, there are often 2 objections to split)Tj
0 Tc 0.075 Tw -1 -1.2381 Td
(dosing. One is that patients are inconvenienced if they)Tj
0.07201 Tw 0 -1.2381 TD
[(have to get up early in the mor)-25 (ning to take the second)]TJ
0.065 Tw 24.57143 65.08569 Td
[(dose. However)40 (, if the importance of split dosing is ex-)]TJ
-0.009 Tc 0.009 Tw 0 -1.23809 TD
(plained to the patient, anecdotal experience suggests that)Tj
-0.02 Tc 0.02 Tw 0 -1.2381 TD
[(nearly all patients will comply)65 (. Second, many anesthesiol-)]TJ
T*
(ogists insist that patients take nothing by mouth after mid-)Tj
-0.017 Tc 0.017 Tw 0 -1.23809 TD
[(night the night before colonoscopy)65 (. This is an unfortunate)]TJ
-0.007 Tc 0.007 Tw 0 -1.2381 TD
[(interference with the ef)20 (ficacy and safety of colonoscopy)65 (,)]TJ
-0.021 Tc 0.021 Tw T*
[(particularly since the of)20 (ficial policy of the American Soci-)]TJ
-0.00301 Tc 0.00301 Tw 0 -1.23809 TD
(ety of Anesthesiologists is that patients may ingest clear)Tj
-0.013 Tc 0.013 Tw 0 -1.2381 TD
(liquids until 2 hours before sedation.)Tj
ET
BT
/T1_1 1 Tf
-0.011 Tc 0 Tw 6 0 0 6 467.3626 630.1197 Tm
(47)Tj
ET
BT
/T1_0 1 Tf
-0.013 Tc 0.013 Tw 10.5 0 0 10.5 475.8283 626.8197 Tm
(In my practice, we)Tj
-0.021 Tc 0.021 Tw -15.03127 -1.2381 Td
[(instruct patients to take the second dose of NaP 4)-110 (\3205 hours)]TJ
-0.019 Tc 0.019 Tw 0 -1.23809 TD
(before the time their colonoscopy is scheduled, with com-)Tj
-0.011 Tc 0.011 Tw 0 -1.2381 TD
(pletion of the accompanying hydration by 3 hours before)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
[(the scheduled time of colonoscopy)65 (.)]TJ
ET
BT
/T1_2 1 Tf
0.011 Tw 9 0 0 9 375.3243 550.7197 Tm
(Split Dosing for NaP Solution)Tj
ET
BT
/T1_0 1 Tf
-0.0154 Tc 0 Tw 10.5 0 0 10.5 328.5 531.6196 Tm
(A)Tj
-0.015 Tc 0.015 Tw 0.95648 0 Td
(prospective study randomized patients scheduled for)Tj
-0.008 Tc 0.008 Tw -1.95648 -1.24762 Td
(colonoscopy to receive 90 mL of NaP solution, adminis-)Tj
-0.019 Tc 0.019 Tw 0 -1.24762 TD
(tered as 45 mL taken at 0700 and 45 mL taken at 1900 on)Tj
-0.02499 Tc 0.013 Tw 0 -1.24761 TD
(the day before examination \(group 1, n = 161\) or as 45 mL)Tj
-0.005 Tc 0.005 Tw 0 -1.24762 TD
(taken at 1800 on the day before colonoscopy and 45 mL)Tj
-0.021 Tc 0.021 Tw T*
[(taken at 0600 on the mor)-25 (ning of the procedure \(group 2, n)]TJ
-0.01649 Tc T*
(=)Tj
-0.01601 Tc 0 Tw 0.7975 0 Td
(166\).)Tj
ET
BT
/T1_1 1 Tf
-0.01401 Tc 6 0 0 6 347.3817 456.3197 Tm
(41)Tj
ET
BT
/T1_0 1 Tf
-0.01601 Tc 0.01601 Tw 10.5 0 0 10.5 355.8098 453.0197 Tm
(Bowel cleansing, rated on a scale of 0 \(worst\) to)Tj
-0.0251 Tc -3.60093 -1.24762 Td
(5)Tj
-0.02499 Tc 0.01801 Tw 0.71734 0 Td
(\(best\), was significantly superior in group 2 versus group)Tj
-0.0051 Tc -0.71734 -1.24763 Td
(1)Tj
-0.005 Tc 0.005 Tw 0.74486 0 Td
(\(4.1 vs 3.2; p < 0.0005\), and the incidence of AEs was)Tj
-0.008 Tc 0.008 Tw -0.74486 -1.24762 Td
(similar between groups. Similarly)Tj
-0.0085 Tc 13.23499 0 Td
(,)Tj
-0.008 Tc 0.49139 0 Td
(Berkelhammer et al.)Tj
ET
BT
/T1_1 1 Tf
-0.006 Tc 0 Tw 6 0 0 6 546.0491 417.0197 Tm
(42)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.02499 Tw 10.5 0 0 10.5 318 400.6196 Tm
(reported that significantly more patients \(84% vs 73%; p <)Tj
-0.005 Tc 0.004 Tw T*
(0.001\) achieved good or excellent colon cleansing when)Tj
-0.00101 Tc 0.00101 Tw T*
(NaP solution was taken as 45 mL on the evening before)Tj
-0.02299 Tc 0.02299 Tw T*
[(and 45 mL on the mor)-25 (ning of the day of colonoscopy \(n =)]TJ
-0.02499 Tc 0.00101 Tw T*
(297\) compared with patients who received two 45 mL dos-)Tj
0.013 Tw T*
(es 9 hours apart on the day before colonoscopy \(n = 160\). )Tj
-0.0251 Tc 1 -1.24762 Td
(A)Tj
-0.02499 Tc 0.011 Tw 0.93271 0 Td
(more recent study of 44 patients who took two 45 mL)Tj
-0.021 Tc -1.93271 -1.24762 Td
[(d)-10 (o)-10 (s)-10 (e)-10 (s of NaP 5 hours apart on the day before colonoscopy)]TJ
-0.01401 Tc 0.004 Tw T*
(\(group 1\) and 45 patients who took 1 dose on the evening)Tj
-0.02699 Tc 0.017 Tw T*
[(before colonoscopy and the second dose on the mor)-25 (ning of)]TJ
-0.01801 Tc 0.008 Tw T*
(the procedure \(group 2\) reported a significant benefit with)Tj
-0.026 Tc 0.01601 Tw T*
(the latter dosing schedule, not only in the percentage of pa-)Tj
-0.034 Tc 0.024 Tw T*
(tients who achieved good or excellent colon cleansing \(80%)Tj
-0.035 Tc 0.013 Tw T*
(vs 7%; p < 0.01\) but also in the detection of flat lesions.)Tj
ET
BT
/T1_1 1 Tf
-0.033 Tc 0 Tw 6 0 0 6 533.0066 233.6196 Tm
(43)Tj
ET
BT
/T1_0 1 Tf
-0.008 Tc 0.008 Tw 10.5 0 0 10.5 328.5 217.2195 Tm
(One advantage of split dosing, with the second 45 mL)Tj
-0.021 Tc 0.021 Tw -1 -1.24762 Td
[(dose of NaP administered on the mor)-25 (ning of colonoscopy)65 (,)]TJ
-0.019 Tc 0.019 Tw T*
(is that the time between the bowel preparation and the ex-)Tj
-0.02499 Tc 0.015 Tw T*
(amination is minimized. One group of investigators report-)Tj
-0.022 Tc 0.022 Tw T*
[(ed that cleansing ef)20 (ficacy was inversely related to the time)]TJ
0 Tc 0.321 Tw T*
(from administration of the second dose of NaP to)Tj
0.22 Tw T*
(colonoscopy \(p = 0.0001\).)Tj
ET
BT
/T1_1 1 Tf
0.002 Tc 0 Tw 6 0 0 6 435.5478 141.9195 Tm
(44)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.22 Tw 10.5 0 0 10.5 446.4866 138.6195 Tm
(Patients who underwent)Tj
-0.008 Tc 0.008 Tw -12.23682 -1.24762 Td
(colonoscopy within 6 hours of ingesting the second dose)Tj
-0.007 Tc 0.007 Tw T*
(of NaP achieved significantly better cleansing compared)Tj
-0.008 Tc 0.008 Tw 0 -1.24761 TD
[(with those who underwent colonoscopy 6)-120.2 (\32012 hours \(p =)]TJ
-0.013 Tc 0.013 Tw 0 -1.24762 TD
(0.023\) or 12 hours or more \(p = 0.0001\) after administra)Tj
0 Tc 21.95309 0.00001 Td
(-)Tj
-0.02499 Tc -21.95309 -1.24762 Td
(tion of the second dose.)Tj
0.021 Tw 1 -1.2381 Td
(Another advantage of split dosing is that the interval be-)Tj
-0.011 Tc 0.011 Tw -1 -1.2381 Td
(tween doses is maximized. A thorough investigation was)Tj
ET
0 0 0 0 k
318 745 234 10 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 8 0 0 8 418.5493 749.5293 Tm
(Sodium Phosphate Dosing in Colonoscopy)Tj
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
10 0 0 10 259.0939 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 392.2189 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 405.4 23.9116 Tm
[(2007 September)110 (, V)110 (olume 41    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 519.569 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.024 Tc 10 0 0 10 532.75 23.9116 Tm
(1471)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
BT
0 g
/GS2 gs
/T1_6 1 Tf
0 Tc 5 0 0 5 302.24986 11 Tm
( at DALHOUSIE UNIV on May 19, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
122 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
123 0 obj
<</OP false/OPM 0/op false>>
endobj
124 0 obj
<</A 125 0 R/Border[0 0 0]/Rect[261.505 9.0 303.25 16.0]/Subtype/Link/Type/Annot>>
endobj
125 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
116 0 obj
[126 0 R]
endobj
117 0 obj
<</Length 12737>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.032 Tc 0.022 Tw 10.5 0 0 10.5 60 730.8196 Tm
[(sing observed in 87% of patients who received a)-10 ( )-10 (9)-10 (0)-10 ( )-10 (m)-10 (L)-10 ( )-10 (s)-10 (o)-10 (-)]TJ
-0.02499 Tc 0.007 Tw 0 -1.23809 TD
(lution \(59.4 g of NaP; n = 106\) and in 83% of patients who)Tj
0.00101 Tw 0 -1.2381 TD
[(received a regimen of 24 or 32 tablets \(36 g or 48 g of NaP)110 (,)]TJ
0 Tc 0.058 Tw T*
(respectively; n = 99\).)Tj
ET
BT
/T1_1 1 Tf
0 Tw 6 0 0 6 151.1154 695.1196 Tm
(5)Tj
ET
BT
/T1_0 1 Tf
0.058 Tw 10.5 0 0 10.5 157.3443 691.8196 Tm
[(However)40 (, patient tolerability fa-)]TJ
-0.021 Tc 0.021 Tw -9.27088 -1.23809 Td
(vored tablets; more patients in the NaP tablet groups com-)Tj
-0.01401 Tc 0.01401 Tw T*
(pared with those in the NaP solution group rated the taste)Tj
0 Tc 0.17101 Tw T*
(as \322no taste/pleasant\323 \(59% vs 5%, respectively; p <)Tj
-0.02499 Tc 0.022 Tw 0 -1.23809 TD
(0.001\) and would choose the same preparation again \(82%)Tj
0 Tc 0.047 Tw 0 -1.2381 TD
(vs 53%, respectively; p < 0.001\). In contrast, a smaller)Tj
-0.02499 Tc 0.008 Tw T*
(study of 100 patients reported better cleansing \(good or ex-)Tj
-0.02299 Tc 0.02299 Tw 0 -1.23809 TD
(cellent cleansing in 92% vs 74% of patients; p = 0.03\) and)Tj
-0.02499 Tc 0.02499 Tw 0 -1.2381 TD
(greater willingness to repeat the preparation \(90% vs 74%;)Tj
-0.00011 Tc 0 -1.23809 TD
[(p)-391.7 (<)]TJ
0 Tc 0.142 Tw 1.84714 0 Td
(0.04\) with a 90 mL NaP solution versus 40 NaP)Tj
-0.01601 Tc 0 Tw -1.84714 -1.2381 Td
(tablets.)Tj
ET
BT
/T1_1 1 Tf
-0.013 Tc 6 0 0 6 88.7334 565.1197 Tm
(33)Tj
ET
BT
/T1_0 1 Tf
-0.01601 Tc 0.015 Tw 10.5 0 0 10.5 97.173 561.8197 Tm
[(Thus, additional studies are needed to deter)-25 (mine)]TJ
-0.024 Tc 0.024 Tw -3.54029 -1.2381 Td
[(whether NaP solution and tablets dif)20 (fer with regard to ef)20 (fi)-1 (-)]TJ
-0.02499 Tc 0.013 Tw T*
[(cacy or tolerability)65 (.)]TJ
-0.022 Tc 0.022 Tw 1 -1.2381 Td
[(The MCC-free tablet for)-26.7 (mulation demonstrated compa-)]TJ
-0.02499 Tc 0.002 Tw -1 -1.23809 Td
[(rable or better ef)20 (ficacy than the MCC-containing tablet for-)]TJ
0 Tc 0.11301 Tw T*
(mulation in clinical trials published in 2006 and 2007)Tj
-0.009 Tc 0 Tw 0 -1.2381 TD
(\(T)Tj
0.008 Tw 0.85664 0 Td
(able 3\).)Tj
ET
BT
/T1_1 1 Tf
-0.007 Tc 0 Tw 6 0 0 6 99.856 487.1197 Tm
(35,36)Tj
ET
BT
/T1_0 1 Tf
-0.009 Tc 0.008 Tw 10.5 0 0 10.5 115.7276 483.8197 Tm
(This result is almost certainly related to the)Tj
0 Tc 0.019 Tw -5.30739 -1.2381 Td
(elimination of MCC, which is reported to impair bowel)Tj
-0.02499 Tc 0.009 Tw 0 -1.23809 TD
[(preparation. In addition to measures of ef)22.6 (ficacy)65 (, patient tol-)]TJ
0.01801 Tw 0 -1.2381 TD
(erability and acceptance also favored the newer)Tj
-0.0251 Tc 17.88346 0 Td
(,)Tj
-0.02499 Tc 0 Tw 0.46813 0 Td
(MCC-free)Tj
-0.01601 Tc 0.01601 Tw -18.35159 -1.2381 Td
[(tablet for)-25 (mulation. Rex et al.)]TJ
ET
BT
/T1_1 1 Tf
-0.01401 Tc 0 Tw 6 0 0 6 176.6049 435.1197 Tm
(35)Tj
ET
BT
/T1_0 1 Tf
-0.01601 Tc 0.01601 Tw 10.5 0 0 10.5 185.038 431.8197 Tm
(reported that more patients)Tj
-0.02299 Tc 0.02299 Tw -11.90838 -1.23809 Td
(who took 32 MCC-free tablets versus 40 MCC-containing)Tj
-0.02 Tc 0.02 Tw 0 -1.23809 TD
(tablets found the preparation \322easy\323 to take \(77% vs 48%;)Tj
-0.0181 Tc 0 -1.2381 TD
[(p)-249.9 (<)]TJ
-0.01801 Tc 0.01801 Tw 1.52768 0 Td
(0.0001\), tolerated the liquid requirements easily \(71%)Tj
-0.011 Tc 0.011 Tw 23.04374 32.19048 Td
(vs 52%; p = 0.0002\), and expressed willingness to repeat)Tj
-0.02499 Tc 0.01601 Tw 0 -1.23809 TD
(the preparation \(95% vs 88%; p = 0.003\). These results are)Tj
-0.01401 Tc 0.01401 Tw 0 -1.2381 TD
[(not surprising, given that the newer tablet for)-25 (mulation in-)]TJ
0 Tc 0.052 Tw T*
[(cludes smaller tablets with a smoother)40 (, waxier coating,)]TJ
0.07401 Tw 0 -1.23809 TD
(fewer tablets to ingest, and reduced fluid requirements)Tj
-0.02499 Tc 0.013 Tw 0 -1.2381 TD
[(compared with the older tablet for)-25 (mulation. )]TJ
0 Tc 0.02901 Tw 1 -1.2381 Td
(Preliminary studies comparing 45 mL plus 45 mL of)Tj
0.019 Tw -1 -1.23809 Td
(NaP solution \(90 mL, 59.4 g of NaP\) with the lower 45)Tj
-0.02499 Tc 0.02 Tw T*
(mL plus 30 mL dose \(75 mL, 49.5 g NaP\) reported similar)Tj
-0.00999 Tc 0.00999 Tw T*
[(e)1 (f)21 (ficacy with both preparations. In one study)65 (, 98% of pa-)]TJ
0 Tc 0.20799 Tw 0 -1.23809 TD
(tients who received the 90 mL preparation \(n = 40\))Tj
-0.02499 Tc 0.02499 Tw 0 -1.2381 TD
(achieved good or excellent colon cleansing compared with)Tj
-0.015 Tc 0.015 Tw 0 -1.23809 TD
(88% of patients who received the 75 mL preparation \(n =)Tj
-0.02499 Tc 0 Tw 0 -1.2381 TD
[(40\); the dif)20 (ference was not significant.)]TJ
ET
BT
/T1_1 1 Tf
-0.02299 Tc 6 0 0 6 469.4001 565.1197 Tm
(37)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 10.5 0 0 10.5 477.467 561.8197 Tm
(More patients who)Tj
-0.02 Tc 0.019 Tw -15.18733 -1.2381 Td
(took the 75 mL regimen \(95%\) versus the 90 mL regimen)Tj
-0.015 Tc 0.015 Tw 0 -1.23809 TD
(\(88%\) expressed willingness to repeat the preparation but)Tj
0 Tc 0 Tw 0 -1.2381 TD
[(reported no dif)25.7 (ference in ease of drinking or taste of the)]TJ
-0.01401 Tc 0.01401 Tw 0 -1.23809 TD
[(preparation. A lar)20 (ger study of 321 subjects reported com-)]TJ
-0.015 Tc 0.015 Tw T*
(parable cleansing with 90 mL and 75 mL regimens; good)Tj
-0.02499 Tc 0.009 Tw 0 -1.2381 TD
(or excellent cleansing was reported in 90% of patients who)Tj
-0.015 Tc 0.015 Tw T*
(took the 90 mL regimen and in 87% of patients who took)Tj
-0.011 Tc 0.011 Tw 0 -1.23809 TD
(the 75 mL regimen.)Tj
ET
BT
/T1_1 1 Tf
-0.009 Tc 0 Tw 6 0 0 6 399.0126 461.1197 Tm
(34)Tj
ET
BT
/T1_0 1 Tf
-0.01199 Tc 0.011 Tw 10.5 0 0 10.5 407.5009 457.8197 Tm
(While these preliminary trials were)Tj
0 Tc 0.006 Tw -8.52389 -1.23809 Td
(not powered to establish equivalence between the study)Tj
-0.024 Tc 0.024 Tw 0 -1.2381 TD
[(ar)-25 (ms, they suggest very similar ef)20 (ficacy for the 90 mL and)]TJ
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(75 mL preparations.)Tj
0 Tc 0.03 Tw 1 -1.23809 Td
(The results of these studies suggest that reducing the)Tj
0.032 Tw -1 -1.2381 Td
[(dose of NaP associated with liquid and tablet pur)20 (gative)]TJ
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.024 Tc 0 Tw 10 0 0 10 60.5 23.9116 Tm
(1470)Tj
ET
BT
/T1_2 1 Tf
0 Tc 5 0 0 5 89 25.4116 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 102.181 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 5 0 0 5 235.3059 25.4116 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 248.487 23.9116 Tm
[(2007 September)110 (, V)110 (olume 41)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0 Tc 8 0 0 8 60 749.5293 Tm
[(DK)-250 (Rex)]TJ
ET
0 0 0 0 k
60.5 48.5 491 310.06 re
f
0 0 0 1 K
0.5 w 
60.5 341.822 m
551.5 341.822 l
S
BT
0 0 0 1 k
/T1_5 1 Tf
9 0 0 9 204.7056 347.5716 Tm
(T)Tj
-0.02499 Tc 0.011 Tw 0.51186 0 Td
(able 3.)Tj
ET
BT
/T1_6 1 Tf
0 Tw 9 0 0 9 238.2212 347.5716 Tm
(Ef)Tj
0.011 Tw 0.877 0 Td
[(ficacy of Dif)19 (ferent NaP T)112.2 (ablet Formulations)]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 7.5 0 0 7.5 196.1381 331.5716 Tm
(MCC-Containing )Tj
ET
192.5 319.322 m
257.5 319.322 l
S
BT
/T1_5 1 Tf
7.5 0 0 7.5 211.2626 323.5716 Tm
[(T)74 (ablets)]TJ
ET
BT
/T1_5 1 Tf
5 0 0 5 236.9578 326.3216 Tm
(a)Tj
ET
BT
/T1_5 1 Tf
-0.01401 Tw 7.5 0 0 7.5 384.5693 323.5716 Tm
[(MCC-Free T)74 (ablets)]TJ
ET
BT
/T1_5 1 Tf
0 Tw 5 0 0 5 447.6511 326.3216 Tm
(a)Tj
ET
287.5 319.322 m
548.5 319.322 l
S
60.5 305.322 m
551.5 305.322 l
S
BT
/T1_5 1 Tf
7.5 0 0 7.5 102.6419 309.5716 Tm
(Study)Tj
-0.01401 Tw 12.43479 0 Td
[(40 T)74 (ablets \(60 g\))-5297 (40 T)74 (ablets \(60 g\))-5296 (32 T)74 (ablets \(48 g\))-5297 (28 T)74 (ablets \(42 g\))]TJ
ET
BT
/T1_6 1 Tf
7.5 0 0 7.5 63.5 293.5716 Tm
(Rex \(2006\))Tj
ET
BT
/T1_5 1 Tf
0 Tw 5 0 0 5 100.482 296.3216 Tm
(35)Tj
ET
BT
/T1_6 1 Tf
-0.00011 Tc 7.5 0 0 7.5 211.5024 293.5716 Tm
[(n)-264 (=)]TJ
0 Tc -0.01401 Tw 1.66774 0 Td
[(235)-10063 (n = 233)-9406 (n = 236)-10763 (NA)]TJ
-20.90139 -1.33334 Td
(overall colon cleansing)Tj
0.5 -1.33333 Td
(pts. with good or excellent )Tj
18.54689 0.00001 Td
[(222 \(95\))-9690 (226 \(97\))-9032 (225 \(95\))]TJ
-18.04689 -1.20001 Td
(cleansing, n \(%\))Tj
-0.5 -1.2 Td
[(mean score \261)-229 (SD)-10799 (1.5 \261)-229 (0.6)-9339 (1.3 \261)-229 (0.6)]TJ
ET
BT
/T1_5 1 Tf
0 Tw 5 0 0 5 337.4329 258.3216 Tm
(b)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tw 7.5 0 0 7.5 404.0691 255.5716 Tm
[(1.3 \261)-229 (0.6)]TJ
ET
BT
/T1_5 1 Tf
0 Tw 5 0 0 5 432.9891 258.3216 Tm
(b)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tw 7.5 0 0 7.5 67.25 245.5716 Tm
(ascending colon cleansing)Tj
0.5 -1.33334 Td
[(pts. with good or excellent )-6781 (208 \(89\))-9689 (220 \(96\))-9032 (220 \(94\))]TJ
0.5 -1.2 Td
(cleansing, n \(%\))Tj
-0.5 -1.2 Td
[(mean score \261)-229 (SD)-10799 (1.6 \261)-229 (0.7)-9339 (1.3 \261)-229 (0.5)]TJ
ET
BT
/T1_5 1 Tf
0 Tw 5 0 0 5 337.4329 220.3216 Tm
(b)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tw 7.5 0 0 7.5 404.0691 217.5715 Tm
[(1.3 \261)-229 (0.6)]TJ
ET
BT
/T1_5 1 Tf
0 Tw 5 0 0 5 432.9891 220.3216 Tm
(b)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tw 7.5 0 0 7.5 67.25 207.5716 Tm
(irrigation requirements, )Tj
0 Tw 18.9734 0.00001 Td
[(0.9 )14.4 (\261)-228.7 (1.1)]TJ
-0.01401 Tw 13.19498 0.00003 Td
[(0.4 \261)-229 (0.9)]TJ
ET
BT
/T1_5 1 Tf
0 Tw 5 0 0 5 337.4329 210.3216 Tm
(b)Tj
ET
BT
/T1_6 1 Tf
7.5 0 0 7.5 404.0691 207.5716 Tm
[(0.5 )14.4 (\261)-228.8 (0.9)]TJ
ET
BT
/T1_5 1 Tf
5 0 0 5 432.9891 210.3216 Tm
(b)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tw 7.5 0 0 7.5 71 198.5716 Tm
[(mean score )1 (\261)]TJ
0 Tw 6.28572 0.00002 Td
(SD)Tj
ET
BT
/T1_5 1 Tf
5 0 0 5 128.5597 201.3216 Tm
(c)Tj
ET
BT
/T1_6 1 Tf
7.5 0 0 7.5 63.5 186.5716 Tm
(W)Tj
-0.01401 Tw 0.92603 0.00001 Td
(ruble \(2007\))Tj
ET
BT
/T1_5 1 Tf
0 Tw 5 0 0 5 110.7615 189.3216 Tm
(36)Tj
ET
BT
/T1_6 1 Tf
-0.00011 Tc 7.5 0 0 7.5 213.587 186.5716 Tm
[(n)-264 (=)]TJ
0 Tc 1.66771 0 Td
(29)Tj
-0.00011 Tc 11.73089 0.00001 Td
[(n)-264 (=)]TJ
0 Tc 1.6677 0 Td
(29)Tj
-0.00011 Tc 11.07311 0.00001 Td
[(n)-264 (=)]TJ
0 Tc 1.6677 0 Td
(33)Tj
-0.00011 Tc 11.45762 0.00001 Td
[(n)-264 (=)]TJ
0 Tc 1.66771 0 Td
(29)Tj
-0.01401 Tw -60.44408 -1.33336 Td
(overall colon cleansing)Tj
0.5 -1.2 Td
(pts. with good or excellent )Tj
18.82696 0 Td
[(2)-1 (5 \(86\))]TJ
13.12199 0 Td
(29 \(100\))Tj
13.01999 0 Td
(32 \(97\))Tj
13.127 0 Td
(26 \(90\))Tj
-57.59594 -1.2 Td
(cleansing, n \(%\))Tj
-0.5 -1.2 Td
[(mean score \261)-229 (SD)]TJ
18.47498 0 Td
[(1.7 \261)-229 (0.7)]TJ
13.19599 0 Td
[(1.2 \261)-229 (0.4)]TJ
ET
BT
/T1_5 1 Tf
0 Tw 5 0 0 5 337.4329 152.3215 Tm
(b)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tw 7.5 0 0 7.5 404.0691 149.5716 Tm
[(1.2 \261)-229 (0.5)]TJ
ET
BT
/T1_5 1 Tf
0 Tw 5 0 0 5 432.9891 152.3215 Tm
(b)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tw 7.5 0 0 7.5 504.0362 149.5716 Tm
[(1.4 \261)-229 (0.8)]TJ
-58.23816 -1.33334 Td
(ascending colon cleansing)Tj
0.5 -1.33333 Td
[(pts. with good or excellent )-7058 (2)-1 (3 \(82\))-9967 (28 \(100\))-9032 (33 \(100\))-9695 (26 \(90\))]TJ
0.5 -1.2 Td
(cleansing, n \(%\))Tj
ET
60.5 105.322 m
551.5 105.322 l
S
BT
/T1_6 1 Tf
7.5 0 0 7.5 71 111.5716 Tm
[(mean score \261)-229 (SD)]TJ
18.47498 0 Td
[(1.8 \261)-229 (0.7)]TJ
13.196 0 Td
[(1.3 \261)-229 (0.4)]TJ
ET
BT
/T1_5 1 Tf
0 Tw 5 0 0 5 337.4329 114.3216 Tm
(b)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tw 7.5 0 0 7.5 404.0691 111.5716 Tm
[(1.2 \261)-229 (0.4)]TJ
ET
BT
/T1_5 1 Tf
0 Tw 5 0 0 5 432.9891 114.3216 Tm
(b)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tw 7.5 0 0 7.5 504.0362 111.5716 Tm
[(1.5 \261)-229 (0.8)]TJ
-58.73816 -2.4 Td
(MCC = microcrystalline cellulose; NA = not assessed; NaP = sodium phosph\ate.)Tj
ET
BT
/T1_5 1 Tf
0 Tw 5 0 0 5 63.5 86.3215 Tm
(a)Tj
ET
BT
/T1_6 1 Tf
-0.02 Tw 7.5 0 0 7.5 66.25 83.5716 Tm
[(In both studies, tablets were taken as recommended in T)111 (able 1. Quality of cleansing was rated by endoscopist as 1 \(excellent\)\, 2 \(good\), 3 \(fair\), or)]TJ
-0.00011 Tc 0 -1.2 TD
(4)Tj
0 Tc 0 Tw 0.81983 0 Td
(\(inadequate\). )Tj
ET
BT
/T1_5 1 Tf
5 0 0 5 63.5 67.3216 Tm
(b)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tw 7.5 0 0 7.5 66.5 64.5715 Tm
[(Significant dif)18 (ference between MCC-free tablets and MCC-containing tablets. )]TJ
ET
BT
/T1_5 1 Tf
0 Tw 5 0 0 5 63.5 57.3216 Tm
(c)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tw 7.5 0 0 7.5 66.25 54.5716 Tm
(Irrigation requirements were scored as 0 \(none\), 1 \(<50 mL\), 2 \(50\320\100 mL\), or 3 \(>100 mL\).)Tj
ET
60.25 48.25 491.5 310.56 re
h
S
BT
0 g
/GS2 gs
/T1_7 1 Tf
0 Tw 5 0 0 5 302.24986 11 Tm
( at DALHOUSIE UNIV on May 19, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
118 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
119 0 obj
<</OP false/OPM 0/op false>>
endobj
126 0 obj
<</A 127 0 R/Border[0 0 0]/Rect[261.505 9.0 303.25 16.0]/Subtype/Link/Type/Annot>>
endobj
127 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
112 0 obj
[128 0 R]
endobj
113 0 obj
<</Length 13862>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00101 Tc 0.00101 Tw 10.5 0 0 10.5 60 730.8196 Tm
[(addition, NaP solution is available in a lower)20 (-)-75 (dose regi-)]TJ
-0.015 Tc 0.015 Tw 0 -1.24286 TD
(men of 75 mL versus 90 mL.)Tj
ET
BT
/T1_1 1 Tf
-0.013 Tc 0 Tw 6 0 0 6 179.0481 721.0696 Tm
(34)Tj
ET
BT
/T1_0 1 Tf
-0.015 Tc 10.5 0 0 10.5 187.4941 717.7697 Tm
(A)Tj
0.015 Tw 0.9569 0 Td
(limited number of stud-)Tj
-0.013 Tc 0.013 Tw -13.09919 -1.24286 Td
[(ies, discussed below)65 (, suggest that administration of lower)]TJ
-0.02499 Tc 0.021 Tw T*
(doses of NaP may translate into an improved safety profile)Tj
0.013 Tw T*
[(with comparable or better ef)20 (ficacy)65 (.)]TJ
ET
BT
/T1_1 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 197.6424 681.9197 Tm
[(3)-1 (4)-24 (-36)]TJ
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0.011 Tw 8 0 0 8 70.5 650.6197 Tm
[(SERUM ELECTROL)92 (YTE SHIFTS AND SAFETY CONCERNS)]TJ
ET
BT
/T1_0 1 Tf
-0.009 Tc 0.009 Tw 10.5 0 0 10.5 70.5 629.7197 Tm
[(Dif)20 (ferences between liquid and tablet for)-25 (mulations re-)]TJ
-0.02499 Tc 0.02 Tw -1 -1.22857 Td
(garding shifts in serum electrolyte levels were not assessed)Tj
-0.021 Tc 0.021 Tw 0 -1.22857 TD
[(in the 2 available studies comparing these for)-25 (mulations,)]TJ
ET
BT
/T1_1 1 Tf
-0.02 Tc 0 Tw 6 0 0 6 283.8775 607.2197 Tm
(5,33)Tj
ET
BT
/T1_0 1 Tf
-0.015 Tc 0.005 Tw 10.5 0 0 10.5 60 591.0197 Tm
[(b)-10 (u)-10 (t)-10 ( )-10 (recent investigations compared clinical laboratory pa-)]TJ
-0.022 Tc 0.01199 Tw T*
[(rameters in patients taking dif)20 (ferent regimens of NaP solu-)]TJ
-0.01601 Tc 0 Tw 0 -1.22858 TD
(tion)Tj
ET
BT
/T1_1 1 Tf
-0.01401 Tc 6 0 0 6 75.6785 568.5197 Tm
(34)Tj
ET
BT
/T1_0 1 Tf
-0.01601 Tc 0.006 Tw 10.5 0 0 10.5 84.0112 565.2197 Tm
(or tablets.)Tj
ET
BT
/T1_1 1 Tf
-0.015 Tc 0 Tw 6 0 0 6 123.6665 568.5197 Tm
(35,36)Tj
ET
BT
/T1_0 1 Tf
-0.01601 Tc 0.006 Tw 10.5 0 0 10.5 139.218 565.2197 Tm
(In a preliminary study of 321 patients,)Tj
-0.02499 Tc 0.015 Tw -7.54457 -1.22857 Td
(Rex et al.)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 97.6584 555.6198 Tm
(34)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.015 Tw 10.5 0 0 10.5 105.8819 552.3197 Tm
(found that administration of 45 mL plus 30 mL)Tj
-0.028 Tc 0.01801 Tw -4.3697 -1.22857 Td
(of NaP solution \(75 mL regimen containing 49.5 g of NaP\))Tj
-0.017 Tc 0.007 Tw 0 -1.22857 TD
(resulted in significantly less pronounced mean shifts from)Tj
-0.02 Tc 0.00999 Tw 0 -1.22856 TD
(baseline in several laboratory parameters, including serum)Tj
-0.034 Tc 0.024 Tw 0 -1.22858 TD
(sodium and phosphate levels, compared with administration)Tj
-0.02901 Tc 0.019 Tw 0 -1.22857 TD
(of the standard 45 mL plus 45 mL regimen of NaP solution)Tj
-0.035 Tc 0.013 Tw T*
(\(90 mL regimen containing 59.4 g of NaP\) \(p )Tj
/T1_3 1 Tf
0 Tc 17.01138 0 Td
(\262)Tj
/T1_0 1 Tf
-0.035 Tc 0 Tw 0.74134 0 Td
(0.01\). )Tj
-0.00101 Tc 0.00101 Tw -16.75272 -1.24762 Td
[(Similar results have been reported for tablet for)-25 (mula-)]TJ
-0.02299 Tc 0.02299 Tw -1 -1.24761 Td
(tions associated with a lower NaP dose. For example, a 32)Tj
0 Tc 0 -1.24762 TD
(tablet regimen \(48 g NaP\) of MCC-free tablets induced)Tj
-0.02499 Tc 0.015 Tw 0 -1.24763 TD
(significantly smaller mean shifts in serum phosphate levels)Tj
0 Tc 0.009 Tw 0 -1.24762 TD
(compared with a 40 tablet regimen \(60 g of NaP\) of the)Tj
-0.00301 Tc 0.00301 Tw T*
[(older)40 (, MCC-containing tablet for)-25 (mulation \(T)70 (able 2\).)]TJ
ET
BT
/T1_1 1 Tf
-0.00101 Tc 0 Tw 6 0 0 6 277.8307 399.6198 Tm
(35)Tj
ET
BT
/T1_0 1 Tf
0 Tc 10.5 0 0 10.5 286.4208 396.3197 Tm
(A)Tj
-0.02499 Tc 0.01601 Tw -21.56389 -1.24762 Td
(similar study reported smaller mean changes from baseline)Tj
-0.01199 Tc 0.01199 Tw T*
(in serum phosphate levels in patients who took 28 MCC-)Tj
-0.02499 Tc 0.005 Tw T*
(free tablets \(42 g of NaP; n = 31; mean shift, 2.8 mg/dL\) or)Tj
-0.02 Tc 0.02 Tw T*
(32 MCC-free tablets \(48 g of NaP; n = 33; mean shift, 3.4)Tj
-0.015 Tc 0.015 Tw T*
(mg/dL\) compared with those who took 40 MCC-contain)Tj
0 Tc 21.95304 0.00001 Td
(-)Tj
-0.017 Tc 0.017 Tw -21.95304 -1.24762 Td
(ing tablets \(60 g of NaP; n = 30; mean shift, 4.2 mg/dL; p)Tj
-0.0251 Tc T*
(<)Tj
-0.02499 Tc 0.024 Tw 0.78778 0 Td
(0.05 for comparison between 28 tablet and 40 tablet reg)Tj
0 Tc 21.16515 0 Td
(-)Tj
-0.015 Tc 0 Tw -21.95293 -1.24762 Td
(imens\).)Tj
ET
BT
/T1_1 1 Tf
-0.013 Tc 6 0 0 6 90.1276 294.8197 Tm
(36)Tj
ET
BT
/T1_0 1 Tf
-0.015 Tc 0.015 Tw 10.5 0 0 10.5 98.5779 291.5197 Tm
[(Thus, although additional peer)20 (-reviewed studies)]TJ
-0.02499 Tc 0.007 Tw 20.89734 41.83809 Td
(are warranted, recent evidence suggests that the lower dose)Tj
-0.01241 Tc T*
(of)Tj
-0.01199 Tc 0.01199 Tw 1.05816 -0.00001 Td
(NaP associated with the 75 mL liquid regimen and the)Tj
0.011 Tw -1.05816 -1.24762 Td
(32 tablet regimen reduces the disturbance in serum phos-)Tj
-0.019 Tc 0.019 Tw T*
(phate levels compared with the 90 mL liquid regimen and)Tj
-0.02499 Tc 0.013 Tw T*
[(the 40 tablet regimen, respectively)65 (. )]TJ
-0.006 Tc 0.006 Tw 1 -1.22857 Td
(In addition to evaluation of laboratory parameters, as-)Tj
-0.02 Tc 0.02 Tw -1 -1.22857 Td
(sessment of AEs is an important measure of safety associ-)Tj
-0.006 Tc 0.006 Tw 0 -1.22857 TD
(ated with bowel preparations. One study of patients who)Tj
-0.01801 Tc 0.01801 Tw T*
(received a 90 mL NaP solution \(n = 106\) or 24 or 32 NaP)Tj
-0.02499 Tc 0.01401 Tw T*
(tablets \(n = 99\) reported no clinically significant AEs in ei-)Tj
-0.002 Tc 0.002 Tw T*
(ther treatment group and significantly less nausea in pa-)Tj
-0.02499 Tc 0.009 Tw T*
(tients who took tablets compared with those who took NaP)Tj
0.01199 Tw T*
(solution \(24% vs 40%; p = 0.01\).)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 6 0 0 6 449.8607 578.5197 Tm
(5)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 10.5 0 0 10.5 455.2027 575.2197 Tm
(In a study comparing 45)Tj
0.00999 Tw -13.06692 -1.22857 Td
(mL plus 30 mL of NaP solution versus the standard 45 mL)Tj
-0.019 Tc 0.019 Tw T*
(plus 45 mL regimen, the lower dose regimen significantly)Tj
-0.00999 Tc 0.00999 Tw T*
(reduced the incidence of vomiting \(3% vs 8%; p = 0.04\),)Tj
0 Tc 0.01601 Tw 0 -1.22855 TD
(abdominal cramps \(36% vs 48%; p = 0.02\), and overall)Tj
-0.00101 Tc 0.00101 Tw 0 -1.22857 TD
(discomfort \(58% vs 69%; p = 0.03\).)Tj
ET
BT
/T1_1 1 Tf
0.00101 Tc 0 Tw 6 0 0 6 468.7777 514.0198 Tm
(34)Tj
ET
BT
/T1_0 1 Tf
-0.00101 Tc 0.00101 Tw 10.5 0 0 10.5 477.3882 510.7198 Tm
[(However)40 (, another)]TJ
-0.007 Tc 0.007 Tw -15.17983 -1.22857 Td
(study comparing these NaP liquid regimens failed to ob-)Tj
-0.017 Tc 0.017 Tw T*
[(serve a dif)16.9 (ference in the frequency of reported AEs.)]TJ
ET
BT
/T1_1 1 Tf
-0.015 Tc 0 Tw 6 0 0 6 527.8914 488.2198 Tm
(37)Tj
ET
BT
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 10.5 0 0 10.5 536.318 484.9198 Tm
(In a)Tj
-0.02 Tc 0.02 Tw -20.79219 -1.22857 Td
[(study comparing dif)24.5 (ferent NaP tablet for)-19.2 (mulations, Rex et)]TJ
-0.02499 Tc 0 Tw 0 -1.22858 TD
(al.)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 6 0 0 6 327.4151 462.4198 Tm
(35)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.015 Tw 10.5 0 0 10.5 335.6343 459.1198 Tm
(reported significant reductions in the incidence of AEs)Tj
0 Tc 0.021 Tw -1.67946 -1.22857 Td
(\(58% vs 68%; p = 0.03\) and GI AEs \(56% vs 66%; p <)Tj
-0.004 Tc 0.004 Tw 0 -1.22857 TD
(0.05\) in patients who received 32 MCC-free tablets \(n =)Tj
-0.0238 Tc T*
(239\))Tj
-0.024 Tc 0.024 Tw 1.98775 0 Td
(compared with those who received 40 MCC-contain)Tj
0 Tc 19.96522 0 Td
(-)Tj
-0.01401 Tc 0.01401 Tw -21.95297 -1.22857 Td
[(ing tablets \(n = 238\), respectively)65 (. In addition, abdominal)]TJ
-0.02499 Tc 0.007 Tw T*
(distention was reported by significantly fewer patients who)Tj
0 Tc 0.02901 Tw T*
(took the 32 tablet regimen versus the 40 tablet regimen)Tj
0.091 Tw T*
[(\(31% vs 42%, respectively; p < 0.05\). T)72.2 (aken together)40 (,)]TJ
0.01401 Tw T*
(these results suggest that decreasing the phosphate load)Tj
-0.02299 Tc 0.02299 Tw T*
(improves the safety and tolerability profile associated with)Tj
-0.02499 Tc 0.02499 Tw T*
(NaP preparations by causing less-pronounced shifts in lab-)Tj
0.013 Tw 0 -1.22856 TD
(oratory parameters and reducing the incidence of AEs. )Tj
-0.022 Tc 0 Tw 1 -1.23809 Td
(Appropriately)Tj
-0.0217 Tc 5.26297 0 Td
(,)Tj
-0.022 Tc 0.022 Tw 0.47826 0 Td
(these and other studies excluded patients)Tj
-0.011 Tc 0.011 Tw -6.74123 -1.23809 Td
(with heart failure, renal failure, GI obstruction, and base-)Tj
0 Tc 0.054 Tw 4.57143 -1.23809 Td
(line electrolyte abnor)Tj
0 Tw 8.62883 0.00001 Td
(malities.)Tj
ET
BT
/T1_1 1 Tf
0.00101 Tc 6 0 0 6 492.4683 281.5199 Tm
(5,26,33,34,36)Tj
ET
BT
/T1_0 1 Tf
0 Tc 10.5 0 0 10.5 528.662 278.2199 Tm
(Rigid)Tj
-0.02499 Tc 0.02499 Tw -15.49162 -1.2381 Td
(exclusion criteria must be employed in clinical)Tj
0.021 Tw 0 -1.2381 TD
(practice to promote safe administration of NaP)Tj
0 Tc 0.16701 Tw 0 -1.23809 TD
(preparations in appropriate patient popula-)Tj
-0.008 Tc 0 Tw 0 -1.2381 TD
(tions.)Tj
ET
BT
/T1_1 1 Tf
-0.007 Tc 6 0 0 6 388.5528 229.5199 Tm
(26,27)Tj
ET
BT
/T1_0 1 Tf
-0.008 Tc 0.008 Tw 10.5 0 0 10.5 404.4444 226.2199 Tm
(In addition, patient selection should)Tj
-0.02499 Tc 0.02499 Tw -3.66137 -1.23809 Td
(involve more than a checklist for contraindica-)Tj
-0.01601 Tc 0.01601 Tw T*
(tions, because other risk factors such as an in-)Tj
-0.01801 Tc 0.01801 Tw T*
(ability to maintain adequate hydration may be)Tj
-0.02499 Tc 0 Tw 0 -1.23809 TD
(identified.)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 6 0 0 6 405.9711 177.5199 Tm
(26)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0.011 Tw 8 0 0 8 376.5 146.2199 Tm
[(EFFICACY AND T)18 (OLERABILITY)]TJ
ET
BT
/T1_0 1 Tf
-0.024 Tc 0.024 Tw 10.5 0 0 10.5 376.5 125.2199 Tm
(As discussed, NaP preparations are general)Tj
0 Tc 16.38153 0.00001 Td
(-)Tj
-0.02499 Tc 0.00999 Tw -17.38153 -1.2381 Td
[(ly more favorable than PEG-ELS for)-25 (mulations)]TJ
0 Tc 0 Tw T*
(in)Tj
-0.00999 Tc 0.077 Tw 1.09437 0.00001 Td
[(measures of ef)22.6 (ficacy and tolerability)]TJ
0 Tc 14.45391 0.00002 Td
(.)Tj
ET
BT
/T1_1 1 Tf
-0.009 Tc 0 Tw 6 0 0 6 531.777 102.5198 Tm
[(1-3,5)-24 (-14)]TJ
ET
BT
/T1_0 1 Tf
-0.00999 Tc 0.043 Tw 10.5 0 0 10.5 366 86.2199 Tm
(Few studies have directly compared aqueous)Tj
-0.02699 Tc 0.017 Tw 0 -1.2381 TD
[(and tablet NaP for)-25 (mulations. One study report-)]TJ
-0.00999 Tc 0.01801 Tw 0 -1.23809 TD
(ed comparable colon cleansing with dif)Tj
0 Tw 15.43319 0.00001 Td
(ferent)Tj
-0.033 Tc 0.02299 Tw -15.43319 -1.2381 Td
(NaP preparations, with good or excellent clean-)Tj
ET
0 0 0 0 k
318 745 234 10 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 8 0 0 8 418.5493 749.5293 Tm
(Sodium Phosphate Dosing in Colonoscopy)Tj
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
10 0 0 10 259.0939 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 5 0 0 5 392.2189 25.4116 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 405.4 23.9116 Tm
[(2007 September)110 (, V)110 (olume 41    )]TJ
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 5 0 0 5 519.569 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.024 Tc 10 0 0 10 532.75 23.9116 Tm
(1469)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0 k
60.5 48.5 275 204.866 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tc 9 0 0 9 109.1229 242.4747 Tm
(T)Tj
-0.02499 Tc 0.011 Tw 0.51187 0.00001 Td
(able 2.)Tj
ET
BT
/T1_7 1 Tf
9 0 0 9 142.6385 242.4747 Tm
(Shifts in Serum Electrolyte Levels with )Tj
ET
0 0 0 1 K
0.5 w 
60.5 225.7249 m
335.5 225.7249 l
S
BT
/T1_7 1 Tf
9 0 0 9 148.5782 231.4746 Tm
[(NaP T)111 (ablet Formulations)]TJ
ET
BT
/T1_2 1 Tf
0 Tw 5 0 0 5 242.1127 234.2247 Tm
(35)Tj
ET
BT
/T1_2 1 Tf
0 Tc -0.01401 Tw 7.5 0 0 7.5 217.0648 215.4747 Tm
(Mean Change from )Tj
ET
170.5 203.2249 m
332.5 203.2249 l
S
BT
/T1_2 1 Tf
7.5 0 0 7.5 206.0208 207.4746 Tm
(Baseline to Colonoscopy)Tj
-4.31757 -1.86666 Td
(40 MCC-Containing)Tj
0 Tw -10.89604 -1.06666 Td
(Laboratory )Tj
13.78583 0.00001 Td
[(T)74.1 (ablets)]TJ
-0.01401 Tw 8.38776 0.00002 Td
(32 MCC-Free T)Tj
0 Tw 6.8975 0.00001 Td
(ablets)Tj
ET
60.5 173.2249 m
335.5 173.2249 l
S
BT
/T1_2 1 Tf
-0.01401 Tw 7.5 0 0 7.5 93.162 177.4746 Tm
(Parameter)Tj
13.306 0 Td
(\(n = 236\))Tj
11.56898 0 Td
(\(n = 239\))Tj
ET
BT
/T1_7 1 Tf
7.5 0 0 7.5 63.5 161.4747 Tm
(Inorganic phosphorus, mg/dL)Tj
0 Tw 18.64409 0.00001 Td
(4.0)Tj
ET
BT
/T1_2 1 Tf
5 0 0 5 213.753 164.2246 Tm
(a)Tj
ET
BT
/T1_7 1 Tf
7.5 0 0 7.5 289.0828 161.4747 Tm
(3.5)Tj
-0.01401 Tw -30.07771 -1.33334 Td
[(Sodium, mEq/L)-11824 (1.7)-10044 (2.0)]TJ
0 -1.33334 TD
[(Calcium, mg/dL)-11158 (\3200.6)-9488 (\3200.6)]TJ
0 -1.33333 TD
(Potassium, mEq/L)Tj
0 Tw 18.08819 0.00001 Td
(\3200.7)Tj
11.43362 0.00001 Td
(\3200.6)Tj
-0.01401 Tw -29.5218 -1.33335 Td
[(Magnesium, mg/dL)-9601 (\3200.07)-8933 (\3200.08)]TJ
T*
[(Chloride, mEq/L)-10935 (\3200.2)-9488 (\3200.1)]TJ
T*
[(Bicarbonate, mEq/L)-9322 (\3201.0)]TJ
ET
BT
/T1_2 1 Tf
0 Tw 5 0 0 5 213.753 104.2246 Tm
(a)Tj
ET
BT
/T1_7 1 Tf
7.5 0 0 7.5 284.9135 101.4747 Tm
(\3200.06)Tj
-0.01401 Tw -29.5218 -1.33334 Td
[(Creatinine, mg/dL)-10212 (\3200.02)-8933 (\3200.01)]TJ
ET
60.5 75.2249 m
335.5 75.2249 l
S
BT
/T1_7 1 Tf
7.5 0 0 7.5 63.5 81.4747 Tm
(Blood urea nitrogen, mg/dL)Tj
0 Tw 18.08819 0.00001 Td
(\3205.1)Tj
ET
BT
/T1_2 1 Tf
5 0 0 5 213.753 84.2247 Tm
(a)Tj
ET
BT
/T1_7 1 Tf
7.5 0 0 7.5 284.9135 81.4747 Tm
(\3204.0)Tj
-0.01401 Tw -29.5218 -2.26667 Td
(MCC = microcrystalline cellulose; NaP = sodium phosphate.)Tj
ET
BT
/T1_2 1 Tf
0 Tw 5 0 0 5 63.5 57.2247 Tm
(a)Tj
ET
BT
/T1_7 1 Tf
-0.01401 Tw 7.5 0 0 7.5 66.2795 54.4747 Tm
[(Significant dif)19.1 (ference between treatment groups.)]TJ
ET
60.25 48.25 275.5 205.3661 re
h
S
BT
0 g
/GS2 gs
/T1_8 1 Tf
0 Tw 5 0 0 5 302.24986 11 Tm
( at DALHOUSIE UNIV on May 19, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
54 0 obj
<</BaseFont/HYQSED+Symbol/Encoding 51 0 R/FirstChar 178/FontDescriptor 53 0 R/LastChar 179/Subtype/Type1/Type/Font/Widths[549 549]>>
endobj
51 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[178/lessequal/greaterequal]/Type/Encoding>>
endobj
53 0 obj
<</Ascent 921/CapHeight 671/Descent -223/Flags 34/FontBBox[-180 -292 1090 1005]/FontFile3 52 0 R/FontName/HYQSED+Symbol/ItalicAngle 0/StemH 0/StemV 41/Type/FontDescriptor/XHeight 684>>
endobj
52 0 obj
<</Length 399/Length1 399/Subtype/Type1C>>stream
  HYQSED+Symbol   Fø øøøø)ÁûHû¸úÖú
 ‹‹
 ‹‹      ª  p ”›greaterequallessequal002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Simpele is a trademark of Stream Technologies Inc.Simpele    ‡ˆ .Z&‹Ã¨øƒø ÷îÊüƒ÷xMøEûZüEûZNøƒû
ÃüƒS&‹Ã¨øƒø ÷
ÈüE÷ZøE÷ZÉüƒûxLøƒûîÃüƒSs£ø†÷?˜÷‹ûv¯
´
_÷ù
endstream
endobj
114 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
115 0 obj
<</OP false/OPM 0/op false>>
endobj
128 0 obj
<</A 129 0 R/Border[0 0 0]/Rect[261.505 9.0 303.25 16.0]/Subtype/Link/Type/Annot>>
endobj
129 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
108 0 obj
[130 0 R]
endobj
109 0 obj
<</Length 12659>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.0251 Tc 8 0 0 8 70.5 732.1699 Tm
(A)Tj
-0.02499 Tc 0.011 Tw [(CUTE PHOSPHA)74 (TE NEPHROP)74 (A)74 (THY)]TJ
ET
BT
/T1_1 1 Tf
0 Tc 0.04201 Tw 10.5 0 0 10.5 70.5 711.0699 Tm
[(Recently)65 (, 24 cases of acute renal failure followed by)]TJ
0.01601 Tw -1 -1.24762 Td
[(chronic renal insuf)20 (ficiency have been documented after)]TJ
-0.02499 Tc 0.007 Tw 0 -1.24762 TD
[(NaP bowel preparation for colonoscopy)65 (. This phenomenon)]TJ
-0.02 Tc 0.02 Tw T*
[(has been ter)-25 (med acute phosphate nephropathy because re-)]TJ
0 Tc 0.058 Tw T*
(nal biopsies in all cases were characterized by calcium)Tj
-0.00999 Tc 0.00999 Tw 0 -1.24761 TD
(phosphate crystal deposition in renal tubules. Cases have)Tj
-0.02499 Tc 0.01801 Tw 0 -1.24762 TD
(been linked to administration of NaP solution \(23 cases\) or)Tj
-0.01801 Tc T*
[(tablet for)-25 (mulations \(1 case\).)]TJ
ET
BT
/T1_2 1 Tf
-0.017 Tc 0 Tw 6 0 0 6 173.0744 622.6699 Tm
[(1)-1 (6)-24 (-19)]TJ
ET
BT
/T1_1 1 Tf
-0.01801 Tc 0.01801 Tw 10.5 0 0 10.5 189.2999 619.3699 Tm
(These cases occurred pre-)Tj
0 Tc 0.00999 Tw -12.31427 -1.24762 Td
[(dominately in patients with nor)-25 (mal renal function; mild)]TJ
-0.011 Tc 0.019 Tw T*
[(b)8 (a)8 (s)8 (e)8 (l)8 (i)8 (n)8 (e)8 ( )8 (r)8 (e)8 (n)8 (a)8 (l)8 ( )8 (i)8 (n)8 (s)8 (u)8 (f)28 (ficiency was reported in only 4 \(17%\))]TJ
-0.01801 Tc 0.00999 Tw T*
(cases. Predisposing factors appear to be female sex \(83%\))Tj
-0.00999 Tc 0.01801 Tw T*
(and hypertension \(71%\). As might be expected in hyper-)Tj
-0.01601 Tc 0.02299 Tw T*
(tensive patients, the majority of patients were taking anti-)Tj
0.002 Tc 0.005 Tw T*
(hypertensive drugs including diuretics, ACE inhibitors,)Tj
-0.005 Tc 0.013 Tw T*
[(and ARBs. Recently)65 (, the Food and Drug Administration)]TJ
0.007 Tc 0.07401 Tw T*
[(issued a war)-25 (ning that risk factors for acute phosphate)]TJ
-0.013 Tc 0.02 Tw T*
(nephropathy include advanced age, kidney disease or de)Tj
0 Tc 21.95288 0.00001 Td
(-)Tj
-0.011 Tc 0.019 Tw -21.95288 -1.24762 Td
(creased intravascular volume, and use of drugs known to)Tj
0.007 Tc 0.224 Tw T*
[(af)20 (fect renal perfusion or function \(eg, antihyperten)-1 (-)]TJ
0 Tw T*
(sives\).)Tj
ET
BT
/T1_2 1 Tf
0.00951 Tc 6 0 0 6 87.6651 465.4698 Tm
(25)Tj
ET
BT
/T1_1 1 Tf
0.007 Tc 0.239 Tw 10.5 0 0 10.5 98.9728 462.1698 Tm
(Although the incidence of acute phosphate)Tj
-0.01401 Tc 0.022 Tw -3.7117 -1.24762 Td
(nephropathy after NaP preparation is unknown, it is clear)Tj
-0.017 Tc 0.024 Tw T*
(that the risk of serious toxicity associated with this prepa-)Tj
0.007 Tc 0 Tw T*
[(ration has been expanded to patients with nor)-25 (mal renal)]TJ
-0.01801 Tc T*
(function. )Tj
-0.0251 Tc 1 -1.24762 Td
(A)Tj
-0.02499 Tc 0.00301 Tw 0.92512 0 Td
(recent single-center report of 12 cases of renal impair-)Tj
-0.024 Tc 0.02299 Tw -1.92513 -1.24762 Td
(ment after bowel preparation with NaP solution in patients)Tj
-0.02299 Tc 0.022 Tw T*
[(in whom renal biopsies were not perfor)-25 (med confir)-25 (med the)]TJ
-0.01401 Tc 0.01401 Tw T*
(clinical associations described above and further elevated)Tj
-0.02499 Tc 0.013 Tw 0 -1.24763 TD
[(concer)-25 (n about NaP safety)65 (.)]TJ
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 163.6042 347.5698 Tm
(28)Tj
ET
BT
/T1_1 1 Tf
-0.00999 Tc 0.00999 Tw 10.5 0 0 10.5 70.5 331.1697 Tm
[(Recent recommendations on the safe and ef)18.7 (fective use)]TJ
-0.00301 Tc 0.00301 Tw -1 -1.24762 Td
(of NaP products have emphasized the importance of pa-)Tj
-0.01199 Tc 0.011 Tw 0 -1.24762 TD
[(tient selection, not exceeding recommended doses \(T)70 (able)]TJ
-0.017 Tc 0.017 Tw T*
(1\), proper spacing of doses, and aggressive oral hydration)Tj
-0.02499 Tc 0.008 Tw T*
(prior to and during the preparation and also after the proce-)Tj
-0.017 Tc 0 Tw T*
(dure.)Tj
ET
BT
/T1_2 1 Tf
-0.015 Tc 6 0 0 6 80.4075 268.9697 Tm
(27)Tj
ET
BT
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 10.5 0 0 10.5 88.8331 265.6696 Tm
(Hydration results in dilute urine, reducing the con-)Tj
0 Tc 0.131 Tw -2.74601 -1.24761 Td
(centration of calcium and phosphate in the urine, and)Tj
-0.01401 Tc 0.01401 Tw T*
[(thereby reducing the risk of crystal for)-25 (mation and tubular)]TJ
-0.02499 Tc 0 Tw T*
(damage.)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 6 0 0 6 93.4358 229.6696 Tm
(19,29)Tj
ET
BT
/T1_0 1 Tf
-0.03999 Tc 0.011 Tw 8 0 0 8 70.5 198.2697 Tm
[(RENAL HANDLING OF SODIUM PHOSPHA)77.2 (TE PREP)74 (ARA)74 (TIONS)]TJ
ET
BT
/T1_1 1 Tf
-0.01401 Tc 0.01401 Tw 10.5 0 0 10.5 70.5 177.1696 Tm
(In the numerous published clinical trials of NaP prepa-)Tj
-0.002 Tc 0.002 Tw -1 -1.24762 Td
[(ration for colonoscopy)65 (, which typically exclude patients)]TJ
-0.02499 Tc 0.004 Tw T*
[(with serum creatinine levels above 1.5)-25 (\320)-25 (2.0 mg/dL and pre-)]TJ
-0.006 Tc 0.006 Tw T*
[(scribe specific fluid volumes to be taken with NaP)110 (, there)]TJ
-0.02299 Tc 0.02299 Tw 0 -1.24761 TD
(has never been a clinical adverse event \(AE\) reported with)Tj
-0.021 Tc 0.021 Tw 0 -1.24762 TD
(regard to renal damage.)Tj
ET
BT
/T1_2 1 Tf
-0.02 Tc 0 Tw 6 0 0 6 154.7422 114.9697 Tm
(3,26)Tj
ET
BT
/T1_1 1 Tf
-0.021 Tc 0.021 Tw 10.5 0 0 10.5 167.3685 111.6697 Tm
(Although serum phosphate lev)Tj
0 Tc 11.7275 0.00001 Td
(-)Tj
-0.007 Tc 0.007 Tw -21.95308 -1.24763 Td
(els typically increase transiently above baseline after ad-)Tj
-0.02 Tc 0.02 Tw T*
(ministration of NaP bowel preparations, the well-hydrated)Tj
-0.02499 Tc 0.007 Tw T*
[(adult with nor)-25 (mal kidney function can tolerate the standard)]TJ
-0.004 Tc 0.004 Tw T*
(phosphate load \(60 g\) without any clinically meaningful)Tj
-0.02499 Tc 0 Tw T*
(AEs.)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 6 0 0 6 79.6526 49.4696 Tm
(30)Tj
ET
BT
/T1_1 1 Tf
-0.00011 Tc 10.5 0 0 10.5 328.5 730.8196 Tm
(A)Tj
0 Tc 0.00101 Tw 0.97332 0 Td
(small study of 5 healthy subjects \(age 27\32055 y\) as-)Tj
0.00999 Tw -1.97332 -1.23809 Td
(sessed the metabolism of NaP solution, administered as)Tj
-0.01401 Tc 0.01401 Tw 0 -1.2381 TD
[(two 45 mL doses taken 1)35 (1 hours apart, by quantifying fe-)]TJ
0 Tc 0.03799 Tw T*
(cal and urinary excretion of phosphate.)Tj
ET
BT
/T1_2 1 Tf
0.002 Tc 0 Tw 6 0 0 6 483.8496 695.1196 Tm
(29)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0.03799 Tw 10.5 0 0 10.5 492.8766 691.8196 Tm
(During the 18)Tj
-0.02499 Tc 0.008 Tw -16.65491 -1.23809 Td
(hour period beginning with ingestion of the first dose, 57%)Tj
0.022 Tw T*
(of ingested phosphate was excreted in the stool, and an ad-)Tj
-0.015 Tc 0.015 Tw T*
(ditional 15% was eliminated in the urine. These data sug-)Tj
-0.005 Tc 0.005 Tw 0 -1.23809 TD
(gested that 28% of the phosphate ingested with the stan-)Tj
0 Tc 0.063 Tw 0 -1.2381 TD
(dard dose of NaP solution was retained in the body 18)Tj
-0.017 Tc 0.017 Tw T*
(hours after beginning the bowel preparation. Clearance of)Tj
-0.015 Tc 0.015 Tw 0 -1.23809 TD
(retained phosphate was not assessed beyond 6 hours after)Tj
-0.005 Tc 0.005 Tw 0 -1.2381 TD
(the second dose. Consistent with previous recommenda-)Tj
-0.01801 Tc 0 Tw 0 -1.23809 TD
(tions,)Tj
ET
BT
/T1_2 1 Tf
-0.017 Tc 6 0 0 6 339.9179 578.1197 Tm
(1,19,27)Tj
ET
BT
/T1_1 1 Tf
-0.01801 Tc 0.01801 Tw 10.5 0 0 10.5 359.7928 574.8197 Tm
(the authors emphasized that adequate hydration)Tj
-0.02499 Tc 0.013 Tw -3.98027 -1.2381 Td
(plays a key role in renal handling of NaP preparations.)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 533.9 565.1197 Tm
(29)Tj
ET
BT
/T1_1 1 Tf
-0.008 Tc 0.008 Tw 10.5 0 0 10.5 328.5 548.7697 Tm
(Estimates of volume loss during NaP preparation sug-)Tj
-0.004 Tc 0.004 Tw -1 -1.24286 Td
[(gest that patients average 3)-50 (\320)-150 (4 L of fluid loss during and)]TJ
-0.01199 Tc 0.01199 Tw 0 -1.24285 TD
(following a 60 g phosphate load.)Tj
ET
BT
/T1_2 1 Tf
-0.011 Tc 0 Tw 6 0 0 6 452.2462 525.9696 Tm
(29,31)Tj
ET
BT
/T1_1 1 Tf
-0.01199 Tc 0.01199 Tw 10.5 0 0 10.5 468.0125 522.6697 Tm
(If the urine becomes)Tj
-0.02499 Tc 0.00301 Tw -14.2869 -1.24286 Td
(concentrated as a result of dehydration, the urinary calcium)Tj
0.008 Tw T*
[(phosphate product could rise suf)23.9 (ficiently to result in crystal)]TJ
0 Tc 0.026 Tw T*
[(for)-25 (mation, deposition, and tubular injury)65 (.)]TJ
ET
BT
/T1_2 1 Tf
0.00101 Tc 0 Tw 6 0 0 6 492.1778 486.8197 Tm
(19,29)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0.026 Tw 10.5 0 0 10.5 508.5783 483.5197 Tm
(Thus, pre-)Tj
-0.01199 Tc 0.01199 Tw -18.15031 -1.24286 Td
(scription of adequate fluid volume intake before and dur-)Tj
-0.022 Tc 0.022 Tw T*
(ing NaP preparation can ensure dilute urine and, in theory)Tj
0 Tc 22.03553 0 Td
(,)Tj
-0.01601 Tc 0.01601 Tw -22.03553 -1.24286 Td
[(prevent the development of acute phosphate nephropathy)65 (.)]TJ
-0.017 Tc 0.017 Tw T*
(In support of this contention, in the 5 cases of acute phos)Tj
0 Tc 21.95302 0 Td
(-)Tj
-0.004 Tc 0.004 Tw -21.95302 -1.24286 Td
(phate nephropathy for which fluid volume intake during)Tj
-0.02499 Tc 0.02 Tw 0 -1.24286 TD
(the preparation was described, intake was inadequate com-)Tj
-0.004 Tc 0.004 Tw 0 -1.24285 TD
(pared with recommended volume intake.)Tj
ET
BT
/T1_2 1 Tf
-0.002 Tc 0 Tw 6 0 0 6 488.2071 395.4697 Tm
(32)Tj
ET
BT
/T1_1 1 Tf
-0.004 Tc 0.004 Tw 10.5 0 0 10.5 496.7795 392.1697 Tm
(The probable)Tj
-0.006 Tc 0.006 Tw -17.02662 -1.24286 Td
(mechanism of calcium phosphate crystal deposition also)Tj
-0.02299 Tc 0.02299 Tw T*
(emphasizes the importance of identifying the lowest ef)Tj
0 Tw 20.80191 0 Td
(fec)Tj
0 Tc 1.15115 0 Td
(-)Tj
-0.02499 Tc 0.013 Tw -21.95306 -1.24286 Td
(tive doses of NaP liquid and tablets.)Tj
ET
BT
/T1_0 1 Tf
0.011 Tw 10.5 0 0 10.5 318 324.9697 Tm
(Sodium Phosphate Preparations)Tj
ET
BT
/T1_0 1 Tf
8 0 0 8 328.5 303.9197 Tm
(COMPOSITION OF FORMULA)Tj
0 Tw 13.45118 0 Td
(TIONS)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0.037 Tw 10.5 0 0 10.5 328.5 282.8695 Tm
(Each 45 mL dose of NaP solution contains 29.7 g of)Tj
-0.01801 Tc 0.01801 Tw -1 -1.24286 Td
[(NaP in stable, buf)20 (fered aqueous solution. Each NaP tablet)]TJ
-0.024 Tc 0.024 Tw 0 -1.24286 TD
(contains 1.5 g of NaP and 0.5 g of inactive ingredients. In-)Tj
-0.017 Tc 0.017 Tw 0 -1.24285 TD
[(active ingredients in 1 NaP tablet for)-14.8 (mulation include mi-)]TJ
-0.009 Tc 0.009 Tw T*
(crocrystalline cellulose \(MCC\), magnesium stearate, and)Tj
-0.02499 Tc 0.015 Tw 0 -1.24286 TD
(colloidal silicon dioxide. Given reports that MCC hindered)Tj
-0.005 Tc 0.005 Tw T*
(visibility of the colonic mucosa during colonoscopic ex-)Tj
-0.004 Tc 0 Tw T*
(amination,)Tj
ET
BT
/T1_2 1 Tf
-0.002 Tc 6 0 0 6 362.1878 194.8195 Tm
(33)Tj
ET
BT
/T1_1 1 Tf
-0.0042 Tc 10.5 0 0 10.5 370.764 191.5195 Tm
(a)Tj
-0.004 Tc 0.004 Tw 0.68969 0 Td
[(newer tablet for)-25 (mulation does not contain)]TJ
0 Tc 0.129 Tw -5.71484 -1.24285 Td
(this insoluble, inert binder; inactive ingredients in the)Tj
0.19701 Tw T*
(MCC-free tablets include PEG 8000 and magnesium)Tj
-0.004 Tc 0.004 Tw T*
(stearate. The recommended dose of NaP with liquid and)Tj
-0.011 Tc 0.011 Tw T*
[(tablet for)-25 (mulations ranges from 48 to 60 g of NaP \(T)70 (able)]TJ
0 Tc 0.22 Tw T*
(1\). Whereas NaP solution and MCC-containing NaP)Tj
-0.01199 Tc 0.01199 Tw 0 -1.24285 TD
[(tablets contain similar amounts of NaP)110 (, the newer)40 (, MCC-)]TJ
-0.01801 Tc 0.01801 Tw 0 -1.24286 TD
(free tablet regimen contains a 20% lower dose of NaP be-)Tj
-0.005 Tc 0.005 Tw T*
(cause the dosage has been reduced from 40 tablets \(60 g)Tj
-0.02499 Tc 0.013 Tw T*
(NaP\) to 32 tablets \(48 g NaP\). )Tj
-0.015 Tc 0.015 Tw 1 -1.24285 Td
(From an endoscopist\325)Tj
-0.0148 Tc 8.34367 0.00001 Td
(s)Tj
-0.015 Tc 0.62408 0 Td
(perspective, there is no longer a)Tj
-0.011 Tc 0.011 Tw -9.96775 -1.24286 Td
(rationale for the use of MCC-containing NaP tablets.)Tj
ET
BT
/T1_2 1 Tf
-0.009 Tc 0 Tw 6 0 0 6 534.8828 51.2696 Tm
(27)Tj
ET
BT
/T1_1 1 Tf
-0.011 Tc 10.5 0 0 10.5 543.3735 47.9696 Tm
(In)Tj
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.024 Tc 10 0 0 10 60.5 23.9116 Tm
(1468)Tj
ET
BT
/T1_3 1 Tf
0 Tc 5 0 0 5 89 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 102.181 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 5 0 0 5 235.3059 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 248.487 23.9116 Tm
[(2007 September)110 (, V)110 (olume 41)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tc 8 0 0 8 60 749.5293 Tm
[(DK)-250 (Rex)]TJ
ET
BT
0 g
/GS2 gs
/T1_6 1 Tf
5 0 0 5 302.24986 11 Tm
( at DALHOUSIE UNIV on May 19, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
110 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
111 0 obj
<</OP false/OPM 0/op false>>
endobj
130 0 obj
<</A 131 0 R/Border[0 0 0]/Rect[261.505 9.0 303.25 16.0]/Subtype/Link/Type/Annot>>
endobj
131 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
104 0 obj
[132 0 R]
endobj
105 0 obj
<</Length 11383>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.01601 Tc 0.01601 Tw 10.5 0 0 10.5 60 730.8196 Tm
(motically balanced, nonabsorbable solutions that promote)Tj
-0.02499 Tc 0.002 Tw 0 -1.23809 TD
(bowel cleansing without substantial shifts in fluid and elec-)Tj
0.004 Tw 0 -1.2381 TD
(trolyte levels, NaP preparations employ an osmotic mecha-)Tj
-0.00301 Tc 0.00301 Tw T*
(nism of action, drawing water from the colonic mucosal)Tj
0 Tc 0.088 Tw 0 -1.23809 TD
(lining into the bowel lumen. Retention of water in the)Tj
-0.006 Tc 0.006 Tw 0 -1.2381 TD
(bowel lumen stimulates peristalsis and evacuation of the)Tj
-0.02499 Tc 0 Tw T*
[(colo)15 (n)15 (.)]TJ
ET
BT
/T1_1 1 Tf
-0.03799 Tc 6 0 0 6 83.9051 656.1197 Tm
(15)Tj
ET
BT
/T1_0 1 Tf
-0.03999 Tc 0.022 Tw 10.5 0 0 10.5 91.8641 652.8196 Tm
(Thus, NaP preparations can result in substantial fluid)Tj
-0.034 Tc 0.019 Tw -3.03468 -1.23809 Td
(shifts, alteration of electrolyte levels, and dehydration due to)Tj
-0.02299 Tc 0.008 Tw T*
(their osmotic nature. Thus, administration of NaP products)Tj
-0.02901 Tc 0.01401 Tw T*
(should be restricted to patients who are at low risk for com-)Tj
-0.035 Tc 0.02 Tw 0 -1.23809 TD
(plications of fluid shifts and who are able to maintain hydra-)Tj
-0.03999 Tc 0.005 Tw 0 -1.2381 TD
(tion during the preparation process. In addition, recent reports)Tj
-0.028 Tc 0.013 Tw 0 -1.23809 TD
(of renal damage following NaP preparation in patients with)Tj
-0.03799 Tc 0.02299 Tw 0 -1.2381 TD
[(previously nor)-25 (mal renal function have raised major concer)-25 (ns)]TJ
-0.03999 Tc 0.013 Tw T*
(about the use of NaP in general.)Tj
ET
BT
/T1_1 1 Tf
-0.039 Tc 0 Tw 6 0 0 6 181.7527 552.1197 Tm
[(1)-1 (6)-24 (-19)]TJ
ET
BT
/T1_0 1 Tf
-0.00301 Tc 0.002 Tw 10.5 0 0 10.5 70.5 535.7196 Tm
[(This review discusses the ef)20 (fect of NaP pur)20 (gatives on)]TJ
-0.01601 Tc 0.01601 Tw -1 -1.24762 Td
(serum electrolyte levels, with particular attention to phos-)Tj
-0.002 Tc 0.002 Tw 0 -1.24762 TD
[(phate load, as well as available for)-25 (mulations and dosing)]TJ
-0.022 Tc 0.022 Tw T*
(schedules designed to minimize risks and maximize ef)Tj
0 Tw 20.79787 0.00001 Td
(fec-)Tj
-0.02299 Tc 0.022 Tw -20.79787 -1.24763 Td
(tiveness associated with administration of NaP products in)Tj
-0.008 Tc 0.008 Tw T*
(appropriate patient populations. Given that NaP prepara-)Tj
-0.01601 Tc 0.01601 Tw T*
[(tions appear to be more ef)20 (fective and better tolerated than)]TJ
-0.006 Tc 0.006 Tw T*
(PEG-ELS preparations, improving the safety profile and)Tj
-0.01801 Tc 0.01801 Tw T*
[(maximizing ef)23.6 (ficacy and tolerability through optimal dos)]TJ
0 Tc 21.95287 0 Td
(-)Tj
0.11301 Tw -21.95287 -1.24763 Td
(ing schedules are critical to the current use of NaP in)Tj
-0.02499 Tc 0.013 Tw T*
(colonoscopy preparation. )Tj
ET
BT
/T1_2 1 Tf
0.011 Tw 10.5 0 0 10.5 60 376.5196 Tm
(Safety Issues with NaP Bowel Preparations)Tj
ET
BT
/T1_2 1 Tf
8 0 0 8 70.5 355.3196 Tm
[(SODIUM PHOSPHA)74 (TE PURGA)74 (TIVES AND ELECTROL)91 (YTE)]TJ
0 Tw 0 -1.65 TD
(DISTURBANCES)Tj
ET
BT
/T1_0 1 Tf
0 Tc 10.5 0 0 10.5 70.5 320.9197 Tm
(T)Tj
-0.01801 Tc 0.01801 Tw 0.55729 0 Td
(ransient shifts in serum electrolyte levels are common)Tj
-0.01199 Tc 0.01199 Tw -1.5573 -1.25715 Td
[(with hyperosmotic pur)20 (gatives. A recent meta-analysis re-)]TJ
-0.02499 Tc 0.02499 Tw 0 -1.25714 TD
(viewed 9 studies that evaluated electrolyte disturbances re)Tj
0 Tc 21.95303 0.00001 Td
(-)Tj
-0.024 Tc 0.02299 Tw -21.95303 -1.25715 Td
[(lated to pur)20 (gative administration and reported significantly)]TJ
-0.02499 Tc 0.02 Tw 24.57143 42.80952 Td
(increased biochemical changes associated with NaP prepa-)Tj
0 Tc 0.008 Tw T*
(rations versus PEG-ELS products.)Tj
ET
BT
/T1_1 1 Tf
0 Tw 6 0 0 6 462.298 720.9197 Tm
(3)Tj
ET
BT
/T1_0 1 Tf
0.008 Tw 10.5 0 0 10.5 468.0093 717.6196 Tm
[(In particular)40 (, hyper-)]TJ
-0.02499 Tc 0.009 Tw -14.2866 -1.25714 Td
(phosphatemia and hypokalemia occurred more often in pa-)Tj
-0.01649 Tc T*
(t)Tj
-0.017 Tc 0.01601 Tw [(ients who took NaP liquid and tablet for)-25 (mulations versus)]TJ
-0.02499 Tc 0.013 Tw 0 -1.25715 TD
(PEG-ELS preparations.)Tj
ET
BT
/T1_1 1 Tf
-0.0242 Tc 0 Tw 6 0 0 6 411.7456 681.3196 Tm
(7)Tj
-0.024 Tc [(,9,20)-24 (-23)]TJ
ET
BT
/T1_0 1 Tf
0 Tc 0.06799 Tw 10.5 0 0 10.5 328.5 664.8196 Tm
(The disturbance in electrolyte levels associated with)Tj
-0.02499 Tc 0.019 Tw -1 -1.25714 Td
[(NaP pur)20 (gatives is an important safety consideration for pa-)]TJ
-0.01601 Tc 0.015 Tw T*
(tients with certain risk factors, including preexisting renal)Tj
-0.00999 Tc 0.00999 Tw 0 -1.25714 TD
[(insuf)20 (ficiency)65 (, dehydration, advanced age, and concurrent)]TJ
-0.002 Tc 0.002 Tw T*
(treatment with medications known to decrease gastroin-)Tj
-0.006 Tc 0.006 Tw T*
[(testinal \(GI\) motility or to af)20 (fect kidney function \(eg, di-)]TJ
-0.01401 Tc 0.01401 Tw T*
(uretics, angiotensin-converting enzyme [ACE] inhibitors,)Tj
-0.02499 Tc 0.019 Tw 0 -1.25715 TD
(angiotensin receptor blockers [ARBs]\).)Tj
ET
BT
/T1_1 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 473.6454 575.7198 Tm
(19,24)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.019 Tw 10.5 0 0 10.5 488.9611 572.4197 Tm
(Preexisting kid-)Tj
-0.01601 Tc 0.01601 Tw -16.28201 -1.25714 Td
(ney disease and medical conditions \(eg, hypertension\) as-)Tj
0 -1.25713 TD
[(sociated with administration of medications that af)20 (fect re-)]TJ
-0.01801 Tc 0.01801 Tw T*
(nal perfusion or function can have a substantial impact on)Tj
0 Tc 0.092 Tw T*
(electrolyte balance.)Tj
ET
BT
/T1_1 1 Tf
0.00101 Tc 0 Tw 6 0 0 6 400.5836 522.9197 Tm
(19,25)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.092 Tw 10.5 0 0 10.5 417.6789 519.6198 Tm
(Sodium phosphate preparations)Tj
-0.02499 Tc 0.02 Tw -9.49323 -1.25714 Td
(should not be administered to patients with kidney disease,)Tj
-0.021 Tc 0.021 Tw 0 -1.25714 TD
(megacolon, bowel obstruction, ascites, or congestive heart)Tj
-0.02299 Tc 0.02299 Tw T*
(failure and should be administered with caution in patients)Tj
-0.01801 Tc 0.01801 Tw T*
(with impaired renal function, preexisting or increased risk)Tj
-0.008 Tc 0.008 Tw T*
(for electrolyte disturbances, heart disease, acute myocar)Tj
0 Tc 21.95301 0.00001 Td
(-)Tj
-0.02 Tc 0.02 Tw -21.95301 -1.25715 Td
(dial infarction, unstable angina, and in elderly or debilitat-)Tj
-0.02499 Tc 0.013 Tw T*
(ed patients.)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 6 0 0 6 362.7976 430.5198 Tm
(2)Tj
ET
BT
/T1_0 1 Tf
-0.00101 Tc 0.00101 Tw 10.5 0 0 10.5 328.5 414.0198 Tm
(Most fatalities following NaP preparations have been)Tj
0 Tc 0.054 Tw -1 -1.25715 Td
(related to arrhythmias or seizures associated with elec-)Tj
-0.005 Tc 0.005 Tw T*
(trolyte and fluid shifts. The patients were typically inap)Tj
0 Tc 21.95306 0 Td
(-)Tj
0.11 Tw -21.95306 -1.25715 Td
(propriate candidates for NaP or received overdoses of)Tj
0 Tw T*
[(NaP)110 (.)]TJ
ET
BT
/T1_1 1 Tf
0.002 Tc 6 0 0 6 337.5465 364.5198 Tm
(26)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.198 Tw 10.5 0 0 10.5 348.2474 361.2198 Tm
[(Thus, clinicians need ef)20 (fective mechanisms to)]TJ
-0.02499 Tc 0.01199 Tw -2.8807 -1.25714 Td
[(screen patients for their candidacy to receive NaP)117.5 (,)-236.6 (and dos)]TJ
0 Tc 21.95293 0.00001 Td
(-)Tj
-0.017 Tc 0.017 Tw -21.95293 -1.25715 Td
(es should never exceed the maximum recommended dose)Tj
-0.01801 Tc 0.01801 Tw T*
[(of 90 mL \(59.4 g NaP\) or 40 tablets \(60 g NaP\) \(T)74.3 (able 1\).)]TJ
-0.02499 Tc 0.005 Tw 0 -1.25715 TD
[(Patients who are not ef)20 (fectively prepared after 90 mL or 40)]TJ
-0.024 Tc 0.024 Tw 0 -1.25714 TD
(tablets should have their preparation completed with PEG-)Tj
-0.02499 Tc 0.013 Tw T*
[(ELS or another non-NaP pur)20 (gative and/or enemas.)]TJ
ET
BT
/T1_1 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 518.7797 285.3198 Tm
(27)Tj
ET
0 0 0 0 k
318 745 234 10 re
f
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 259.0939 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 392.2189 25.4116 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 405.4 23.9116 Tm
[(2007 September)110 (, V)110 (olume 41    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 519.569 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.024 Tc 10 0 0 10 532.75 23.9116 Tm
(1467)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0 k
60.5 48.5 491 192.957 re
f
0 0 0 1 K
0.5 w 
60.5 224.27 m
551.5 224.27 l
S
BT
0 0 0 1 k
/T1_2 1 Tf
0.011 Tw 9 0 0 9 156.8925 230.02 Tm
[(T)74 (able 1.)]TJ
ET
BT
/T1_5 1 Tf
9 0 0 9 190.4081 230.02 Tm
(FDA-Approved Dosing Regimens for Sodium Phosphate Preparations)Tj
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 7.5 0 0 7.5 337.1381 214.0201 Tm
(MCC-Containing)Tj
ET
60.5 201.77 m
551.5 201.77 l
S
BT
/T1_2 1 Tf
-0.01401 Tw 7.5 0 0 7.5 100.5586 206.02 Tm
(Parameter)Tj
17.131 0 Td
(Solution)Tj
16.617 0 Td
[(T)74 (ablets)]TJ
14.438 0 Td
[(MCC-Free T)74 (ablets)]TJ
ET
BT
/T1_5 1 Tf
7.5 0 0 7.5 63.5 191.02 Tm
(Preparation)Tj
17.201 0 Td
(75\32090 mL)Tj
16.10499 0 Td
(40 tablets)Tj
17.09699 0 Td
(32 tablets)Tj
-50.40299 -1.6 Td
(NaP dose, g)Tj
17.20098 0 Td
(49.5\32059.4)Tj
16.104 0 Td
(60)Tj
17.09699 0 Td
(48)Tj
-50.40198 -1.6 Td
[(Minimum number of 8-oz glasses )-2269 (9)]TJ
33.30696 0 Td
(14)Tj
17.097 0 Td
(8)Tj
-49.90397 -1.2 Td
(of clear liquids required )Tj
0 Tw -0.5 -1.6 Td
(Instructions)Tj
-0.01401 Tw 0.5 -1.33333 Td
[(evening before colonoscopy)-4277 (45 mL, mixed in 1 glass of cold, )-1931.3 (20 tablets, taken as 3 tablets with )-2134 (2)15 (0)15 ( )15 (t)15 (a)15 (b)15 (l)15 (e)15 (t)15 (s)15 (,)15 ( )15 (t)15 (a)15 (k)15 (e)15 (n)15 ( )15 (a)15 (s)15 ( )15 (4)15 ( )15 (t)15 (a)15 (b)15 (l)15 (e)15 (t)15 (s)15 ( )15 (w)15 (i)15 (t)15 (h)15 ( )]TJ
17.2 -1.2 Td
(clear liquid, followed by )Tj
/T1_6 1 Tf
10.55673 0.00001 Td
(\263)Tj
/T1_5 1 Tf
-0.00031 Tc [0.2 (6)]TJ
-0.00011 Tc 5.54644 0.00001 Td
(1)Tj
0 Tc 0.8199 0 Td
[(glass of clear liquid every )-4845 (1 glass of clear liquid every)]TJ
-16.92307 -1.20002 Td
(glasses of clear liquid)Tj
16.10317 0.00001 Td
[(15 min \(last dose is 2 tablets\))-4175.9 (15 min)]TJ
-33.30318 -1.33334 Td
(day of colonoscopy)Tj
16.70098 0 Td
[(30\32045 mL, mixed in 1 glass of )-2642 (20 tablets, taken as 3 tablets )-4176 (1)15 (2)15 ( )15 (t)15 (a)15 (b)15 (l)15 (e)15 (t)15 (s)15 (,)15 ( )15 (t)15 (a)15 (k)15 (e)15 (n)15 ( )15 (a)15 (s)15 ( )15 (4)15 ( )15 (t)15 (a)15 (b)15 (l)15 (e)15 (t)15 (s)15 ( )15 (w)15 (i)15 (t)15 (h)15 ( )]TJ
0.49902 -1.2 Td
[(cold, clear liquid, followed)-4755 (with 1 glass of clear liquid )]TJ
33.20493 0 Td
(1 glass of clear liquid every)Tj
-33.20493 -1.2 Td
(immediately by )Tj
/T1_6 1 Tf
6.91655 0 Td
(\263)Tj
/T1_5 1 Tf
-0.00011 Tc 0.47485 0 Td
(1)Tj
0 Tc 0.81991 0 Td
(glass )Tj
7.89199 0 Td
(every 15 min \(last dose is)Tj
17.09995 0 Td
(15 min, starting 3\3205 h before)Tj
-33.20326 -1.2 Td
(of clear liquid)Tj
16.10498 0 Td
[(2 tablets\), starting 3\3205 h before)-3329 (procedure)]TJ
ET
60.5 65.77 m
551.5 65.77 l
S
BT
/T1_5 1 Tf
0 Tw 7.5 0 0 7.5 317.0238 72.02 Tm
(procedure)Tj
-0.01401 Tw -33.80317 -2.26666 Td
(FDA = Food and Drug Administration; MCC = microcrystalline cellulose; Na\P = sodium phosphate.)Tj
ET
60.25 48.25 491.5 193.457 re
h
S
BT
0 g
/GS2 gs
/T1_7 1 Tf
0 Tw 5 0 0 5 302.24986 11 Tm
( at DALHOUSIE UNIV on May 19, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
106 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
107 0 obj
<</OP false/OPM 0/op false>>
endobj
132 0 obj
<</A 133 0 R/Border[0 0 0]/Rect[261.505 9.0 303.25 16.0]/Subtype/Link/Type/Annot>>
endobj
133 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
100 0 obj
[134 0 R]
endobj
101 0 obj
<</Length 10502>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 18.25 391 13 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.024 Tc 10 0 0 10 60 24.4116 Tm
(1466)Tj
ET
BT
/T1_1 1 Tf
0 Tc 5 0 0 5 88.4999 25.9116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 101.6809 24.4116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 5 0 0 5 234.8059 25.9116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 247.987 24.4116 Tm
[(2007 September)110 (, V)110 (olume 41)]TJ
ET
0 0 0 0 k
472 18 79.5 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tw 10 0 0 10 475.7004 24.1616 Tm
[(www)75 (.theannals.com)]TJ
ET
0 0 0 0 k
60 36.7199 492 472.221 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
0 Tc 27.357 0 0 27.357 59.6707 488.7603 Tm
(T)Tj
ET
BT
/T1_4 1 Tf
-0.013 Tc 0.013 Tw 10.5 0 0 10.5 76.375 501.7603 Tm
(he 2 main classes of bowel prepara-)Tj
0 Tc 0.032 Tw 0 -1.23809 TD
(tion for colonoscopy in the US are)Tj
0.063 Tw -1.55952 -1.23809 Td
(sodium phosphate \(NaP\) products and)Tj
0.093 Tw T*
(polyethylene glycol electrolyte lavage)Tj
-0.02499 Tc 0.00301 Tw 0 -1.2381 TD
(solution \(PEG-ELS\). Bowel preparations)Tj
0 Tc 0.123 Tw 0 -1.23809 TD
(are typically judged by their ef)Tj
0 Tw 12.89685 0.00001 Td
[(ficacy)66.1 (,)]TJ
-0.01801 Tc -12.89685 -1.2381 Td
(safety)Tj
-0.01781 Tc 2.2159 0.00001 Td
(,)Tj
-0.01801 Tc 0.01801 Tw 0.48211 0 Td
(and tolerability)Tj
-0.01781 Tc 5.75103 0 Td
(,)Tj
-0.01801 Tc 0.48208 0 Td
(with all 3 criteria)Tj
-0.015 Tc 0.015 Tw -8.93113 -1.2381 Td
(having obvious clinical importance. Re-)Tj
-0.01801 Tc 0.01801 Tw T*
(cent reviews and a meta-analysis report-)Tj
0 Tc 0.045 Tw T*
(ed that NaP preparations are generally)Tj
0.052 Tw 0 -1.2381 TD
[(more ef)20 (fective)]TJ
ET
BT
/T1_0 1 Tf
0.00101 Tc 0 Tw 6 0 0 6 121.2493 375.0604 Tm
(1-3)Tj
ET
BT
/T1_4 1 Tf
0 Tc 0.052 Tw 10.5 0 0 10.5 132.4196 371.7603 Tm
(and better tolerated)Tj
ET
BT
/T1_0 1 Tf
0.0018 Tc 0 Tw 6 0 0 6 214.5536 375.0604 Tm
(1-)Tj
0 Tc 0.90771 0 Td
(4)Tj
ET
BT
/T1_4 1 Tf
-0.011 Tc 0.011 Tw 10.5 0 0 10.5 60 358.7603 Tm
(compared with PEG-ELS for)Tj
0 Tw 11.42538 0 Td
(mulations.)Tj
0 Tc 0.021 Tw -11.42538 -1.2381 Td
(The meta-analysis included 16 clinical)Tj
0.022 Tw T*
(trials involving 3484 patients and con-)Tj
-0.01401 Tc 0.01401 Tw 0 -1.23809 TD
(cluded that NaP solution is significantly)Tj
0 Tc 0.078 Tw T*
(more likely than PEG-ELS to provide)Tj
-0.02499 Tc 0.02499 Tw T*
(good or excellent bowel preparation \(p =)Tj
-0.00999 Tc 0 Tw 0 -1.2381 TD
(0.0004\).)Tj
ET
BT
/T1_0 1 Tf
0 Tc 6 0 0 6 94.1404 284.0603 Tm
(3)Tj
ET
BT
/T1_4 1 Tf
-0.00999 Tc 0.00999 Tw 10.5 0 0 10.5 99.7044 280.7603 Tm
[(T)70 (olerability of bowel prepara-)]TJ
-0.02 Tc 0.02 Tw -3.78137 -1.2381 Td
(tion, measured as the ability to complete)Tj
-0.01199 Tc 0.01199 Tw 0 -1.23809 TD
(the entire preparation, also favored NaP)Tj
0 Tc 0.01401 Tw 0 -1.2381 TD
(solution; data pooled from 15 trials in-)Tj
-0.01601 Tc 0.01601 Tw T*
(volving 3293 patients demonstrated sig-)Tj
0 Tc 0.146 Tw 0 -1.23809 TD
(nificantly higher completion rates for)Tj
-0.02499 Tc 0.017 Tw 0 -1.2381 TD
(NaP versus PEG-ELS \(94% vs 71%; p <)Tj
0 Tw T*
(0.00001\).)Tj
ET
BT
/T1_0 1 Tf
0 Tc 6 0 0 6 97.8814 193.0604 Tm
(3)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.015 Tw 10.5 0 0 10.5 103.2495 189.7603 Tm
[(Similarly)65 (, a limited number of)]TJ
-0.002 Tc 0.002 Tw -4.119 -1.23809 Td
(studies that compared NaP tablets with)Tj
-0.005 Tc 0.004 Tw T*
[(PEG-ELS favored NaP tablets in ter)-25 (ms)]TJ
0 Tc 0.095 Tw T*
(of completion of the preparation.)Tj
ET
BT
/T1_0 1 Tf
0.026 Tc 0 Tw 6 0 0 6 202.4847 154.0604 Tm
[(5-)24 (7)]TJ
ET
BT
/T1_4 1 Tf
0 Tc 10.5 0 0 10.5 214.2559 150.7603 Tm
(In)Tj
-0.01401 Tc 0.01401 Tw -14.69104 -1.23809 Td
(addition to measures of compliance, pa-)Tj
-0.01601 Tc 0.01601 Tw T*
(tient tolerability for NaP preparations was further demon-)Tj
-0.017 Tc 0.017 Tw T*
(strated by willingness to repeat the preparation, expressed)Tj
-0.0242 Tc 0 -1.23809 TD
(by)Tj
-0.024 Tc 0.024 Tw 1.20158 0 Td
(significantly more patients who received NaP tablets)Tj
ET
BT
/T1_0 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 282.576 102.0604 Tm
(5,6,8)Tj
ET
BT
/T1_4 1 Tf
0 Tc 0.047 Tw 10.5 0 0 10.5 60 85.7603 Tm
(or NaP solution)Tj
ET
BT
/T1_0 1 Tf
0.00101 Tc 0 Tw 6 0 0 6 126.8985 89.0604 Tm
[(5,9)-24 (-14)]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0.047 Tw 10.5 0 0 10.5 145.6652 85.7603 Tm
(compared with those who received)Tj
-0.02299 Tc 0.02299 Tw 16.41284 3.76104 Td
(PEG-ELS preparations. Thus, NaP preparations are gener-)Tj
-0.02499 Tc 0.02 Tw T*
(ally superior to PEG-ELS regimens with regard to ef)Tj
0 Tw 19.96859 0.00001 Td
(ficacy)Tj
0.013 Tw -19.96859 -1.2381 Td
[(and tolerability)65 (.)]TJ
0 Tc 0.157 Tw 1 -1.2381 Td
(While complications can result from either NaP or)Tj
-0.011 Tc 0.011 Tw -1 -1.23809 Td
[(PEG-ELS as bowel preparations, there is concer)-25 (n among)]TJ
-0.019 Tc 0.019 Tw 0 -1.2381 TD
(clinical gastroenterologists that NaP products pose greater)Tj
-0.01601 Tc 0.01601 Tw T*
(risks for patients. Whereas PEG-ELS preparations are os-)Tj
ET
0 0 0 0 k
60 564.836 492 93.105 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
-0.02499 Tc 0.011 Tw 16.8 0 0 16 60 637.028 Tm
[(Dosing Considerations in the Use of Sodium Phosphate Bo)35 (w)20 (el)]TJ
0 -1.5 TD
[(Pr)20 (eparations f)9 (or Colonoscop)35 (y)]TJ
ET
BT
/T1_3 1 Tf
10.5 0 0 10 60 577.028 Tm
(Douglas K Rex )Tj
ET
0 0 0 0 k
60 716.25 492 21 re
f
0 0 0 1 K
0.5 w 
60 721.136 m
552 721.136 l
S
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tc 0 Tw 13 0 0 13 60 728.3855 Tm
[(Gastr)27 (oenter)28 (olo)16 (g)-22 (y)]TJ
ET
60 60.253 m
294 60.253 l
S
BT
/T1_3 1 Tf
-0.02499 Tc 0.011 Tw 8.5 0 0 8.5 60 48.0032 Tm
(Author information provided at the end of the text.)Tj
ET
0 0 0 0.14999 k
239 148.432 313 360.509 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
-0.009 Tc 0 Tw 7 0 0 7 251 491.4731 Tm
(OBJECTIVE)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 290.128 491.4731 Tm
(:)Tj
ET
BT
/T1_3 1 Tf
-0.006 Tc 0.006 Tw 8.5 0 0 8.5 295.757 491.4731 Tm
[(T)111 (o review dosing considerations and other treatment recommend-)]TJ
0 Tc 0.077 Tw -5.26553 -1.29412 Td
[(ations to maximize the ef)18 (ficacy)74 (, tolerability)73 (, and safety of sodium phosphate)]TJ
-0.02499 Tc 0.011 Tw 0 -1.29412 TD
(\(NaP\) preparations.)Tj
ET
BT
/T1_6 1 Tf
-0.0359 Tc 0 Tw 7 0 0 7 251 455.4731 Tm
(D)Tj
-0.036 Tc [(A)74 (T)74 (A)-376 (SOURCES)]TJ
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 303.8908 455.4731 Tm
(:)Tj
ET
BT
/T1_3 1 Tf
-0.02499 Tc 0.00999 Tw 8.5 0 0 8.5 309.2027 455.4731 Tm
(Literature was accessed through PubMed \(1990\320May 2007\) and)Tj
0.011 Tw -6.84738 -1.29412 Td
(abstracts from scientific meetings.)Tj
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 7 0 0 7 251 430.4731 Tm
[(STUDY)-809.5 (SELECTION)-808.9 (AND)-810 (DA)74 (T)74 (A)-810 (EXTRACTION)]TJ
ET
BT
/T1_6 1 Tf
10 0 0 10 416.5043 430.4731 Tm
(:)Tj
ET
BT
/T1_3 1 Tf
0.289 Tw 8.5 0 0 8.5 424.6503 430.4731 Tm
(English-language publications)Tj
0.27699 Tw -20.42945 -1.29412 Td
(including clinical trials and case reports were evaluated. Recent report\s)Tj
0.04201 Tw T*
(assessing newer bowel preparations containing reduced doses of NaP were)Tj
-0.02499 Tc 0.011 Tw T*
(reviewed to evaluate ef)Tj
0 Tw 9.721 0.00001 Td
(ficacy)Tj
-0.0251 Tc 2.33168 0 Td
(,)Tj
-0.02499 Tc 0.51686 0 Td
(tolerability)Tj
-0.0251 Tc 4.12566 0 Td
(,)Tj
-0.02499 Tc 0.011 Tw 0.51687 0 Td
(and safety)Tj
0 Tc 4.30007 0 Td
(.)Tj
ET
BT
/T1_6 1 Tf
0 Tw 7 0 0 7 251 383.4731 Tm
[(DA)74.1 (T)74.2 (A)-795 (SYNTHESIS)]TJ
ET
BT
/T1_6 1 Tf
10 0 0 10 314.6415 383.4731 Tm
(:)Tj
ET
BT
/T1_3 1 Tf
0.27901 Tw 8.5 0 0 8.5 322.7026 383.4731 Tm
(Among commonly administered bowel preparations for)Tj
-0.02 Tc 0 Tw -8.4356 -1.29412 Td
(colonoscopy)Tj
-0.01981 Tc 5.26654 0 Td
(,)Tj
-0.02 Tc 0.02 Tw 0.53603 0 Td
[(NaP preparations are generally more ef)12.9 (fective and better tolerated)]TJ
0 Tc 0.33299 Tw -5.80257 -1.29413 Td
(compared with polyethylene glycol electrolyte lavage solution regimens.)Tj
-0.009 Tc 0.009 Tw T*
[(However)55 (, NaP preparations are contraindicated in specific patient populations,)]TJ
-0.02499 Tc 0.021 Tw T*
[(and clinicians must use ef)20.9 (fective screening mechanisms to select proper patients)]TJ
-0.005 Tc 0.005 Tw T*
[(to receive NaP preparation for colonoscopy)74 (. Recently)74 (, cases of renal failure in)]TJ
0 Tc 0.06 Tw T*
(patients with previously normal renal function have been reported after \NaP)Tj
0.05 Tw T*
(preparation for colonoscopy)Tj
-0.00011 Tc 12.36263 0 Td
(,)Tj
0 Tc 0.606 0 Td
(heightening concerns about the safety of these)Tj
0.01401 Tw -12.96862 -1.29413 Td
(agents. Newer products contain reduced doses of NaP and may improve the)Tj
-0.01401 Tc T*
[(safety and tolerability of NaP purgatives without compromising ef)17 (ficacy of colon)]TJ
-0.00301 Tc 0.00301 Tw T*
(cleansing. In addition, accumulating clinical data and/or rationale supp\ort split)Tj
-0.02499 Tc 0.019 Tw T*
(dosing of NaP products, wide intervals between doses, and aggressive hyd\ration)Tj
0.011 Tw T*
(before and during bowel preparation and after the colonoscopy procedure.\)Tj
ET
BT
/T1_6 1 Tf
-0.035 Tc 0 Tw 7 0 0 7 251 237.473 Tm
(CONCLUSIONS)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 299.9946 237.473 Tm
(:)Tj
ET
BT
/T1_3 1 Tf
-0.02499 Tc 0.02499 Tw 8.5 0 0 8.5 305.4364 237.473 Tm
(Safe administration of NaP products requires rigorous attention to)Tj
0 Tc 0.43401 Tw -6.40428 -1.29412 Td
(dosing considerations and other treatment recommendations, including)Tj
-0.008 Tc 0.008 Tw T*
[(administration of minimally ef)11.1 (fective doses of NaP)]TJ
-0.00771 Tc 21.57582 0.00002 Td
(,)Tj
-0.008 Tc 0.54819 0 Td
(split-dosing schedules, and)Tj
-0.02499 Tc 0.011 Tw -22.12402 -1.29414 Td
(aggressive hydration.)Tj
ET
BT
/T1_6 1 Tf
-0.036 Tc 0 Tw 7 0 0 7 251 190.4731 Tm
[(KEY)-377 (WORDS)]TJ
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 292.8581 190.4731 Tm
(:)Tj
ET
BT
/T1_3 1 Tf
-0.02499 Tc 0.011 Tw 8.5 0 0 8.5 298.1792 190.4731 Tm
(bowel purgatives, sodium phosphate.)Tj
ET
BT
/T1_7 1 Tf
8.5 0 1.80673 8.5 251 175.4731 Tm
(Ann Pharmacother)Tj
ET
BT
/T1_3 1 Tf
0 Tw 8.5 0 0 8.5 322.581 175.4731 Tm
(2007;41:1466-75.)Tj
0.011 Tw -8.42129 -1.76471 Td
(Published Online, 24 Jul 2007, )Tj
ET
BT
/T1_7 1 Tf
0 Tw 8.5 0 1.80673 8.5 362.5064 160.4731 Tm
[(www)55.2 (.theannals.com)]TJ
ET
BT
/T1_3 1 Tf
-0.0251 Tc 8.5 0 0 8.5 434.462 160.4731 Tm
(,)Tj
-0.02499 Tc 0.011 Tw 0.51686 0 Td
(DOI 10.1345/aph.1K206)Tj
1 g
/T1_8 1 Tf
-0.278 Tc 0 Tw 1 0 0 1 -1000 1792 Tm
( )Tj
ET
BT
0 g
/GS2 gs
/T1_9 1 Tf
0 Tc 5 0 0 5 302.24986 11 Tm
( at DALHOUSIE UNIV on May 19, 2015)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
38 0 obj
<</BaseFont/UQIHIB+GillSans-Bold/Encoding 35 0 R/FirstChar 32/FontDescriptor 37 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 698 771 802 0 0 813 0 0 0 0 0 0 0 0 656 0 0 604 0 823 0 0 0 0 0 0 0 0 0 0 0 531 0 500 583 552 302 542 583 271 0 0 271 958 583 594 583 0 448 427 406 583 0 781 0 510]>>
endobj
46 0 obj
<</BaseFont/SOQYBX+Helvetica-Oblique/Encoding 43 0 R/FirstChar 32/FontDescriptor 45 0 R/LastChar 119/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 556 0 500 0 556 0 0 556 0 0 0 222 833 556 556 0 0 333 500 278 0 0 722]>>
endobj
50 0 obj
<</BaseFont/CHYTVZ+Helvetica-Bold/Encoding 47 0 R/FirstChar 32/FontDescriptor 49 0 R/LastChar 32/Subtype/Type1/Type/Font/Widths[278]>>
endobj
47 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space]/Type/Encoding>>
endobj
49 0 obj
<</Ascent 750/CapHeight 717/Descent -205/Flags 262178/FontBBox[-170 -227 1001 963]/FontFile3 48 0 R/FontName/CHYTVZ+Helvetica-Bold/ItalicAngle 0/StemH 0/StemV 140/Type/FontDescriptor/XHeight 737>>
endobj
48 0 obj
<</Length 313/Length1 313/Subtype/Type1C>>stream
  CHYTVZ+Helvetica-Bold   @ø øøøøû>ûwú}úW
 ‹‹
 ‹‹      ²   €•002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki BoldHelsinki      üwŸø§š÷,—’Ÿ˜‹÷£—ü|‹õ
÷ Œ
_÷ªù
endstream
endobj
43 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 46/period 65/A 80/P 97/a 99/c 101/e 104/h 108/l/m/n/o 114/r/s/t 119/w]/Type/Encoding>>
endobj
45 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 32/FontBBox[-214 -224 1198 931]/FontFile3 44 0 R/FontName/SOQYBX+Helvetica-Oblique/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
44 0 obj
<</Length 1421/Length1 1421/Subtype/Type1C>>stream
  SOQYBX+Helvetica-Oblique   Eø øøøøû:ûtú|ú7
 ‹
 o
 ‹‹      ü  !¬  l €ˆ002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki    " O  1 I B S N D P U F X  M T    < ~  Ã ı‰Â!sºëH†–«%œ v÷dâø:w™ùù û˜ùaûû ıaîÖ÷d÷³Òûd!÷»ûr÷÷Ğ- vø^Û|wÌŞ8ä÷âôø€÷÷÷IÎûEZpM_‰ôÕ8üŸìä÷°÷ÀÌåÕ­`.ûÖüœ v÷ÂŞ÷İáí÷çîùø˜÷6Ûûû×ıaí÷Â÷u÷áá÷(‰6Y_+ûU÷÷Xé¼b;- vø_Û÷FwÌã÷âø÷÷÷
KÍûHbtLY‰÷œ3ıaã÷±÷ÂÊëĞªf:ûé-|Ô[v÷‰Í÷8Ô¯äLÛ÷…ã6àµø¤Ë‡~ƒŠ„vƒ”¡÷Áæ@ÂûûHTû
„ÛÑ•°©ÙÖ·kSi{wl‡û$y¹$~SQ.0ÍOí×Ã¤ÇÄöQ‘¤tÃ–”¡ºû%÷HK>Q5Qf«¿À¯©Ø”÷˜†Š³ŸûÑ vøPé|wØİ9ãğ÷ßøPæ~„Œ‡QamB]‰ğã9üŸèã÷ÄÜÃÆÙ÷K vø_Ú|wÌŞ8ã÷qã÷nãöù”÷ş÷KÎ%Lp|EJÅo^¦IGYoNc‰öÕ8üŸîã÷±ôÁĞß¾«fOûşã÷ÓÙÁÉÎÌ«c:ûæû*{Øø"Ú©é÷ à7ßèøq÷L7<y]_I1ZÒ÷÷ÂÕçğÏ±h>šà÷}GÌûû)*ûû?û8ç ÷"÷ÛÖ÷™-}×ø$×®æ÷Äæø÷š÷7'÷û#û#'ûû7û8îû÷$÷$î÷÷80ûP=..PÙ÷÷ÆÙèèÆ=ûü„×øÕßã÷•Ğmez—¨÷çßÕ7÷&3û&EAÑûì?¬gĞœ™Œ‘³-|×÷@Ñ÷/Û³è÷´â8æôø˜÷}÷V:÷û%û1.û ûKû6ç'÷*ø÷ØÈ÷
§4J{YeC.WÃ÷†ô÷¸Ñû¸ì”ÇÅİï°@;Ó vøŸw›ùIùYøŸ4 ü.‰&ø.)&ü.‰'ø.,÷+üŸåñø)ôü)æü‹õâó÷Sõ#!ü@ vùawÎã÷/ùa3ıaû*|Ö÷2ÙVÖ÷$×«ßGß÷yàDãÕøc÷2Ôc± ¦ö4¡<Ÿy˜‹±·µ¨ÊÜ±pNà÷ ‚FÃûû=J%I³aİwÙğrŞv }‹dW]k@2d©Ù7T’qp«\Óoæ‹÷‹ŞĞ‹óu¡øŸš÷)›™Ÿ÷¡–ü}š×
ã
_÷ªù
endstream
endobj
35 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 66/B/C/D 71/G 80/P 83/S 85/U 97/a 99/c/d/e/f/g/h/i 108/l/m/n/o/p 114/r/s/t/u 119/w 121/y]/Type/Encoding>>
endobj
37 0 obj
<</Ascent 716/CapHeight 682/Descent -221/Flags 262176/FontBBox[-177 -230 1167 929]/FontFile3 36 0 R/FontName/UQIHIB+GillSans-Bold/ItalicAngle 0/StemH 0/StemV 145/Type/FontDescriptor/XHeight 728>>
endobj
36 0 obj
<</Length 2473/Length1 2473/Subtype/Type1C>>stream
  UQIHIB+GillSans-Bold   Aø øøøøûEûzú5
 ‹‹
 ‹‹       ;±  	ƒ }‹”Copyright (c) 1990 Adobe Systems Incorporated. All Rights Reserved.Gill Sans is a trademark of The Monotype Corporation Plc.Gill Sans BoldGill Sans    % P T J O H  $ E F S B U I 6 G 4 V N 1 Q # X M D Z (    I  ã^'*uÏ!aÑPÔ-mÜvÜ0t ü÷,‹÷øD÷Ö÷>÷á÷CÖù>ı>÷®÷¤÷÷$÷X÷Oû÷/ûûû÷÷5Ê(û	'Xûû?ûS‚á÷Çá°÷/÷f÷/øÁ÷z÷Eû&Êûûû9û1û%÷,÷+ñ÷1Ã÷Kû/&gSGTX®÷ó¶¼ÊÔªO1ûs‚ì÷v¾á°÷ê÷øøH£[`•Qû>R6û+÷y—‹Hvp~`T\Ÿ\%€ŸÒtÕ÷ÏÁë÷.ûy‹¾«¬¨ÉdÊü vøawå÷4Â÷4û,÷%è÷døaû%üa÷%0BùG_gg__¯g··¯¯··g¯_H vø	ã3ìÇ÷%÷A÷%Ø÷aøaû%üa÷%¸÷½Ä±¦¯´ªpJû­÷%÷¹÷+´CP^uV]û ûzá÷ÿ aÀ ÿ GaHÿ IáHÿ ›ıpì5á§÷û÷1÷÷÷%÷ò€ø¦øaû¦û:cûRñ@6Ñ[Æ‚‰p…R~Zj¤yª‚‰ô@%qvYdN¿B÷V÷)ê»ö¢„¯m©ñ@?ØûD]ÀÁ÷[İİò€¤¤œ®´¦„¡{§Íê€ûíBº¯°»½¬fa[fc]]e±¸ô@÷\ülcpK>a®­µ ÏÓ´yjü÷‚÷"ø4÷"º÷Cù\÷d\)Oo2û"&â÷÷ñá÷%ß×oaÖ÷,³H6Ÿ,û™û)û>ûJûD÷û@÷ğÓ¼êH‚ì3ã÷±ì÷hw®÷'÷Y÷%¼ø ù>û%û…dd•aû/)û!ûç%÷¼±˜¬´|f÷%¼û%÷pmr€lG`Ãßç¶ÀÔ¥­| )‚á÷×ğá°÷*÷_÷ø’÷#ZG^zQ0S»İ†÷ß÷<’ûêûû"&'û!û$ô-÷6¯â‹ÈŞûÔ÷{Ë‘°°ÄÃ±eL‘û^ v÷â÷‚wË÷%°÷eøaû%üa÷%÷[Ğà«­½À¢¤s±³÷aªr–n‹S[^+`‰û‚á÷¼ì¬÷'÷÷%ø§÷si€‰|‚”¢÷fğ<²ûBHxfOû
º¹Í©ÅÊŸi`ˆûUO:uûQÂTÕ½¹™±Ãf•¢|»²Ä£³ûtÚusn~pqv¡¦¹´Ÿáªûˆ‚ö÷œîÙ÷%øøaû<÷%yûUûloÍûZûŞ_ë¸±“ ¾ôwdo„m^q¨¸÷R÷<H vø õ÷hwÉ÷%÷@÷%÷cù>û%ı>÷%÷º¼­¨ ­¸©kFû›÷%÷º÷6¾7R\sVa‰÷A‚÷"ø¹wÑ÷>÷ê÷>øÚù>üû8\1)DÆíøû>üûg÷#/÷Z÷O÷.Ù÷vøûğ v÷şî÷÷‚wÜ÷%è÷vøa¨È®Ÿ¸›–Š†±Ø÷	èue‘oû	6DûtI(Íûş÷%÷şÍî]‚÷øV÷¶÷C÷@÷Cøªù°5F›?û2%=û
û‰÷ï´‹ûchtJ@O¢Ì)û'hÏÆl÷÷,÷×÷÷‚ûïn‹ò­²¡ÈÅÆz_îH‚ì3ãø	wÇ÷%÷A÷%xø÷%øaû&¸ûº^|ci_eh¢Ì÷±û%û»ûÙSæÅ¸¡À¹÷È vø	ì‚wÊ÷%÷[÷%÷[÷%¼÷døaû%üa÷%Ü÷Éµ®±¡±¶¸r@û¥÷%÷»¾¬²¦µÀ«fIû¢÷%÷¼ô@Ğ"FVnFOÍkU«;np†€p¼qqzrt‘ v÷¦÷÷2÷Ş÷>÷M÷CŞù>ı>÷>÷¦÷÷1Ï÷ëèE÷û0ûûÇç¬vQXoo=<Hûev÷qì÷›v°é-òÄ÷%÷[÷'ö÷^øaû%ıG÷%÷‘w­·´÷åì÷(î÷-ñûYb|ib0§¯¢”ªĞ³X35_UDnq” n»‹÷÷5÷÷&÷×÷>÷D÷Cû÷Hø×ù>ı>÷àô÷[µ÷ÙÛ[Ñ*¤øÄ§¯¾Ä×Jêû5ûûäÉ¤fhgreM2û÷ôÇ·pYPjr-+÷—vøjwŠù£ø÷†÷ûĞ÷cøjû(*û’%÷’3$û’*÷’û(÷düjÏü vù>wÊ÷%÷dù>û%ı>÷%û*‚ò÷—vªö³÷/øc÷sKlƒh8TÁİÜÃ¿â¯·€w±÷ [O—\û,û'û!û$ô-÷6¼¼• Åû û\vù>wŒøø‘øaû,#û*÷û/÷Hüûû¼÷.÷7‚÷"ó÷÷O÷"º÷C÷÷“û0÷>øùkù¬G(¢%û‡û<û#ûdû`÷=û%÷‚ô÷÷²À¾÷«øû¡ûôî;wYv‡aû!,Û÷ğÌ÷÷Møßßvaâ‚”ù>”ûz”÷Š—÷Ù’üÆ”î
Œ
yXO	÷ªù
endstream
endobj
102 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
103 0 obj
<</OP false/OPM 0/op false>>
endobj
134 0 obj
<</A 135 0 R/Border[0 0 0]/Rect[261.505 9.0 303.25 16.0]/Subtype/Link/Type/Annot>>
endobj
135 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
73 0 obj
<</CreationDate(D:20070808153611Z)/Creator(QuarkXPress\(tm\) 6.52)/ModDate(D:20150519030044-07'00')/Producer(QuarkXPress\(tm\) 6.52)/Title(Layout 1)/XPressPrivate(%%DocumentProcessColors: Black\n%%EndComments)>>
endobj
xref
0 136
0000000000 65535 f
0000037345 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000001838 00000 n
0000022361 00000 n
0000022897 00000 n
0000022690 00000 n
0000009636 00000 n
0000028834 00000 n
0000029123 00000 n
0000028920 00000 n
0000009482 00000 n
0000029378 00000 n
0000029812 00000 n
0000029604 00000 n
0000009092 00000 n
0000070837 00000 n
0000071440 00000 n
0000071237 00000 n
0000070179 00000 n
0000011097 00000 n
0000011884 00000 n
0000011679 00000 n
0000010308 00000 n
0000177315 00000 n
0000177703 00000 n
0000177491 00000 n
0000173866 00000 n
0000077271 00000 n
0000077788 00000 n
0000077575 00000 n
0000069729 00000 n
0000175447 00000 n
0000175815 00000 n
0000175604 00000 n
0000174247 00000 n
0000174757 00000 n
0000175057 00000 n
0000174844 00000 n
0000174606 00000 n
0000137514 00000 n
0000137820 00000 n
0000137619 00000 n
0000137365 00000 n
0000033548 00000 n
0000033937 00000 n
0000033722 00000 n
0000008710 00000 n
0000001944 00000 n
0000095853 00000 n
0000096162 00000 n
0000096447 00000 n
0000096720 00000 n
0000097017 00000 n
0000097302 00000 n
0000001883 00000 n
0000002046 00000 n
0000002134 00000 n
0000002415 00000 n
0000002696 00000 n
0000002953 00000 n
0000000016 00000 n
0000180517 00000 n
0000000097 00000 n
0000083059 00000 n
0000083084 00000 n
0000095596 00000 n
0000095654 00000 n
0000011008 00000 n
0000053496 00000 n
0000053521 00000 n
0000082802 00000 n
0000082860 00000 n
0000037643 00000 n
0000037668 00000 n
0000053239 00000 n
0000053297 00000 n
0000003210 00000 n
0000003235 00000 n
0000037386 00000 n
0000037444 00000 n
0000037489 00000 n
0000037587 00000 n
0000053342 00000 n
0000053440 00000 n
0000082905 00000 n
0000083003 00000 n
0000095699 00000 n
0000095797 00000 n
0000163284 00000 n
0000163311 00000 n
0000180255 00000 n
0000180314 00000 n
0000151559 00000 n
0000151586 00000 n
0000163022 00000 n
0000163081 00000 n
0000138558 00000 n
0000138585 00000 n
0000151297 00000 n
0000151356 00000 n
0000123423 00000 n
0000123450 00000 n
0000138296 00000 n
0000138355 00000 n
0000110344 00000 n
0000110371 00000 n
0000123161 00000 n
0000123220 00000 n
0000097575 00000 n
0000097602 00000 n
0000110082 00000 n
0000110141 00000 n
0000110187 00000 n
0000110287 00000 n
0000123266 00000 n
0000123366 00000 n
0000138401 00000 n
0000138501 00000 n
0000151402 00000 n
0000151502 00000 n
0000163127 00000 n
0000163227 00000 n
0000180360 00000 n
0000180460 00000 n
trailer
<</Size 136/Root 72 0 R/Info 73 0 R/ID[<CD42E54EF12661F95116DFA5D07C9FEA><6C73541DD21DB2110A005B0910000000>]>>
startxref
180745
%%EOF
